U.S. patent application number 14/930603 was filed with the patent office on 2016-06-09 for assays for detecting t cell immune subsets and methods of use thereof.
This patent application is currently assigned to GENENTECH, INC.. The applicant listed for this patent is GENENTECH, INC.. Invention is credited to Felix CHU, Oded FOREMAN, James ZIAI.
Application Number | 20160161485 14/930603 |
Document ID | / |
Family ID | 54602017 |
Filed Date | 2016-06-09 |
United States Patent
Application |
20160161485 |
Kind Code |
A1 |
CHU; Felix ; et al. |
June 9, 2016 |
ASSAYS FOR DETECTING T CELL IMMUNE SUBSETS AND METHODS OF USE
THEREOF
Abstract
The present disclosure provides methods for measuring the number
of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing cancer
cells and lymphocytes obtained from a subject by labeling
lymphocytes that show CD4 expression in the sample, then labeling
lymphocytes that show OX40 expression in the sample, then labeling
lymphocytes that show Foxp3 expression in the sample, then
measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in the
sample. Further provided are methods for determining the prognosis
of a subject, predicting responsiveness of a subject having cancer
to an OX40 agonist treatment, and methods for treating or delaying
progression of cancer based on the number of CD4+ OX40+ Foxp3+
lymphocytes in a sample.
Inventors: |
CHU; Felix; (San Francisco,
CA) ; FOREMAN; Oded; (Davis, CA) ; ZIAI;
James; (Emeryville, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
GENENTECH, INC. |
South San Francisco |
CA |
US |
|
|
Assignee: |
GENENTECH, INC.
South San Francisco
CA
|
Family ID: |
54602017 |
Appl. No.: |
14/930603 |
Filed: |
November 2, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62074594 |
Nov 3, 2014 |
|
|
|
Current U.S.
Class: |
424/133.1 ;
424/143.1; 435/39; 514/19.3 |
Current CPC
Class: |
C07K 2317/24 20130101;
A61K 38/177 20130101; C07K 2317/75 20130101; G01N 33/57419
20130101; A61P 35/04 20180101; G01N 2333/70514 20130101; G01N
33/56972 20130101; C07K 16/2875 20130101; A61P 35/00 20180101; C12Q
1/06 20130101; G01N 2800/52 20130101; G01N 33/582 20130101; G01N
2800/7028 20130101 |
International
Class: |
G01N 33/569 20060101
G01N033/569; C07K 16/28 20060101 C07K016/28; A61K 38/17 20060101
A61K038/17; G01N 33/58 20060101 G01N033/58; C12Q 1/06 20060101
C12Q001/06 |
Claims
1. A method for determining prognosis of a subject having cancer,
comprising: (a) measuring the number of CD4+ OX40+ Foxp3+
lymphocytes in a sample comprising cancer cells and lymphocytes
obtained from the subject; and (b) determining the prognosis of the
subject based on the number of CD4+ OX40+ Foxp3+ lymphocytes in the
sample, as compared with a reference, wherein an increased number
of CD4+ OX40+ Foxp3+ lymphocytes in the sample indicates that the
subject may have an improved prognosis.
2. The method of claim 1, wherein the improved prognosis comprises
increased overall survival.
3. The method of claim 1, wherein the improved prognosis comprises
increased progression-free survival.
4. A method for treating or delaying progression of cancer in a
subject, comprising: (a) measuring the number of CD4+ OX40+ Foxp3+
lymphocytes in a sample comprising cancer cells and lymphocytes
obtained from the subject; (b) determining the number of CD4+ OX40+
Foxp3+ lymphocytes in the sample, as compared with a reference; and
(c) if the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample is
higher than the reference, administering to the subject an
effective amount of an OX40 agonist.
5. A method for treating or delaying progression of cancer in a
subject, comprising administering to the subject an effective
amount of an OX40 agonist, wherein a sample comprising cancer cells
and lymphocytes obtained from the subject has an increased number
of CD4+ OX40+ Foxp3+ lymphocytes, as compared with a reference.
6. A method for predicting responsiveness of a subject having
cancer to an OX40 agonist treatment, comprising: (a) measuring the
number of CD4+ OX40+ Foxp3+ lymphocytes in a sample comprising
cancer cells and lymphocytes obtained from the subject; and (b)
classifying the subject as a responsive or non-responsive subject
based on the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample,
as compared with a reference, wherein an increased number of CD4+
OX40+ Foxp3+ lymphocytes in the sample indicates the subject may be
responsive to the OX40 agonist treatment.
7. The method of claim 4, wherein the number of CD4+ OX40+ Foxp3+
lymphocytes is a median, mean or average number of CD4+ OX40+
Foxp3+ lymphocytes in different regions of interest of the sample
from the subject.
8. The method of claim 7, wherein the number of CD4+ OX40+ Foxp3+
lymphocytes is normalized to total cells in the region of interest
of the sample.
9. The method of any claim 4, wherein the reference is based on the
number of CD4+ OX40+ Foxp3+ lymphocytes in a sample comprising
cancer cells and lymphocytes obtained from a cancer having the same
type and/or stage as the cancer of the subject.
10. The method of claim 9, wherein the reference is a median, mean,
or average number of CD4+ OX40+ Foxp3+ lymphocytes in samples
obtained from cancers having the same type and/or stage as the
cancer of the subject.
11. The method of claim 4, wherein the OX40 agonist is an agonist
anti-human OX40 antibody.
12-16. (canceled)
17. The method of claim 11, wherein the antibody comprises (a)
HVR-H1 comprising the amino acid sequence of SEQ ID NO:2, 8 or 9;
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:3, 10,
11, 12, 13, or 14; (c) HVR-H3 comprising the amino acid sequence of
SEQ ID NO:4, 15 or 19; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising an amino acid
sequence selected from SEQ ID NO:7, 22, 23, 24, 25, 26, 27 or
28.
18-20. (canceled)
21. The method of claim 11, wherein the antibody is MEDI6469 or
MEDI0562.
22. The method of claim 4, wherein the OX40 agonist comprises one
or more extracellular domains of OX40L.
23. The method of claim 4, wherein the OX40 agonist is
MEDI6383.
24. (canceled)
25. A method for measuring the number of CD4+ OX40+ Foxp3+
lymphocytes in a sample comprising cancer cells and lymphocytes
obtained from a subject, comprising the steps of: (a) labeling
lymphocytes that show CD4 expression in the sample; (b) labeling
lymphocytes that show OX40 expression in the sample after step (a);
(c) labeling lymphocytes that show Foxp3 expression in the sample
after step (b); and (d) measuring the number of CD4+ OX40+ Foxp3+
lymphocytes in the sample after step (c).
26-30. (canceled)
31. The method of claim 4, wherein the cancer is selected from the
group consisting of non-small cell lung cancer, renal cell
carcinoma, bladder cancer, ovarian cancer, glioblastoma,
neuroblastoma, melanoma, triple-negative breast carcinoma, gastric
cancer, colorectal cancer, and hepatocellular carcinoma.
32-35. (canceled)
36. A method for determining prognosis of a subject having cancer,
comprising: (a) measuring the number of OX40+, CD4+ OX40+ Foxp3+,
or CD4+ OX40+ Foxp3- lymphocytes in a sample comprising metastatic
cancer cells and lymphocytes obtained from the subject; and (b)
determining the prognosis of the subject based on the number of
OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in the
sample, as compared with a reference, wherein an increased number
of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in
the sample indicates that the subject may have an improved
prognosis.
37. The method of claim 36, wherein the improved prognosis
comprises increased overall survival.
38. The method of claim 36, wherein the improved prognosis
comprises increased progression-free survival.
39. A method for treating or delaying progression of cancer in a
subject, comprising: (a) measuring the number of OX40+, CD4+ OX40+
Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in a sample comprising
metastatic cancer cells and lymphocytes obtained from the subject;
(b) determining the number of OX40+, CD4+ OX40+ Foxp3+, or CD4+
OX40+ Foxp3- lymphocytes in the sample, as compared with a
reference; and (c) if the number of OX40+, CD4+ OX40+ Foxp3+, or
CD4+ OX40+ Foxp3- lymphocytes in the sample is higher than the
reference, administering to the subject an effective amount of an
OX40 agonist.
40. A method for treating or delaying progression of cancer in a
subject, comprising administering to the subject an effective
amount of an OX40 agonist, wherein a sample comprising metastatic
cancer cells and lymphocytes obtained from the subject has an
increased number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3-
lymphocytes, as compared with a reference.
41. A method for predicting responsiveness of a subject having
cancer to an OX40 agonist treatment, comprising: (a) measuring the
number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3-
lymphocytes in a sample comprising metastatic cancer cells and
lymphocytes obtained from the subject; and (b) classifying the
subject as a responsive or non-responsive subject based on the
number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3-
lymphocytes in the sample, as compared with a reference, wherein an
increased number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3-
lymphocytes in the sample indicates the subject may be responsive
to the OX40 agonist treatment.
42. The method of claim 39, wherein the number of OX40+, CD4+ OX40+
Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes is a median, mean or
average number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3-
lymphocytes in different regions of interest in the sample from the
subject.
43. The method of claim 42, wherein the number of OX40+, CD4+ OX40+
Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes is normalized to total
cells in the region in the sample.
44. The method of claim 39, wherein the reference is based on the
number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3-
lymphocytes in a sample comprising metastatic cancer cells and
lymphocytes obtained from a cancer having the same type and/or
stage as the cancer of the subject.
45. The method of claim 44, wherein the reference is a median,
mean, or average number of CD4+ OX40+ Foxp3+ lymphocytes in samples
obtained from cancers having the same type and/or stage as the
cancer of the subject.
46. The method of claim 39, wherein the OX40 agonist is an agonist
anti-human OX40 antibody.
47-51. (canceled)
52. The method of claim 46, wherein the antibody comprises (a)
HVR-H1 comprising the amino acid sequence of SEQ ID NO:2, 8 or 9;
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:3, 10,
11, 12, 13, or 14; (c) HVR-H3 comprising the amino acid sequence of
SEQ ID NO:4, 15 or 19; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising an amino acid
sequence selected from SEQ ID NO:7, 22, 23, 24, 25, 26, 27 or
28.
53-55. (canceled)
56. The method of claim 46, wherein the antibody is MEDI6469 or
MEDI0562.
57. The method of claim 39, wherein the OX40 agonist comprises one
or more extracellular domains of OX40L.
58. (canceled)
59. (canceled)
60. The method of claim 39, wherein the cancer is selected from the
group consisting of non-small cell lung cancer, renal cell
carcinoma, bladder cancer, ovarian cancer, glioblastoma,
neuroblastoma, melanoma, triple-negative breast carcinoma, gastric
cancer, colorectal cancer, and hepatocellular carcinoma.
61. (canceled)
62. (canceled)
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priority benefit of U.S.
Provisional Application Ser. No. 62/074,594, filed on Nov. 3, 2014,
which is incorporated herein by reference in its entirety.
SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE
[0002] The content of the following submission on ASCII text file
is incorporated herein by reference in its entirety: a computer
readable form (CRF) of the Sequence Listing (file name:
146392029000SEQLIST.TXT, date recorded: Nov. 2, 2015 size: 185
KB).
FIELD
[0003] The present disclosure relates to assays for detecting T
cell immune subsets, as well as methods for determining prognosis,
predicting responsiveness to treatment, and methods of treatment
related thereto.
BACKGROUND
[0004] OX40 (also known as CD134, TNFRSF4 and ACT35) is a member of
the tumor necrosis factor receptor superfamily. OX40 is not
constitutively expressed on naive T cells, but is induced after
engagement of the T cell receptor (TCR). The ligand for OX40,
OX40L, is predominantly expressed on antigen presenting cells. OX40
is highly expressed by activated CD4+ T cells, activated CD8+ T
cells, memory T cells, and regulatory T cells. OX40 signaling can
provide costimulatory signals to CD4 and CD8 T cells, leading to
enhanced cell proliferation, survival, effector function and
migration. OX40 signaling also enhances memory T cell development
and function.
[0005] Regulatory T cells (Treg) cells are highly enriched in
tumors and tumor draining lymph nodes derived from multiple cancer
indications, including melanoma, NSCLC, renal, ovarian, colon,
pancreatic, hepatocellular, and breast cancer. In a subset of these
indications, increased intratumoral T reg cell densities are
associated with poor patient prognosis, suggesting that these cells
play an important role in suppressing antitumor immunity. OX40
positive tumor infiltrating lymphocytes have been described.
[0006] It is clear that there continues to be a need for
diagnostic, prognostic, and predictive methods to identify patients
that are more likely to benefit from anti-tumor treatments that
modulate OX40 activity. The invention described herein meets this
need and provides other benefits.
[0007] All references cited herein, including patent applications,
patent publications, and UniProtKB/Swiss-Prot Accession numbers are
herein incorporated by reference in their entirety, as if each
individual reference were specifically and individually indicated
to be incorporated by reference.
BRIEF SUMMARY
[0008] The present disclosure describes assays for detecting T cell
immune subsets, as well as methods of using these assays to
determine prognosis, predict responsiveness, and/or treating or
delay progress of cancer.
[0009] In certain aspects, the present disclosure provides a method
for determining prognosis of a subject having cancer, comprising:
(a) measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a
sample comprising cancer cells and lymphocytes obtained from the
subject; and (b) determining the prognosis of the subject based on
the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample, as
compared with a reference, wherein an increased number of CD4+
OX40+ Foxp3+ lymphocytes in the sample indicates that the subject
may have an improved prognosis. In some embodiments, the improved
prognosis comprises increased overall survival. In some
embodiments, the improved prognosis comprises increased
progression-free survival.
[0010] In certain aspects, the present disclosure provides a method
for treating or delaying progression of cancer in a subject,
comprising: (a) measuring the number of CD4+ OX40+ Foxp3+
lymphocytes in a sample comprising cancer cells and lymphocytes
obtained from the subject; (b) determining the number of CD4+ OX40+
Foxp3+ lymphocytes in the sample, as compared with a reference; and
(c) if the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample is
higher than the reference, administering to the subject an
effective amount of an OX40 agonist.
[0011] In certain aspects, the present disclosure provides a method
for treating or delaying progression of cancer in a subject,
comprising administering to the subject an effective amount of an
OX40 agonist, wherein a sample comprising cancer cells and
lymphocytes obtained from the subject has an increased number of
CD4+ OX40+ Foxp3+ lymphocytes, as compared with a reference. In
some embodiments, the subject has been tested to determine if a
sample comprising cancer cells and lymphocytes obtained from the
subject has an increased number of CD4+ OX40+ Foxp3+ lymphocytes as
compared with a reference before treatment or is selected for
treatment based on a sample comprising cancer cells and lymphocytes
obtained from the subject has an increased number of CD4+ OX40+
Foxp3+ lymphocytes as compared with a reference.
[0012] In certain aspects, the present disclosure provides a method
for predicting responsiveness of a subject having cancer to an OX40
agonist treatment, comprising: (a) measuring the number of CD4+
OX40+ Foxp3+ lymphocytes in a sample comprising cancer cells and
lymphocytes obtained from the subject; and (b) classifying the
subject as a responsive or non-responsive subject based on the
number of CD4+ OX40+ Foxp3+ lymphocytes in the sample, as compared
with a reference, wherein an increased number of CD4+ OX40+ Foxp3+
lymphocytes in the sample indicates the subject may be responsive
to the OX40 agonist treatment.
[0013] In some embodiments, the number of CD4+ OX40+ Foxp3+
lymphocytes in one or more regions of interest in the sample of a
subject is measured. In some embodiments, the region of interest
includes tumor cells and stroma. In some embodiments, the number of
CD4+ OX40+ Foxp3+ lymphocytes is a median, mean or average number
of CD4+ OX40+ Foxp3+ lymphocytes in different regions of interest
of the sample from the subject. In some embodiments, the number of
CD4+ OX40+ Foxp3+ lymphocytes is normalized to total cells in the
region of interest of the sample. In some embodiments, the
reference is based on the number of CD4+ OX40+ Foxp3+ lymphocytes
in a sample comprising cancer cells and lymphocytes obtained from a
cancer having the same type and/or stage as the cancer of the
subject. In some embodiments, the reference is a median, mean, or
average number of CD4+ OX40+ Foxp3+ lymphocytes in samples obtained
from cancers having the same type and/or stage as the cancer of the
subject. In some embodiments, the OX40 agonist is an agonist
anti-human OX40 antibody. In some embodiments, the antibody is a
monoclonal antibody. In some embodiments, the antibody is a
humanized or human antibody. In some embodiments, the antibody
comprises an IgG1 Fc region. In some embodiments, the antibody
comprises an IgG4 Fc region. In some embodiments, the antibody
comprises an Fc region comprising a mutation that decreases binding
to an Fc receptor. In some embodiments, the antibody comprises (a)
HVR-H1 comprising the amino acid sequence of SEQ ID NO:2, 8 or 9;
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:3, 10,
11, 12, 13, or 14; (c) HVR-H3 comprising the amino acid sequence of
SEQ ID NO:4, 15 or 19; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising an amino acid
sequence selected from SEQ ID NO:7, 22, 23, 24, 25, 26, 27 or 28.
In some embodiments, the antibody comprises (a) HVR-H1 comprising
the amino acid sequence of SEQ ID NO:2; (b) HVR-H2 comprising the
amino acid sequence of SEQ ID NO:3; (c) HVR-H3 comprising the amino
acid sequence of SEQ ID NO:4; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising an amino acid
sequence selected from SEQ ID NO:7. In some embodiments, the
antibody comprises (a) HVR-H1 comprising the amino acid sequence of
SEQ ID NO:2; (b) HVR-H2 comprising the amino acid sequence of SEQ
ID NO:3; (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:4; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:5;
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and
(f) HVR-L3 comprising an amino acid sequence selected from SEQ ID
NO:26. In some embodiments, the antibody comprises (a) HVR-H1
comprising the amino acid sequence of SEQ ID NO:2; (b) HVR-H2
comprising the amino acid sequence of SEQ ID NO:3; (c) HVR-H3
comprising the amino acid sequence of SEQ ID NO:4; (d) HVR-L1
comprising the amino acid sequence of SEQ ID NO:5; (e) HVR-L2
comprising the amino acid sequence of SEQ ID NO:6; and (f) HVR-L3
comprising an amino acid sequence selected from SEQ ID NO:27. In
some embodiments, the antibody is MEDI6469 or MEDI0562. In some
embodiments, the OX40 agonist comprises one or more extracellular
domains of OX40L. In some embodiments, the OX40 agonist is
MEDI6383. In some embodiments, measuring the number of CD4+ OX40+
Foxp3+ lymphocytes in the sample comprises: (a) labeling
lymphocytes that show CD4 expression in the sample; (b) labeling
lymphocytes that show OX40 expression in the sample after step (a);
(c) labeling lymphocytes that show Foxp3 expression in the sample
after step (b); and (d) measuring the number of CD4+ OX40+ Foxp3+
lymphocytes in the sample after step (c).
[0014] In certain aspects, the present disclosure provides a method
for measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a
sample comprising cancer cells and lymphocytes obtained from a
subject, comprising the steps of: (a) labeling lymphocytes that
show CD4 expression in the sample; (b) labeling lymphocytes that
show OX40 expression in the sample after step (a); (c) labeling
lymphocytes that show Foxp3 expression in the sample after step
(b); and (d) measuring the number of CD4+ OX40+ Foxp3+ lymphocytes
in the sample after step (c). In some embodiments, the sample is
treated with a solution comprising EDTA or citrate buffer between
steps (a) and (b) and/or between steps (b) and (c). In some
embodiments, lymphocytes showing CD4 expression, OX40 expression,
and Foxp3 expression are labeled by immunofluorescence staining. In
some embodiments, lymphocytes showing OX40 expression are labeled
using an antibody comprising (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:2; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:3; (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO:4; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising an amino acid
sequence selected from SEQ ID NO:7, 26 or 27. In some embodiments,
quantifying the number of CD4+ OX40+ Foxp3+ lymphocytes in the
sample comprises imaging said immunofluorescence staining.
[0015] In some embodiments, the cancer is colorectal cancer. In
some embodiments, the cancer is selected from the group consisting
of non-small cell lung cancer, renal cell carcinoma, bladder
cancer, ovarian cancer, glioblastoma, neuroblastoma, melanoma,
breast carcinoma, gastric cancer, and hepatocellular carcinoma. In
some embodiments, the breast carcinoma is triple-negative breast
carcinoma. In some embodiments, the sample comprising cancer cells
and lymphocytes, wherein said cancer cells are from a primary
tumor. In some embodiments, the sample comprising cancer cells and
lymphocytes, wherein said cancer cells are from a metastasis. In
some embodiments, the CD4+ OX40+ Foxp3+ lymphocytes are
tumor-infiltrating lymphocytes.
[0016] In certain aspects, the present disclosure provides a method
for determining prognosis of a subject having cancer, comprising:
(a) measuring the number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+
Foxp3- lymphocytes in a sample comprising metastatic cancer cells
and lymphocytes obtained from the subject; and (b) determining the
prognosis of the subject based on the number of OX40+, CD4+ OX40+
Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in the sample, as compared
with a reference, wherein an increased number of OX40+, CD4+ OX40+
Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in the sample indicates
that the subject may have an improved prognosis. In some
embodiments, the improved prognosis comprises increased overall
survival. In some embodiments, the improved prognosis comprises
increased progression-free survival.
[0017] In certain aspects, the present disclosure provides a method
for treating or delaying progression of cancer in a subject,
comprising: (a) measuring the number of OX40+, CD4+ OX40+ Foxp3+,
or CD4+ OX40+ Foxp3- lymphocytes in a sample comprising metastatic
cancer cells and lymphocytes obtained from the subject; (b)
determining the number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+
Foxp3- lymphocytes in the sample, as compared with a reference; and
(c) if the number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3-
lymphocytes in the sample is higher than the reference,
administering to the subject an effective amount of an OX40
agonist.
[0018] In certain aspects, the present disclosure provides a method
for treating or delaying progression of cancer in a subject,
comprising administering to the subject an effective amount of an
OX40 agonist, wherein a sample comprising metastatic cancer cells
and lymphocytes obtained from the subject has an increased number
of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes, as
compared with a reference.
[0019] In certain aspects, the present disclosure provides a method
for predicting responsiveness of a subject having cancer to an OX40
agonist treatment, comprising: (a) measuring the number of OX40+,
CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in a sample
comprising metastatic cancer cells and lymphocytes obtained from
the subject; and (b) classifying the subject as a responsive or
non-responsive subject based on the number of OX40+, CD4+ OX40+
Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in the sample, as compared
with a reference, wherein an increased number of OX40+, CD4+ OX40+
Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in the sample indicates
the subject may be responsive to the OX40 agonist treatment.
[0020] In some embodiments, the number of OX40+, CD4+ OX40+ Foxp3+,
or CD4+ OX40+ Foxp3- lymphocytes in one or more regions of interest
in the sample of a subject is measured. In some embodiments, the
region of interest includes metastatic cancer cells and stroma. In
some embodiments, the number of OX40+, CD4+ OX40+ Foxp3+, or CD4+
OX40+ Foxp3- lymphocytes is a median, mean or average number of
OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in
different regions of interest in the sample from the subject. In
some embodiments, the number of OX40+, CD4+ OX40+ Foxp3+, or CD4+
OX40+ Foxp3- lymphocytes is normalized to total cells in the region
of interest in the sample. In some embodiments, the reference is
based on the number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+
Foxp3- lymphocytes in a sample comprising metastatic cancer cells
and lymphocytes obtained from a cancer having the same type and/or
stage as the cancer of the subject. In some embodiments, the
reference is a median, mean, or average number of CD4+ OX40+ Foxp3+
lymphocytes in samples obtained from cancers having the same type
and/or stage as the cancer of the subject. In some embodiments, the
OX40 agonist is an agonist anti-human OX40 antibody. In some
embodiments, the antibody is a monoclonal antibody. In some
embodiments, the antibody is a humanized or human antibody. In some
embodiments, the antibody comprises an IgG1 Fc region. In some
embodiments, the antibody comprises an IgG4 Fc region. In some
embodiments, the antibody comprises an Fc region comprising a
mutation that decreases binding to an Fc receptor. In some
embodiments, the antibody comprises (a) HVR-H1 comprising the amino
acid sequence of SEQ ID NO:2, 8 or 9; (b) HVR-H2 comprising the
amino acid sequence of SEQ ID NO:3, 10, 11, 12, 13, or 14; (c)
HVR-H3 comprising the amino acid sequence of SEQ ID NO:4, 15 or 19;
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (e)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (f)
HVR-L3 comprising an amino acid sequence selected from SEQ ID NO:7,
22, 23, 24, 25, 26, 27 or 28. In some embodiments, the antibody
comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO:2; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:3;
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:4; (d)
HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (e)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (f)
HVR-L3 comprising an amino acid sequence selected from SEQ ID NO:7.
In some embodiments, the antibody comprises (a) HVR-H1 comprising
the amino acid sequence of SEQ ID NO:2; (b) HVR-H2 comprising the
amino acid sequence of SEQ ID NO:3; (c) HVR-H3 comprising the amino
acid sequence of SEQ ID NO:4; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising an amino acid
sequence selected from SEQ ID NO:26. In some embodiments, the
antibody comprises (a) HVR-H1 comprising the amino acid sequence of
SEQ ID NO:2; (b) HVR-H2 comprising the amino acid sequence of SEQ
ID NO:3; (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:4; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:5;
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and
(f) HVR-L3 comprising an amino acid sequence selected from SEQ ID
NO:27. In some embodiments, the antibody is MEDI6469 or MEDI0562.
In some embodiments, the OX40 agonist comprises one or more
extracellular domains of OX40L. In some embodiments, the OX40
agonist is MEDI6383. In some embodiments, the cancer is colorectal
cancer. In some embodiments, the cancer is selected from the group
consisting of non-small cell lung cancer, renal cell carcinoma,
bladder cancer, ovarian cancer, glioblastoma, neuroblastoma,
melanoma, breast carcinoma, gastric cancer, and hepatocellular
carcinoma. In some embodiments, the breast carcinoma is
triple-negative breast carcinoma. In some embodiments, the OX40+,
CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes are
tumor-infiltrating lymphocytes.
[0021] It is to be understood that one, some, or all of the
properties of the various embodiments described above and herein
may be combined to form other embodiments of the present invention.
These and other aspects of the invention will become apparent to
one of skill in the art. These and other embodiments of the
invention are further described by the detailed description that
follows.
BRIEF DESCRIPTION OF THE DRAWINGS
[0022] FIGS. 1A-1C show representative images of triple
immunofluorescence staining for expression of CD4 (green), OX40
(white), and Foxp3 (red) on stage I colorectal cancer samples. Cell
nuclei are counter-stained using DAPI (blue). Exemplary Treg and
Teff cells are labeled.
[0023] FIGS. 2A-2C show representative images of triple
immunofluorescence staining for expression of CD4 (green), OX40
(white), and Foxp3 (red) on stage II colorectal cancer samples.
Cell nuclei are counter-stained using DAPI (blue).
[0024] FIGS. 3A-3C show representative images of triple
immunofluorescence staining for expression of CD4 (green), OX40
(white), and Foxp3 (red) on stage III colorectal cancer samples.
Cell nuclei are counter-stained using DAPI (blue).
[0025] FIGS. 4A-4C show representative images of triple
immunofluorescence staining for expression of CD4 (green), OX40
(white), and Foxp3 (red) on stage IV colorectal cancer samples.
Cell nuclei are counter-stained using DAPI (blue).
[0026] FIGS. 5A-5C show the correlation between the number of cells
in a sample showing expression of specific marker(s) and cancer
stage at diagnosis. Mean counts of cells that are positive for
expression of specific markers are provided as follows: CD4+ (FIG.
5A), Foxp3+ (FIG. 5B), and OX40+ (FIG. 5C).
[0027] FIGS. 6A-6D show the correlation between the number of cells
in a sample showing expression of specific marker(s) and cancer
stage at diagnosis. Mean counts of cells that are positive for
specific markers are provided as follows: OX40+ CD4+ (FIG. 6A),
OX40+ CD4- (FIG. 6B), OX40+ CD4+ Foxp3+ (FIG. 6C), and OX40+ CD4+
Foxp3- (FIG. 6D).
[0028] FIGS. 7A-7C show the correlation between overall survival
and the number of cells in a sample showing expression of specific
marker(s). Overall survival is shown for patients whose samples
contained greater than or less than the median count (as labeled)
of the following cell types: CD4+ (FIG. 7A), Foxp3+ (FIG. 7B), and
OX40+ (FIG. 7C). P values reflecting the difference between overall
survival of patients whose samples showed cell counts above and
below the median are indicated for each cell type.
[0029] FIGS. 8A-8D show the correlation between overall survival
and the number of cells in a sample showing expression of specific
marker(s). Overall survival is shown for patients whose samples
contained greater than or less than the median count (as labeled)
of the following cell types: OX40+ CD4+ (FIG. 8A), OX40+ CD4- (FIG.
8B), OX40+ CD4+ Foxp3+ (FIG. 8C), and OX40+CD4+ Foxp3- (FIG. 8D). P
values reflecting the difference between overall survival of
patients whose samples showed cell counts above and below the
median are indicated for each cell type.
[0030] FIGS. 9A-9C show the correlation between the number of cells
showing expression of specific marker(s) in paired primary and
metastatic samples (n=19). Mean counts of cells that are positive
for expression of specific markers, normalized to total number of
cells, are provided as follows: CD4+ (FIG. 9A), Foxp3+ (FIG. 9B),
and OX40+ (FIG. 9C). Tissue types are as labeled: Brain (BN), Bone
(BO-Rib), Lymph node (LN), Lung (LU), Liver (LV), Omentum (OM),
Ovary (OV), and Soft tissue/retroperitoneum (SOT-Ret).
[0031] FIGS. 10A-10D show the correlation between the number of
cells showing expression of specific marker(s) in paired primary
and metastatic samples (n=19). Mean counts of cells that are
positive for expression of specific markers, normalized to total
number of cells, are provided as follows: OX40+ CD4+ (FIG. 10A),
OX40+ CD4- (FIG. 10B), OX40+ CD4+ Foxp3+ (FIG. 10C), and OX40+ CD4+
Foxp3- (FIG. 10D). Tissue types are as labeled: Brain (BN), Bone
(BO-Rib), Lymph node (LN), Lung (LU), Liver (LV), Omentum (OM),
Ovary (OV), and Soft tissue/retroperitoneum (SOT-Ret).
[0032] FIGS. 11A-11D provide the results of multivariate Cox model
analyses of CD4 expression (FIG. 11A), OX40 expression (FIG. 11B),
Foxp3 expression (FIG. 11C), and the ratio of OX40+ Teff cells to
OX40+ Treg cells (OX40 Teff/Treg) (FIG. 11D) adjusted for age,
gender and stage (n=32/39).
DETAILED DESCRIPTION
I. General Techniques
[0033] The techniques and procedures described or referenced herein
are generally well understood and commonly employed using
conventional methodology by those skilled in the art, such as, for
example, the widely utilized methodologies described in Sambrook et
al., Molecular Cloning: A Laboratory Manual 3d edition (2001) Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Current
Protocols in Molecular Biology (F. M. Ausubel, et al. eds.,
(2003)); the series Methods in Enzymology (Academic Press, Inc.):
PCR 2: A Practical Approach (M. J. MacPherson, B. D. Hames and G.
R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) Antibodies, A
Laboratory Manual, and Animal Cell Culture (R. I. Freshney, ed.
(1987)); Oligonucleotide Synthesis (M. J. Gait, ed., 1984); Methods
in Molecular Biology, Humana Press; Cell Biology: A Laboratory
Notebook (J. E. Cellis, ed., 1998) Academic Press; Animal Cell
Culture (R. I. Freshney), ed., 1987); Introduction to Cell and
Tissue Culture (J. P. Mather and P. E. Roberts, 1998) Plenum Press;
Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J. B.
Griffiths, and D. G. Newell, eds., 1993-8) J. Wiley and Sons;
Handbook of Experimental Immunology (D. M. Weir and C. C.
Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (J. M.
Miller and M. P. Calos, eds., 1987); PCR: The Polymerase Chain
Reaction, (Mullis et al., eds., 1994); Current Protocols in
Immunology (J. E. Coligan et al., eds., 1991); Short Protocols in
Molecular Biology (Wiley and Sons, 1999); Immunobiology (C. A.
Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997);
Antibodies: A Practical Approach (D. Catty., ed., IRL Press,
1988-1989); Monoclonal Antibodies: A Practical Approach (P.
Shepherd and C. Dean, eds., Oxford University Press, 2000); Using
Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring
Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and J.
D. Capra, eds., Harwood Academic Publishers, 1995); and Cancer:
Principles and Practice of Oncology (V. T. DeVita et al., eds.,
J.B. Lippincott Company, 1993).
II. Definitions
[0034] Before describing the invention in detail, it is to be
understood that this invention is not limited to particular
compositions or biological systems, which can, of course, vary. It
is also to be understood that the terminology used herein is for
the purpose of describing particular embodiments only, and is not
intended to be limiting.
[0035] As used herein and in the appended claims, the singular
forms "a," "or," and "the" include plural referents unless the
context clearly dictates otherwise.
[0036] Reference to "about" a value or parameter herein includes
(and describes) variations that are directed to that value or
parameter per se. For example, description referring to "about X"
includes description of "X".
[0037] It is understood that aspects and variations of the
invention described herein include "consisting" and/or "consisting
essentially of" aspects and variations.
[0038] The term "dysfunction" in the context of immune dysfunction,
refers to a state of reduced immune responsiveness to antigenic
stimulation.
[0039] The term "dysfunctional", as used herein, also includes
refractory or unresponsive to antigen recognition, specifically,
impaired capacity to translate antigen recognition into downstream
T-cell effector functions, such as proliferation, cytokine
production (e.g., gamma interferon) and/or target cell killing.
[0040] "Enhancing T cell function" means to induce, cause or
stimulate an effector or memory T cell to have a renewed, sustained
or amplified biological function. Examples of enhancing T-cell
function include: increased secretion of .gamma.-interferon from
CD8.sup.+ effector T cells, increased secretion of
.gamma.-interferon from CD4+ memory and/or effector T-cells,
increased proliferation of CD4+ effector and/or memory T cells,
increased proliferation of CD8+ effector T-cells, increased antigen
responsiveness (e.g., clearance), relative to such levels before
the intervention. In one embodiment, the level of enhancement is at
least 50%, alternatively 60%, 70%, 80%, 90%, 100%, 120%, 150%,
200%. The manner of measuring this enhancement is known to one of
ordinary skill in the art.
[0041] "Tumor immunity" refers to the process in which tumors evade
immune recognition and clearance. Thus, as a therapeutic concept,
tumor immunity is "treated" when such evasion is attenuated, and
the tumors are recognized and attacked by the immune system.
Examples of tumor recognition include tumor binding, tumor
shrinkage and tumor clearance.
[0042] "Immunogenicity" refers to the ability of a particular
substance to provoke an immune response. Tumors are immunogenic and
enhancing tumor immunogenicity aids in the clearance of the tumor
cells by the immune response.
[0043] An "acceptor human framework" for the purposes herein is a
framework comprising the amino acid sequence of a light chain
variable domain (VL) framework or a heavy chain variable domain
(VH) framework derived from a human immunoglobulin framework or a
human consensus framework, as defined below. An acceptor human
framework "derived from" a human immunoglobulin framework or a
human consensus framework may comprise the same amino acid sequence
thereof, or it may contain amino acid sequence changes. In some
embodiments, the number of amino acid changes are 10 or less, 9 or
less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or
less, or 2 or less. In some embodiments, the VL acceptor human
framework is identical in sequence to the VL human immunoglobulin
framework sequence or human consensus framework sequence.
[0044] "Affinity" refers to the strength of the sum total of
noncovalent interactions between a single binding site of a
molecule (e.g., an antibody) and its binding partner (e.g., an
antigen). Unless indicated otherwise, as used herein, "binding
affinity" refers to intrinsic binding affinity which reflects a 1:1
interaction between members of a binding pair (e.g., antibody and
antigen). The affinity of a molecule X for its partner Y can
generally be represented by the dissociation constant (Kd).
Affinity can be measured by common methods known in the art,
including those described herein. Specific illustrative and
exemplary embodiments for measuring binding affinity are described
in the following.
[0045] An "agonist antibody," as used herein, is an antibody which
activates a biological activity of the antigen it binds.
[0046] An "anti-angiogenic agent" refers to a compound which
blocks, or interferes with to some degree, the development of blood
vessels. An anti-angiogenic agent may, for instance, be a small
molecule or antibody that binds to a growth factor or growth factor
receptor involved in promoting angiogenesis. In one embodiment, an
anti-angiogenic agent is an antibody that binds to vascular
endothelial growth factor (VEGF), such as bevacizumab
(AVASTIN).
[0047] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC"
refers to a form of cytotoxicity in which secreted immunoglobulin
bound onto Fc receptors (FcRs) present on certain cytotoxic cells
(e.g. NK cells, neutrophils, and macrophages) enable these
cytotoxic effector cells to bind specifically to an antigen-bearing
target cell and subsequently kill the target cell with cytotoxins.
The primary cells for mediating ADCC, NK cells, express
Fc.gamma.RIII only, whereas monocytes express Fc.gamma.RI,
Fc.gamma.RII, and Fc.gamma.RIII. FcR expression on hematopoietic
cells is summarized in Table 3 on page 464 of Ravetch and Kinet,
Annu. Rev. Immunol 9:457-92 (1991). To assess ADCC activity of a
molecule of interest, an in vitro ADCC assay, such as that
described in U.S. Pat. No. 5,500,362 or 5,821,337 or U.S. Pat. No.
6,737,056 (Presta), may be performed. Useful effector cells for
such assays include PBMC and NK cells. Alternatively, or
additionally, ADCC activity of the molecule of interest may be
assessed in vivo, e.g., in an animal model such as that disclosed
in Clynes et al. PNAS (USA) 95:652-656 (1998). An exemplary assay
for assessing ADCC activity is provided in the examples herein.
[0048] The terms "anti-OX40 antibody" and "an antibody that binds
to OX40" refer to an antibody that is capable of binding OX40 with
sufficient affinity such that the antibody is useful as a
diagnostic and/or therapeutic agent in targeting OX40. In one
embodiment, the extent of binding of an anti-OX40 antibody to an
unrelated, non-OX40 protein is less than about 10% of the binding
of the antibody to OX40 as measured, e.g., by a radioimmunoassay
(RIA). In certain embodiments, an antibody that binds to OX40 has a
dissociation constant (Kd) of .ltoreq.1 .mu.M, .ltoreq.100 nM,
.ltoreq.10 nM, .ltoreq.1 nM, .ltoreq.0.1 nM, .ltoreq.0.01 nM, or
.ltoreq.0.001 nM (e.g. 10.sup.-8 M or less, e.g. from 10.sup.-8 M
to 10.sup.-13 M, e.g., from 10.sup.-9 M to 10.sup.-13 M). In
certain embodiments, an anti-OX40 antibody binds to an epitope of
OX40 that is conserved among OX40 from different species.
[0049] As use herein, the term "binds", "specifically binds to" or
is "specific for" refers to measurable and reproducible
interactions such as binding between a target and an antibody,
which is determinative of the presence of the target in the
presence of a heterogeneous population of molecules including
biological molecules. For example, an antibody that binds to or
specifically binds to a target (which can be an epitope) is an
antibody that binds this target with greater affinity, avidity,
more readily, and/or with greater duration than it binds to other
targets. In one embodiment, the extent of binding of an antibody to
an unrelated target is less than about 10% of the binding of the
antibody to the target as measured, e.g., by a radioimmunoassay
(RIA). In certain embodiments, an antibody that specifically binds
to a target has a dissociation constant (Kd) of .ltoreq.1 .mu.M,
.ltoreq.100 nM, .ltoreq.10 nM, .ltoreq.1 nM, or .ltoreq.0.1 nM. In
certain embodiments, an antibody specifically binds to an epitope
on a protein that is conserved among the protein from different
species. In another embodiment, specific binding can include, but
does not require exclusive binding.
[0050] The term "antibody" herein is used in the broadest sense and
encompasses various antibody structures, including but not limited
to monoclonal antibodies, polyclonal antibodies, multispecific
antibodies (e.g., bispecific antibodies), and antibody fragments so
long as they exhibit the desired antigen-binding activity.
[0051] An "antibody fragment" refers to a molecule other than an
intact antibody that comprises a portion of an intact antibody that
binds the antigen to which the intact antibody binds. Examples of
antibody fragments include but are not limited to Fv, Fab, Fab',
Fab'-SH, F(ab').sub.2; diabodies; linear antibodies; single-chain
antibody molecules (e.g. scFv); and multispecific antibodies formed
from antibody fragments.
[0052] An "antibody that binds to the same epitope" as a reference
antibody refers to an antibody that blocks binding of the reference
antibody to its antigen in a competition assay by 50% or more, and
conversely, the reference antibody blocks binding of the antibody
to its antigen in a competition assay by 50% or more. An exemplary
competition assay is provided herein.
[0053] The term "binding domain" refers to the region of a
polypeptide that binds to another molecule. In the case of an FcR,
the binding domain can comprise a portion of a polypeptide chain
thereof (e.g. the alpha chain thereof) which is responsible for
binding an Fc region. One useful binding domain is the
extracellular domain of an FcR alpha chain.
[0054] A polypeptide with a variant IgG Fc with "altered" FcR, ADCC
or phagocytosis activity is one which has either enhanced or
diminished FcR binding activity (e.g, Fc.gamma.R) and/or ADCC
activity and/or phagocytosis activity compared to a parent
polypeptide or to a polypeptide comprising a native sequence Fc
region.
[0055] The term "OX40," as used herein, refers to any native OX40
from any vertebrate source, including mammals such as primates
(e.g. humans) and rodents (e.g., mice and rats), unless otherwise
indicated. The term encompasses "full-length," unprocessed OX40 as
well as any form of OX40 that results from processing in the cell.
The term also encompasses naturally occurring variants of OX40,
e.g., splice variants or allelic variants. The amino acid sequence
of an exemplary human OX40 is shown in SEQ ID NO:1.
[0056] "OX40 activation" refers to activation, of the OX40
receptor. Generally, OX40 activation results in signal
transduction.
[0057] The terms "cancer" and "cancerous" refer to or describe the
physiological condition in mammals that is typically characterized
by unregulated cell growth. Examples of cancer include but are not
limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or
lymphoid malignancies. More particular examples of such cancers
include, but not limited to, squamous cell cancer (e.g., epithelial
squamous cell cancer), lung cancer including small-cell lung
cancer, non-small cell lung cancer, adenocarcinoma of the lung and
squamous carcinoma of the lung, cancer of the peritoneum,
hepatocellular cancer, gastric or stomach cancer including
gastrointestinal cancer and gastrointestinal stromal cancer,
pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer,
liver cancer, bladder cancer, cancer of the urinary tract,
hepatoma, breast cancer, colon cancer, rectal cancer, colorectal
cancer, endometrial or uterine carcinoma, salivary gland carcinoma,
kidney or renal cancer, prostate cancer, vulval cancer, thyroid
cancer, hepatic carcinoma, anal carcinoma, penile carcinoma,
melanoma, superficial spreading melanoma, lentigo maligna melanoma,
acral lentiginous melanomas, nodular melanomas, multiple myeloma
and B-cell lymphoma; chronic lymphocytic leukemia (CLL); acute
lymphoblastic leukemia (ALL); hairy cell leukemia; chronic
myeloblastic leukemia; and post-transplant lymphoproliferative
disorder (PTLD), as well as abnormal vascular proliferation
associated with phakomatoses, edema (such as that associated with
brain tumors), Meigs' syndrome, brain, as well as head and neck
cancer, and associated metastases. In certain embodiments, cancers
that are amenable to treatment by the antibodies of the invention
include breast cancer, colorectal cancer, rectal cancer, non-small
cell lung cancer, glioblastoma, non-Hodgkins lymphoma (NHL), renal
cell cancer, prostate cancer, liver cancer, pancreatic cancer,
soft-tissue sarcoma, kaposi's sarcoma, carcinoid carcinoma, head
and neck cancer, ovarian cancer, mesothelioma, and multiple
myeloma. In some embodiments, the cancer is selected from:
non-small cell lung cancer, glioblastoma, neuroblastoma, melanoma,
breast carcinoma (e.g. triple-negative breast cancer), gastric
cancer, colorectal cancer (CRC), and hepatocellular carcinoma. Yet,
in some embodiments, the cancer is selected from: non-small cell
lung cancer, colorectal cancer, glioblastoma and breast carcinoma
(e.g. triple-negative breast cancer), including metastatic forms of
those cancers.
[0058] The term "tumor" refers to all neoplastic cell growth and
proliferation, whether malignant or benign, and all pre-cancerous
and cancerous cells and tissues. The terms "cancer," "cancerous,"
"cell proliferative disorder," "proliferative disorder" and "tumor"
are not mutually exclusive as referred to herein.
[0059] The terms "cell proliferative disorder" and "proliferative
disorder" refer to disorders that are associated with some degree
of abnormal cell proliferation. In one embodiment, the cell
proliferative disorder is cancer.
[0060] The term "chimeric" antibody refers to an antibody in which
a portion of the heavy and/or light chain is derived from a
particular source or species, while the remainder of the heavy
and/or light chain is derived from a different source or
species.
[0061] The "class" of an antibody refers to the type of constant
domain or constant region possessed by its heavy chain. There are
five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and
several of these may be further divided into subclasses (isotypes),
e.g., IgG.sub.1, IgG.sub.2, IgG.sub.3, IgG.sub.4, IgA.sub.1, and
IgA.sub.2. The heavy chain constant domains that correspond to the
different classes of immunoglobulins are called .alpha., .delta.,
.epsilon., .gamma., and .mu., respectively.
[0062] "Complement dependent cytotoxicity" or "CDC" refers to the
lysis of a target cell in the presence of complement. Activation of
the classical complement pathway is initiated by the binding of the
first component of the complement system (C1q) to antibodies (of
the appropriate subclass), which are bound to their cognate
antigen. To assess complement activation, a CDC assay, e.g., as
described in Gazzano-Santoro et al., J. Immunol. Methods 202:163
(1996), may be performed. Polypeptide variants with altered Fc
region amino acid sequences (polypeptides with a variant Fc region)
and increased or decreased C1q binding capability are described,
e.g., in U.S. Pat. No. 6,194,551 B1 and WO 1999/51642. See also,
e.g., Idusogie et al. J. Immunol. 164: 4178-4184 (2000).
[0063] The term "cytostatic agent" refers to a compound or
composition which arrests growth of a cell either in vitro or in
vivo. Thus, a cytostatic agent may be one which significantly
reduces the percentage of cells in S phase. Further examples of
cytostatic agents include agents that block cell cycle progression
by inducing G0/G1 arrest or M-phase arrest. The humanized anti-Her2
antibody trastuzumab (HERCEPTIN.RTM.) is an example of a cytostatic
agent that induces G0/G1 arrest.
[0064] Classical M-phase blockers include the vincas (vincristine
and vinblastine), taxanes, and topoisomerase II inhibitors such as
doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin.
Certain agents that arrest G1 also spill over into S-phase arrest,
for example, DNA alkylating agents such as tamoxifen, prednisone,
dacarbazine, mechlorethamine, cisplatin, methotrexate,
5-fluorouracil, and ara-C. Further information can be found in
Mendelsohn and Israel, eds., The Molecular Basis of Cancer, Chapter
1, entitled "Cell cycle regulation, oncogenes, and antineoplastic
drugs" by Murakami et al. (W.B. Saunders, Philadelphia, 1995),
e.g., p. 13. The taxanes (paclitaxel and docetaxel) are anticancer
drugs both derived from the yew tree. Docetaxel (TAXOTERE.RTM.,
Rhone-Poulenc Rorer), derived from the European yew, is a
semisynthetic analogue of paclitaxel (TAXOL.RTM., Bristol-Myers
Squibb). Paclitaxel and docetaxel promote the assembly of
microtubules from tubulin dimers and stabilize microtubules by
preventing depolymerization, which results in the inhibition of
mitosis in cells.
[0065] The term "cytotoxic agent" as used herein refers to a
substance that inhibits or prevents a cellular function and/or
causes cell death or destruction. Cytotoxic agents include, but are
not limited to, radioactive isotopes (e.g., At.sup.211, I.sup.131,
I.sup.125, Y.sup.90, Re.sup.186, Re.sup.188, Sm.sup.153,
Bi.sup.212, P.sup.32, Pb.sup.212 and radioactive isotopes of Lu);
chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin,
vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin,
melphalan, mitomycin C, chlorambucil, daunorubicin or other
intercalating agents); growth inhibitory agents; enzymes and
fragments thereof such as nucleolytic enzymes; antibiotics; toxins
such as small molecule toxins or enzymatically active toxins of
bacterial, fungal, plant or animal origin, including fragments
and/or variants thereof; and the various antitumor or anticancer
agents disclosed below.
[0066] A "depleting anti-OX40 antibody," is an anti-OX40 antibody
that kills or depletes OX40-expressing cells. Depletion of OX40
expressing cells can be achieved by various mechanisms, such as
antibody-dependent cell-mediated cytotoxicity and/or phagocytosis.
Depletion of OX40-expressing cells may be assayed in vitro, and
exemplary methods for in vitro ADCC and phagocytosis assays are
provided herein. In some embodiments, the OX40-expressing cell is a
human CD4+ effector T cell. In some embodiments, the
OX40-expressing cell is a transgenic BT474 cell that expresses
human OX40.
[0067] "Effector functions" refer to those biological activities
attributable to the Fc region of an antibody, which vary with the
antibody isotype. Examples of antibody effector functions include:
C1q binding and complement dependent cytotoxicity (CDC); Fc
receptor binding; antibody-dependent cell-mediated cytotoxicity
(ADCC); phagocytosis; down regulation of cell surface receptors
(e.g. B cell receptor); and B cell activation.
[0068] An "effective amount" of an agent, e.g., a pharmaceutical
formulation, refers to an amount effective, at dosages and for
periods of time necessary, to achieve the desired therapeutic or
prophylactic result.
[0069] "Fc receptor" or "FcR" describes a receptor that binds to
the Fc region of an antibody. In some embodiments, an FcR is a
native human FcR. In some embodiments, an FcR is one which binds an
IgG antibody (a gamma receptor) and includes receptors of the
Fc.gamma.RI, Fc.gamma.RII, and Fc.gamma.RII subclasses, including
allelic variants and alternatively spliced forms of those
receptors. Fc.gamma.RII receptors include Fc.gamma.RIIA (an
"activating receptor") and Fc.gamma.RIIB (an "inhibiting
receptor"), which have similar amino acid sequences that differ
primarily in the cytoplasmic domains thereof. Activating receptor
Fc.gamma.RIIA contains an immunoreceptor tyrosine-based activation
motif (ITAM) in its cytoplasmic domain Inhibiting receptor
Fc.gamma.RIIB contains an immunoreceptor tyrosine-based inhibition
motif (ITIM) in its cytoplasmic domain. (see, e.g., Daeron, Annu.
Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed, for example,
in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capel et
al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab.
Clin. Med. 126:330-41 (1995). Other FcRs, including those to be
identified in the future, are encompassed by the term "FcR" herein.
The term "Fc receptor" or "FcR" also includes the neonatal
receptor, FcRn, which is responsible for the transfer of maternal
IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim
et al., J. Immunol. 24:249 (1994)) and regulation of homeostasis of
immunoglobulins. Methods of measuring binding to FcRn are known
(see, e.g., Ghetie and Ward., Immunol. Today 18(12):592-598 (1997);
Ghetie et al., Nature Biotechnology, 15(7):637-640 (1997); Hinton
et al., J. Biol. Chem. 279(8):6213-6216 (2004); WO 2004/92219
(Hinton et al.). Binding to human FcRn in vivo and serum half life
of human FcRn high affinity binding polypeptides can be assayed,
e.g., in transgenic mice or transfected human cell lines expressing
human FcRn, or in primates to which the polypeptides with a variant
Fc region are administered. WO 2000/42072 (Presta) describes
antibody variants with improved or diminished binding to FcRs. See
also, e.g., Shields et al. J. Biol. Chem. 9(2):6591-6604
(2001).
[0070] The term "Fc region" herein is used to define a C-terminal
region of an immunoglobulin heavy chain that contains at least a
portion of the constant region. The term includes native sequence
Fc regions and variant Fc regions. In one embodiment, a human IgG
heavy chain Fc region extends from Cys226, or from Pro230, to the
carboxyl-terminus of the heavy chain. However, the C-terminal
lysine (Lys447) of the Fc region may or may not be present. Unless
otherwise specified herein, numbering of amino acid residues in the
Fc region or constant region is according to the EU numbering
system, also called the EU index, as described in Kabat et al.,
Sequences of Proteins of Immunological Interest, 5th Ed. Public
Health Service, National Institutes of Health, Bethesda, Md.,
1991.
[0071] A "functional Fc region" possesses an "effector function" of
a native sequence Fc region. Exemplary "effector functions" include
C1q binding; CDC; Fc receptor binding; ADCC; phagocytosis; down
regulation of cell surface receptors (e.g. B cell receptor; BCR),
etc. Such effector functions generally require the Fc region to be
combined with a binding domain (e.g., an antibody variable domain)
and can be assessed using various assays as disclosed, for example,
in definitions herein.
[0072] "Human effector cells" refer to leukocytes that express one
or more FcRs and perform effector functions. In certain
embodiments, the cells express at least Fc.gamma.RIII and perform
ADCC effector function(s). Examples of human leukocytes which
mediate ADCC include peripheral blood mononuclear cells (PBMC),
natural killer (NK) cells, monocytes, cytotoxic T cells, and
neutrophils. The effector cells may be isolated from a native
source, e.g., from blood.
[0073] "Framework" or "FR" refers to variable domain residues other
than hypervariable region (HVR) residues. The FR of a variable
domain generally consists of four FR domains: FR1, FR2, FR3, and
FR4. Accordingly, the HVR and FR sequences generally appear in the
following sequence in VH (or VL):
FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
[0074] The terms "full length antibody," "intact antibody," and
"whole antibody" are used herein interchangeably to refer to an
antibody having a structure substantially similar to a native
antibody structure or having heavy chains that contain an Fc region
as defined herein.
[0075] The terms "host cell," "host cell line," and "host cell
culture" are used interchangeably and refer to cells into which
exogenous nucleic acid has been introduced, including the progeny
of such cells. Host cells include "transformants" and "transformed
cells," which include the primary transformed cell and progeny
derived therefrom without regard to the number of passages. Progeny
may not be completely identical in nucleic acid content to a parent
cell, but may contain mutations. Mutant progeny that have the same
function or biological activity as screened or selected for in the
originally transformed cell are included herein.
[0076] A "human antibody" is one which possesses an amino acid
sequence which corresponds to that of an antibody produced by a
human or a human cell or derived from a non-human source that
utilizes human antibody repertoires or other human
antibody-encoding sequences. This definition of a human antibody
specifically excludes a humanized antibody comprising non-human
antigen-binding residues.
[0077] A "human consensus framework" is a framework which
represents the most commonly occurring amino acid residues in a
selection of human immunoglobulin VL or VH framework sequences.
Generally, the selection of human immunoglobulin VL or VH sequences
is from a subgroup of variable domain sequences. Generally, the
subgroup of sequences is a subgroup as in Kabat et al., Sequences
of Proteins of Immunological Interest, Fifth Edition, NIH
Publication 91-3242, Bethesda Md. (1991), vols. 1-3. In one
embodiment, for the VL, the subgroup is subgroup kappa I as in
Kabat et al., supra. In one embodiment, for the VH, the subgroup is
subgroup III as in Kabat et al., supra.
[0078] A "humanized" antibody refers to a chimeric antibody
comprising amino acid residues from non-human HVRs and amino acid
residues from human FRs. In certain embodiments, a humanized
antibody will comprise substantially all of at least one, and
typically two, variable domains, in which all or substantially all
of the HVRs (e.g., CDRs) correspond to those of a non-human
antibody, and all or substantially all of the FRs correspond to
those of a human antibody. A humanized antibody optionally may
comprise at least a portion of an antibody constant region derived
from a human antibody. A "humanized form" of an antibody, e.g., a
non-human antibody, refers to an antibody that has undergone
humanization.
[0079] The term "hypervariable region" or "HVR" as used herein
refers to each of the regions of an antibody variable domain which
are hypervariable in sequence ("complementarity determining
regions" or "CDRs") and/or form structurally defined loops
("hypervariable loops") and/or contain the antigen-contacting
residues ("antigen contacts"). Generally, antibodies comprise six
HVRs: three in the VH (H1, H2, H3), and three in the VL (L1, L2,
L3). Exemplary HVRs herein include:
[0080] (a) hypervariable loops occurring at amino acid residues
26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and
96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917
(1987));
[0081] (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56
(L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat
et al., Sequences of Proteins of Immunological Interest, 5th Ed.
Public Health Service, National Institutes of Health, Bethesda, Md.
(1991));
[0082] (c) antigen contacts occurring at amino acid residues 27c-36
(L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101
(H3) (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)); and
[0083] (d) combinations of (a), (b), and/or (c), including HVR
amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2),
26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102
(H3).
[0084] Unless otherwise indicated, HVR residues and other residues
in the variable domain (e.g., FR residues) are numbered herein
according to Kabat et al., supra.
[0085] An "immunoconjugate" is an antibody conjugated to one or
more heterologous molecule(s), including but not limited to a
cytotoxic agent.
[0086] An "individual" or "subject" is a mammal. Mammals include,
but are not limited to, domesticated animals (e.g., cows, sheep,
cats, dogs, and horses), primates (e.g., humans and non-human
primates such as monkeys), rabbits, and rodents (e.g., mice and
rats). In certain embodiments, the individual or subject is a
human.
[0087] "Promoting cell growth or proliferation" means increasing a
cell's growth or proliferation by at least 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90%, 95%, or 100%.
[0088] An "isolated" antibody is one which has been separated from
a component of its natural environment. In some embodiments, an
antibody is purified to greater than 95% or 99% purity as
determined by, for example, electrophoretic (e.g., SDS-PAGE,
isoelectric focusing (IEF), capillary electrophoresis) or
chromatographic (e.g., ion exchange or reverse phase HPLC). For
review of methods for assessment of antibody purity, see, e.g.,
Flatman et al., J. Chromatogr. B 848:79-87 (2007).
[0089] An "isolated" nucleic acid refers to a nucleic acid molecule
that has been separated from a component of its natural
environment. An isolated nucleic acid includes a nucleic acid
molecule contained in cells that ordinarily contain the nucleic
acid molecule, but the nucleic acid molecule is present
extrachromosomally or at a chromosomal location that is different
from its natural chromosomal location.
[0090] "Isolated nucleic acid encoding an anti-OX40 antibody"
refers to one or more nucleic acid molecules encoding antibody
heavy and light chains (or fragments thereof), including such
nucleic acid molecule(s) in a single vector or separate vectors,
and such nucleic acid molecule(s) present at one or more locations
in a host cell.
[0091] The term "monoclonal antibody" as used herein refers to an
antibody obtained from a population of substantially homogeneous
antibodies, i.e., the individual antibodies comprising the
population are identical and/or bind the same epitope, except for
possible variant antibodies, e.g., containing naturally occurring
mutations or arising during production of a monoclonal antibody
preparation, such variants generally being present in minor
amounts. In contrast to polyclonal antibody preparations, which
typically include different antibodies directed against different
determinants (epitopes), each monoclonal antibody of a monoclonal
antibody preparation is directed against a single determinant on an
antigen. Thus, the modifier "monoclonal" indicates the character of
the antibody as being obtained from a substantially homogeneous
population of antibodies, and is not to be construed as requiring
production of the antibody by any particular method. For example,
the monoclonal antibodies to be used in accordance with the present
invention may be made by a variety of techniques, including but not
limited to the hybridoma method, recombinant DNA methods,
phage-display methods, and methods utilizing transgenic animals
containing all or part of the human immunoglobulin loci, such
methods and other exemplary methods for making monoclonal
antibodies being described herein.
[0092] A "naked antibody" refers to an antibody that is not
conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or
radiolabel. The naked antibody may be present in a pharmaceutical
formulation.
[0093] "Native antibodies" refer to naturally occurring
immunoglobulin molecules with varying structures. For example,
native IgG antibodies are heterotetrameric glycoproteins of about
150,000 daltons, composed of two identical light chains and two
identical heavy chains that are disulfide-bonded. From N- to
C-terminus, each heavy chain has a variable region (VH), also
called a variable heavy domain or a heavy chain variable domain,
followed by three constant domains (CH1, CH2, and CH3). Similarly,
from N- to C-terminus, each light chain has a variable region (VL),
also called a variable light domain or a light chain variable
domain, followed by a constant light (CL) domain. The light chain
of an antibody may be assigned to one of two types, called kappa
(.kappa.) and lambda (.lamda.) based on the amino acid sequence of
its constant domain. A "native sequence Fc region" comprises an
amino acid sequence identical to the amino acid sequence of an Fc
region found in nature. Native sequence human Fc regions include a
native sequence human IgG1 Fc region (non-A and A allotypes);
native sequence human IgG2 Fc region; native sequence human IgG3 Fc
region; and native sequence human IgG4 Fc region as well as
naturally occurring variants thereof.
[0094] The term "package insert" is used to refer to instructions
customarily included in commercial packages of therapeutic
products, that contain information about the indications, usage,
dosage, administration, combination therapy, contraindications
and/or warnings concerning the use of such therapeutic
products.
[0095] "Percent (%) amino acid sequence identity" with respect to a
reference polypeptide sequence is defined as the percentage of
amino acid residues in a candidate sequence that are identical with
the amino acid residues in the reference polypeptide sequence,
after aligning the sequences and introducing gaps, if necessary, to
achieve the maximum percent sequence identity, and not considering
any conservative substitutions as part of the sequence identity.
Alignment for purposes of determining percent amino acid sequence
identity can be achieved in various ways that are within the skill
in the art, for instance, using publicly available computer
software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR)
software. Those skilled in the art can determine appropriate
parameters for aligning sequences, including any algorithms needed
to achieve maximal alignment over the full length of the sequences
being compared. For purposes herein, however, % amino acid sequence
identity values are generated using the sequence comparison
computer program ALIGN-2. The ALIGN-2 sequence comparison computer
program was authored by Genentech, Inc., and the source code has
been filed with user documentation in the U.S. Copyright Office,
Washington D.C., 20559, where it is registered under U.S. Copyright
Registration No. TXU510087. The ALIGN-2 program is publicly
available from Genentech, Inc., South San Francisco, Calif., or may
be compiled from the source code. The ALIGN-2 program should be
compiled for use on a UNIX operating system, including digital UNIX
V4.0D. All sequence comparison parameters are set by the ALIGN-2
program and do not vary.
[0096] In situations where ALIGN-2 is employed for amino acid
sequence comparisons, the % amino acid sequence identity of a given
amino acid sequence A to, with, or against a given amino acid
sequence B (which can alternatively be phrased as a given amino
acid sequence A that has or comprises a certain % amino acid
sequence identity to, with, or against a given amino acid sequence
B) is calculated as follows:
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical
matches by the sequence alignment program ALIGN-2 in that program's
alignment of A and B, and where Y is the total number of amino acid
residues in B. It will be appreciated that where the length of
amino acid sequence A is not equal to the length of amino acid
sequence B, the % amino acid sequence identity of A to B will not
equal the % amino acid sequence identity of B to A. Unless
specifically stated otherwise, all % amino acid sequence identity
values used herein are obtained as described in the immediately
preceding paragraph using the ALIGN-2 computer program.
[0097] The term "pharmaceutical formulation" refers to a
preparation which is in such form as to permit the biological
activity of an active ingredient contained therein to be effective,
and which contains no additional components which are unacceptably
toxic to a subject to which the formulation would be
administered.
[0098] A "pharmaceutically acceptable carrier" refers to an
ingredient in a pharmaceutical formulation, other than an active
ingredient, which is nontoxic to a subject. A pharmaceutically
acceptable carrier includes, but is not limited to, a buffer,
excipient, stabilizer, or preservative.
[0099] As used herein, "treatment" (and grammatical variations
thereof such as "treat" or "treating") refers to clinical
intervention in an attempt to alter the natural course of the
individual being treated, and can be performed either for
prophylaxis or during the course of clinical pathology. Desirable
effects of treatment include, but are not limited to, preventing
occurrence or recurrence of disease, alleviation of symptoms,
diminishment of any direct or indirect pathological consequences of
the disease, preventing metastasis, decreasing the rate of disease
progression, amelioration or palliation of the disease state, and
remission or improved prognosis. In some embodiments, antibodies of
the invention are used to delay development of a disease or to slow
the progression of a disease.
[0100] The term "tumor" refers to all neoplastic cell growth and
proliferation, whether malignant or benign, and all pre-cancerous
and cancerous cells and tissues. The terms "cancer," "cancerous,"
"cell proliferative disorder," "proliferative disorder" and "tumor"
are not mutually exclusive as referred to herein.
[0101] The term "variable region" or "variable domain" refers to
the domain of an antibody heavy or light chain that is involved in
binding the antibody to antigen. The variable domains of the heavy
chain and light chain (VH and VL, respectively) of a native
antibody generally have similar structures, with each domain
comprising four conserved framework regions (FRs) and three
hypervariable regions (HVRs). (See, e.g., Kindt et al. Kuby
Immunology, 6.sup.th ed., W.H. Freeman and Co., page 91 (2007).) A
single VH or VL domain may be sufficient to confer antigen-binding
specificity. Furthermore, antibodies that bind a particular antigen
may be isolated using a VH or VL domain from an antibody that binds
the antigen to screen a library of complementary VL or VH domains,
respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887
(1993); Clarkson et al., Nature 352:624-628 (1991).
[0102] A "variant Fc region" comprises an amino acid sequence which
differs from that of a native sequence Fc region by virtue of at
least one amino acid modification, preferably one or more amino
acid substitution(s). Preferably, the variant Fc region has at
least one amino acid substitution compared to a native sequence Fc
region or to the Fc region of a parent polypeptide, e.g. from about
one to about ten amino acid substitutions, and preferably from
about one to about five amino acid substitutions in a native
sequence Fc region or in the Fc region of the parent polypeptide.
The variant Fc region herein will preferably possess at least about
80% homology with a native sequence Fc region and/or with an Fc
region of a parent polypeptide, and most preferably at least about
90% homology therewith, more preferably at least about 95% homology
therewith.
[0103] The term "vector," as used herein, refers to a nucleic acid
molecule capable of propagating another nucleic acid to which it is
linked. The term includes the vector as a self-replicating nucleic
acid structure as well as the vector incorporated into the genome
of a host cell into which it has been introduced. Certain vectors
are capable of directing the expression of nucleic acids to which
they are operatively linked. Such vectors are referred to herein as
"expression vectors."
[0104] A "VH subgroup III consensus framework" comprises the
consensus sequence obtained from the amino acid sequences in
variable heavy subgroup III of Kabat et al. In one embodiment, the
VH subgroup III consensus framework amino acid sequence comprises
at least a portion or all of each of the following sequences:
TABLE-US-00001 (SEQ ID NO: 214) EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID
NO: 215) H1-WVRQAPGKGLEWV (SEQ ID NO: 216)
H2-RFTISRDNSKNTLYLQMNSLRAEDTAVYYC (SEQ ID NO: 217)
H3-WGQGTLVTVSS.
[0105] A "VL subgroup I consensus framework" comprises the
consensus sequence obtained from the amino acid sequences in
variable light kappa subgroup I of Kabat et al. In one embodiment,
the VH subgroup I consensus framework amino acid sequence comprises
at least a portion or all of each of the following sequences:
TABLE-US-00002 (SEQ ID NO: 218) DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO:
219) L1-WYQQKPGKAPKLLIY (SEQ ID NO: 220)
L2-GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 221)
L3-FGQGTKVEIK.
[0106] The term "cytotoxic agent" as used herein refers to a
substance that inhibits or prevents a cellular function and/or
causes cell death or destruction. Cytotoxic agents include, but are
not limited to, radioactive isotopes (e.g., At211, I131, I125, Y90,
Re186, Re188, Sm153, Bi212, P32, Pb212 and radioactive isotopes of
Lu); chemotherapeutic agents; growth inhibitory agents; enzymes and
fragments thereof such as nucleolytic enzymes; and toxins such as
small molecule toxins or enzymatically active toxins of bacterial,
fungal, plant or animal origin, including fragments and/or variants
thereof. Exemplary cytotoxic agents can be selected from
anti-microtubule agents, platinum coordination complexes,
alkylating agents, antibiotic agents, topoisomerase II inhibitors,
antimetabolites, topoisomerase I inhibitors, hormones and hormonal
analogues, signal transduction pathway inhibitors, non-receptor
tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents,
proapoptotic agents, inhibitors of LDH-A; inhibitors of fatty acid
biosynthesis; cell cycle signalling inhibitors; HDAC inhibitors,
proteasome inhibitors; and inhibitors of cancer metabolism.
[0107] In one embodiment the cytotoxic agent is selected from
anti-microtubule agents, platinum coordination complexes,
alkylating agents, antibiotic agents, topoisomerase II inhibitors,
antimetabolites, topoisomerase I inhibitors, hormones and hormonal
analogues, signal transduction pathway inhibitors, non-receptor
tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents,
proapoptotic agents, inhibitors of LDH-A, inhibitors of fatty acid
biosynthesis, cell cycle signalling inhibitors, HDAC inhibitors,
proteasome inhibitors, and inhibitors of cancer metabolism. In one
embodiment the cytotoxic agent is a taxane. In one embodiment the
taxane is paclitaxel or docetaxel. In one embodiment the cytotoxic
agent is a platinum agent. In one embodiment the cytotoxic agent is
an antagonist of EGFR. In one embodiment the antagonist of EGFR is
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
(e.g., erlotinib). In one embodiment the cytotoxic agent is a RAF
inhibitor. In one embodiment, the RAF inhibitor is a BRAF and/or
CRAF inhibitor. In one embodiment the RAF inhibitor is vemurafenib.
In one embodiment the cytotoxic agent is a PI3K inhibitor.
[0108] "Chemotherapeutic agent" includes chemical compounds useful
in the treatment of cancer. Examples of chemotherapeutic agents
include erlotinib (TARCEVA.RTM., Genentech/OSI Pharm.), bortezomib
(VELCADE.RTM., Millennium Pharm.), disulfiram, epigallocatechin
gallate, salinosporamide A, carfilzomib, 17-AAG (geldanamycin),
radicicol, lactate dehydrogenase A (LDH-A), fulvestrant
(FASLODEX.RTM., AstraZeneca), sunitib (SUTENT.RTM., Pfizer/Sugen),
letrozole (FEMARA.RTM., Novartis), imatinib mesylate (GLEEVEC.RTM.,
Novartis), finasunate (VATALANIB.RTM., Novartis), oxaliplatin
(ELOXATIN.RTM., Sanofi), 5-FU (5-fluorouracil), leucovorin,
Rapamycin (Sirolimus, RAPAMUNE.RTM., Wyeth), Lapatinib
(TYKERB.RTM., GSK572016, Glaxo Smith Kline), Lonafamib (SCH 66336),
sorafenib (NEXAVAR.RTM., Bayer Labs), gefitinib (IRESSA.RTM.,
AstraZeneca), AG1478, alkylating agents such as thiotepa and
CYTOXAN.RTM. cyclosphosphamide; alkyl sulfonates such as busulfan,
improsulfan and piposulfan; aziridines such as benzodopa,
carboquone, meturedopa, and uredopa; ethylenimines and
methylamelamines including altretamine, triethylenemelamine,
triethylenephosphoramide, triethylenethiophosphoramide and
trimethylomelamine; acetogenins (especially bullatacin and
bullatacinone); a camptothecin (including topotecan and
irinotecan); bryostatin; callystatin; CC-1065 (including its
adozelesin, carzelesin and bizelesin synthetic analogs);
cryptophycins (particularly cryptophycin 1 and cryptophycin 8);
adrenocorticosteroids (including prednisone and prednisolone);
cyproterone acetate; 5.alpha.-reductases including finasteride and
dutasteride); vorinostat, romidepsin, panobinostat, valproic acid,
mocetinostat dolastatin; aldesleukin, talc duocarmycin (including
the synthetic analogs, KW-2189 and CB1-TM1); eleutherobin;
pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards
such as chlorambucil, chlomaphazine, chlorophosphamide,
estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide
hydrochloride, melphalan, novembichin, phenesterine, prednimustine,
trofosfamide, uracil mustard; nitrosoureas such as carmustine,
chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine;
antibiotics such as the enediyne antibiotics (e.g., calicheamicin,
especially calicheamicin .gamma.1I and calicheamicin .phi.1I (Angew
Chem. Intl. Ed. Engl. 1994 33:183-186); dynemicin, including
dynemicin A; bisphosphonates, such as clodronate; an esperamicin;
as well as neocarzinostatin chromophore and related chromoprotein
enediyne antibiotic chromophores), aclacinomysins, actinomycin,
authramycin, azaserine, bleomycins, cactinomycin, carabicin,
caminomycin, carzinophilin, chromomycinis, dactinomycin,
daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine,
ADRIAMYCIN.RTM. (doxorubicin), morpholino-doxorubicin,
cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and
deoxydoxorubicin), epirubicin, esorubicin, idarubicin,
marcellomycin, mitomycins such as mitomycin C, mycophenolic acid,
nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin,
quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin,
ubenimex, zinostatin, zorubicin; anti-metabolites such as
methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as
denopterin, methotrexate, pteropterin, trimetrexate; purine analogs
such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine;
pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine,
carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine,
floxuridine; androgens such as calusterone, dromostanolone
propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals
such as aminoglutethimide, mitotane, trilostane; folic acid
replenisher such as frolinic acid; aceglatone; aldophosphamide
glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil;
bisantrene; edatraxate; defofamine; demecolcine; diaziquone;
elfomithine; elliptinium acetate; an epothilone; etoglucid; gallium
nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as
maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamnol;
nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;
podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK.RTM.
polysaccharide complex (JHS Natural Products, Eugene, Oreg.);
razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid;
triaziquone; 2,2',2''-trichlorotriethylamine; trichothecenes
(especially T-2 toxin, verracurin A, roridin A and anguidine);
urethan; vindesine; dacarbazine; mannomustine; mitobronitol;
mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C");
cyclophosphamide; thiotepa; taxoids, e.g., TAXOL (paclitaxel;
Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE.RTM.
(Cremophor-free), albumin-engineered nanoparticle formulations of
paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.),
and TAXOTERE.RTM. (docetaxel, doxetaxel; Sanofi-Aventis);
chloranmbucil; GEMZAR.RTM. (gemcitabine); 6-thioguanine;
mercaptopurine; methotrexate; platinum analogs such as cisplatin
and carboplatin; vinblastine; etoposide (VP-16); ifosfamide;
mitoxantrone; vincristine; NAVELBINE.RTM. (vinorelbine);
novantrone; teniposide; edatrexate; daunomycin; aminopterin;
capecitabine (XELODA.RTM.); ibandronate; CPT-11; topoisomerase
inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such
as retinoic acid; and pharmaceutically acceptable salts, acids and
derivatives of any of the above.
[0109] Chemotherapeutic agent also includes (i) anti-hormonal
agents that act to regulate or inhibit hormone action on tumors
such as anti-estrogens and selective estrogen receptor modulators
(SERMs), including, for example, tamoxifen (including
NOLVADEX.RTM.; tamoxifen citrate), raloxifene, droloxifene,
iodoxyfene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018,
onapristone, and FARESTON.RTM. (toremifine citrate); (ii) aromatase
inhibitors that inhibit the enzyme aromatase, which regulates
estrogen production in the adrenal glands, such as, for example,
4(5)-imidazoles, aminoglutethimide, MEGASE.RTM. (megestrol
acetate), AROMASIN.RTM. (exemestane; Pfizer), formestanie,
fadrozole, RIVISOR.RTM. (vorozole), FEMARA.RTM. (letrozole;
Novartis), and ARIMIDEX.RTM. (anastrozole; AstraZeneca); (iii)
anti-androgens such as flutamide, nilutamide, bicalutamide,
leuprolide and goserelin; buserelin, tripterelin,
medroxyprogesterone acetate, diethylstilbestrol, premarin,
fluoxymesterone, all transretionic acid, fenretinide, as well as
troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv)
protein kinase inhibitors; (v) lipid kinase inhibitors; (vi)
antisense oligonucleotides, particularly those which inhibit
expression of genes in signaling pathways implicated in aberrant
cell proliferation, such as, for example, PKC-alpha, Ralf and
H-Ras; (vii) ribozymes such as VEGF expression inhibitors (e.g.,
ANGIOZYME.RTM.) and HER2 expression inhibitors; (viii) vaccines
such as gene therapy vaccines, for example, ALLOVECTIN.RTM.,
LEUVECTIN.RTM., and VAXID.RTM.; PROLEUKIN.RTM., rIL-2; a
topoisomerase 1 inhibitor such as LURTOTECAN.RTM.; ABARELIX.RTM.
rmRH; and (ix) pharmaceutically acceptable salts, acids and
derivatives of any of the above.
[0110] Chemotherapeutic agent also includes antibodies such as
alemtuzumab (Campath), bevacizumab (AVASTIN.RTM., Genentech);
cetuximab (ERBITUX.RTM., Imclone); panitumumab (VECTIBIX.RTM.,
Amgen), rituximab (RITUXAN.RTM., Genentech/Biogen Idec), pertuzumab
(OMNITARG.RTM., 2C4, Genentech), trastuzumab (HERCEPTIN.RTM.,
Genentech), tositumomab (Bexxar, Corixia), and the antibody drug
conjugate, gemtuzumab ozogamicin (MYLOTARG.RTM., Wyeth). Additional
humanized monoclonal antibodies with therapeutic potential as
agents in combination with the compounds of the invention include:
apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab
mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol,
cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab,
epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab
ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab,
lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab,
natalizumab, nimotuzumab, nolovizumab, numavizumab, ocrelizumab,
omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab,
pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab,
resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab,
sontuzumab, tacatuzumab tetraxetan, tadocizumab, talizumab,
tefibazumab, tocilizumab, toralizumab, tucotuzumab celmoleukin,
tucusituzumab, umavizumab, urtoxazumab, ustekinumab, visilizumab,
and the anti-interleukin-12 (ABT-874/J695, Wyeth Research and
Abbott Laboratories) which is a recombinant exclusively
human-sequence, full-length IgG1 .lamda. antibody genetically
modified to recognize interleukin-12 p40 protein.
[0111] Chemotherapeutic agent also includes "EGFR inhibitors,"
which refers to compounds that bind to or otherwise interact
directly with EGFR and prevent or reduce its signaling activity,
and is alternatively referred to as an "EGFR antagonist." Examples
of such agents include antibodies and small molecules that bind to
EGFR. Examples of antibodies which bind to EGFR include MAb 579
(ATCC CRL HB 8506), MAb 455 (ATCC CRL HB8507), MAb 225 (ATCC CRL
8508), MAb 528 (ATCC CRL 8509) (see, U.S. Pat. No. 4,943,533,
Mendelsohn et al.) and variants thereof, such as chimerized 225
(C225 or Cetuximab; ERBUTIX.RTM.) and reshaped human 225 (H225)
(see, WO 96/40210, Imclone Systems Inc.); IMC-11F8, a fully human,
EGFR-targeted antibody (Imclone); antibodies that bind type II
mutant EGFR (U.S. Pat. No. 5,212,290); humanized and chimeric
antibodies that bind EGFR as described in U.S. Pat. No. 5,891,996;
and human antibodies that bind EGFR, such as ABX-EGF or Panitumumab
(see WO98/50433, Abgenix/Amgen); EMD 55900 (Stragliotto et al. Eur.
J. Cancer 32A:636-640 (1996)); EMD7200 (matuzumab) a humanized EGFR
antibody directed against EGFR that competes with both EGF and
TGF-alpha for EGFR binding (EMD/Merck); human EGFR antibody,
HuMax-EGFR (GenMab); fully human antibodies known as E1.1, E2.4,
E2.5, E6.2, E6.4, E2.11, E6. 3 and E7.6. 3 and described in U.S.
Pat. No. 6,235,883; MDX-447 (Medarex Inc); and mAb 806 or humanized
mAb 806 (Johns et al., J. Biol. Chem. 279(29):30375-30384 (2004)).
The anti-EGFR antibody may be conjugated with a cytotoxic agent,
thus generating an immunoconjugate (see, e.g., EP659,439A2, Merck
Patent GmbH). EGFR antagonists include small molecules such as
compounds described in U.S. Pat. Nos. 5,616,582, 5,457,105,
5,475,001, 5,654,307, 5,679,683, 6,084,095, 6,265,410, 6,455,534,
6,521,620, 6,596,726, 6,713,484, 5,770,599, 6,140,332, 5,866,572,
6,399,602, 6,344,459, 6,602,863, 6,391,874, 6,344,455, 5,760,041,
6,002,008, and 5,747,498, as well as the following PCT
publications: WO98/14451, WO98/50038, WO99/09016, and WO99/24037.
Particular small molecule EGFR antagonists include OSI-774
(CP-358774, erlotinib, TARCEVA.RTM. Genentech/OSI Pharmaceuticals);
PD 183805 (CI 1033,2-propenamide,
N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quin-
azolinyl]-, dihydrochloride, Pfizer Inc.); ZD1839, gefitinib
(IRESSA.RTM.)
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoli-
ne, AstraZeneca); ZM 105180
((6-amino-4-(3-methylphenyl-amino)-quinazoline, Zeneca); BIBX-1382
(N8-(3-chloro-4-fluoro-phenyl)-N2-(1-methyl-piperidin-4-yl)-pyrimido[5,4--
d]pyrimidine-2,8-diamine, Boehringer Ingelheim); PKI-166
((R)-4-[4-[(1-phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenol)-
;
(R)-6-(4-hydroxyphenyl)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimi-
dine); CL-387785
(N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide); EKB-569
(N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(-
dimethylamino)-2-butenamide) (Wyeth); AG1478 (Pfizer); AG1571 (SU
5271; Pfizer); dual EGFR/HER2 tyrosine kinase inhibitors such as
lapatinib (TYKERB.RTM., GSK572016 or N-[3-chloro-4-[(3
fluorophenyl)methoxy]phenyl]-6[5[[[2methylsulfonyl)ethyl]amino]methyl]-2--
furanyl]-4-quinazolinamine).
[0112] Chemotherapeutic agents also include "tyrosine kinase
inhibitors" including the EGFR-targeted drugs noted in the
preceding paragraph; small molecule HER2 tyrosine kinase inhibitor
such as TAK165 available from Takeda; CP-724,714, an oral selective
inhibitor of the ErbB2 receptor tyrosine kinase (Pfizer and OSI);
dual-HER inhibitors such as EKB-569 (available from Wyeth) which
preferentially binds EGFR but inhibits both HER2 and
EGFR-overexpressing cells; lapatinib (GSK572016; available from
Glaxo-SmithKline), an oral HER2 and EGFR tyrosine kinase inhibitor;
PKI-166 (available from Novartis); pan-HER inhibitors such as
canertinib (CI-1033; Pharmacia); Raf-1 inhibitors such as antisense
agent ISIS-5132 available from ISIS Pharmaceuticals which inhibit
Raf-1 signaling; non-HER targeted TK inhibitors such as imatinib
mesylate (GLEEVEC.RTM., available from Glaxo SmithKline);
multi-targeted tyrosine kinase inhibitors such as sunitinib
(SUTENT.RTM., available from Pfizer); VEGF receptor tyrosine kinase
inhibitors such as vatalanib (PTK787/ZK222584, available from
Novartis/Schering AG); MAPK extracellular regulated kinase I
inhibitor CI-1040 (available from Pharmacia); quinazolines, such as
PD 153035,4-(3-chloroanilino)quinazoline; pyridopyrimidines;
pyrimidopyrimidines; pyrrolopyrimidines, such as CGP 59326, CGP
60261 and CGP 62706; pyrazolopyrimidines,
4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidines; curcumin (diferuloyl
methane, 4,5-bis(4-fluoroanilino)phthalimide); tyrphostines
containing nitrothiophene moieties; PD-0183805 (Warner-Lamber);
antisense molecules (e.g. those that bind to HER-encoding nucleic
acid); quinoxalines (U.S. Pat. No. 5,804,396); tryphostins (U.S.
Pat. No. 5,804,396); ZD6474 (Astra Zeneca); PTK-787
(Novartis/Schering AG); pan-HER inhibitors such as CI-1033
(Pfizer); Affinitac (ISIS 3521; Isis/Lilly); imatinib mesylate
(GLEEVEC.RTM.); PKI 166 (Novartis); GW2016 (Glaxo SmithKline);
CI-1033 (Pfizer); EKB-569 (Wyeth); Semaxinib (Pfizer); ZD6474
(AstraZeneca); PTK-787 (Novartis/Schering AG); INC-1C11 (Imclone),
rapamycin (sirolimus, RAPAMUNE.RTM.); or as described in any of the
following patent publications: U.S. Pat. No. 5,804,396; WO
1999/09016 (American Cyanamid); WO 1998/43960 (American Cyanamid);
WO 1997/38983 (Warner Lambert); WO 1999/06378 (Warner Lambert); WO
1999/06396 (Warner Lambert); WO 1996/30347 (Pfizer, Inc); WO
1996/33978 (Zeneca); WO 1996/3397 (Zeneca) and WO 1996/33980
(Zeneca).
[0113] Chemotherapeutic agents also include dexamethasone,
interferons, colchicine, metoprine, cyclosporine, amphotericin,
metronidazole, alemtuzumab, alitretinoin, allopurinol, amifostine,
arsenic trioxide, asparaginase, BCG live, bevacuzimab, bexarotene,
cladribine, clofarabine, darbepoetin alfa, denileukin, dexrazoxane,
epoetin alfa, elotinib, filgrastim, histrelin acetate, ibritumomab,
interferon alfa-2a, interferon alfa-2b, lenalidomide, levamisole,
mesna, methoxsalen, nandrolone, nelarabine, nofetumomab,
oprelvekin, palifermin, pamidronate, pegademase, pegaspargase,
pegfilgrastim, pemetrexed disodium, plicamycin, porfimer sodium,
quinacrine, rasburicase, sargramostim, temozolomide, VM-26, 6-TG,
toremifene, tretinoin, ATRA, valrubicin, zoledronate, and
zoledronic acid, and pharmaceutically acceptable salts thereof.
[0114] Chemotherapeutic agents also include hydrocortisone,
hydrocortisone acetate, cortisone acetate, tixocortol pivalate,
triamcinolone acetonide, triamcinolone alcohol, mometasone,
amcinonide, budesonide, desonide, fluocinonide, fluocinolone
acetonide, betamethasone, betamethasone sodium phosphate,
dexamethasone, dexamethasone sodium phosphate, fluocortolone,
hydrocortisone-17-butyrate, hydrocortisone-17-valerate,
aclometasone dipropionate, betamethasone valerate, betamethasone
dipropionate, prednicarbate, clobetasone-17-butyrate,
clobetasol-17-propionate, fluocortolone caproate, fluocortolone
pivalate and fluprednidene acetate; immune selective
anti-inflammatory peptides (ImSAIDs) such as
phenylalanine-glutamine-glycine (FEG) and its D-isomeric form (feG)
(IMULAN BioTherapeutics, LLC); anti-rheumatic drugs such as
azathioprine, ciclosporin (cyclosporine A), D-penicillamine, gold
salts, hydroxychloroquine, leflunomideminocycline, sulfasalazine,
tumor necrosis factor alpha (TNF.alpha.) blockers such as
etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira),
certolizumab pegol (Cimzia), golimumab (Simponi), Interleukin 1
(IL-1) blockers such as anakinra (Kineret), T cell costimulation
blockers such as abatacept (Orencia), Interleukin 6 (IL-6) blockers
such as tocilizumab (ACTEMERA.RTM.); Interleukin 13 (IL-13)
blockers such as lebrikizumab; Interferon alpha (IFN) blockers such
as Rontalizumab; Beta 7 integrin blockers such as rhuMAb Beta7; IgE
pathway blockers such as Anti-M1 prime; Secreted homotrimeric LTa3
and membrane bound heterotrimer LTa1/.beta.2 blockers such as
Anti-lymphotoxin alpha (LTa); radioactive isotopes (e.g., At211,
I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 and
radioactive isotopes of Lu); miscellaneous investigational agents
such as thioplatin, PS-341, phenylbutyrate, ET-18-OCH3, or farnesyl
transferase inhibitors (L-739749, L-744832); polyphenols such as
quercetin, resveratrol, piceatannol, epigallocatechine gallate,
theaflavins, flavanols, procyanidins, betulinic acid and
derivatives thereof; autophagy inhibitors such as chloroquine;
delta-9-tetrahydrocannabinol (dronabinol, MARINOL.RTM.);
beta-lapachone; lapachol; colchicines; betulinic acid;
acetylcamptothecin, scopolectin, and 9-aminocamptothecin);
podophyllotoxin; tegafur (UFTORAL.RTM.); bexarotene
(TARGRETIN.RTM.); bisphosphonates such as clodronate (for example,
BONEFOS.RTM. or OSTAC.RTM.), etidronate (DIDROCAL.RTM.), NE-58095,
zoledronic acid/zoledronate (ZOMETA.RTM.), alendronate
(FOSAMAX.RTM.), pamidronate (AREDIA.RTM.), tiludronate
(SKELID.RTM.), or risedronate (ACTONEL.RTM.); and epidermal growth
factor receptor (EGF-R); vaccines such as THERATOPE.RTM. vaccine;
perifosine, COX-2 inhibitor (e.g. celecoxib or etoricoxib),
proteosome inhibitor (e.g. PS341); CCI-779; tipifarnib (R11577);
orafenib, ABT510; Bcl-2 inhibitor such as oblimersen sodium
(GENASENSE.RTM.); pixantrone; farnesyltransferase inhibitors such
as lonafarnib (SCH 6636, SARASAR.TM.); and pharmaceutically
acceptable salts, acids or derivatives of any of the above; as well
as combinations of two or more of the above such as CHOP, an
abbreviation for a combined therapy of cyclophosphamide,
doxorubicin, vincristine, and prednisolone; and FOLFOX, an
abbreviation for a treatment regimen with oxaliplatin
(ELOXATIN.TM.) combined with 5-FU and leucovorin.
[0115] Chemotherapeutic agents also include non-steroidal
anti-inflammatory drugs with analgesic, antipyretic and
anti-inflammatory effects. NSAIDs include non-selective inhibitors
of the enzyme cyclooxygenase. Specific examples of NSAIDs include
aspirin, propionic acid derivatives such as ibuprofen, fenoprofen,
ketoprofen, flurbiprofen, oxaprozin and naproxen, acetic acid
derivatives such as indomethacin, sulindac, etodolac, diclofenac,
enolic acid derivatives such as piroxicam, meloxicam, tenoxicam,
droxicam, lornoxicam and isoxicam, fenamic acid derivatives such as
mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic
acid, and COX-2 inhibitors such as celecoxib, etoricoxib,
lumiracoxib, parecoxib, rofecoxib, rofecoxib, and valdecoxib.
NSAIDs can be indicated for the symptomatic relief of conditions
such as rheumatoid arthritis, osteoarthritis, inflammatory
arthropathies, ankylosing spondylitis, psoriatic arthritis,
Reiter's syndrome, acute gout, dysmenorrhoea, metastatic bone pain,
headache and migraine, postoperative pain, mild-to-moderate pain
due to inflammation and tissue injury, pyrexia, ileus, and renal
colic.
[0116] The term "cytokine" is a generic term for proteins released
by one cell population that act on another cell as intercellular
mediators. Examples of such cytokines are lymphokines, monokines;
interleukins (ILs) such as IL-1, IL-1a, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, IL-15; a tumor necrosis
factor such as TNF-.alpha. or TNF-.beta.; and other polypeptide
factors including LIF and kit ligand (KL) and gamma interferon. As
used herein, the term cytokine includes proteins from natural
sources or from recombinant cell culture and biologically active
equivalents of the native-sequence cytokines, including
synthetically produced small-molecule entities and pharmaceutically
acceptable derivatives and salts thereof.
[0117] The term "PD-1 axis binding antagonist" is a molecule that
inhibits the interaction of a PD-1 axis binding partner with either
one or more of its binding partner, so as to remove T-cell
dysfunction resulting from signaling on the PD-1 signaling
axis--with a result being to restore or enhance T-cell function
(e.g., proliferation, cytokine production, target cell killing). As
used herein, a PD-1 axis binding antagonist includes a PD-1 binding
antagonist, a PD-L1 binding antagonist and a PD-L2 binding
antagonist.
[0118] The term "PD-1 binding antagonists" is a molecule that
decreases, blocks, inhibits, abrogates or interferes with signal
transduction resulting from the interaction of PD-1 with one or
more of its binding partners, such as PD-L1, PD-L2. In some
embodiments, the PD-1 binding antagonist is a molecule that
inhibits the binding of PD-1 to its binding partners. In a specific
aspect, the PD-1 binding antagonist inhibits the binding of PD-1 to
PD-L1 and/or PD-L2. For example, PD-1 binding antagonists include
anti-PD-1 antibodies, antigen binding fragments thereof,
immunoadhesins, fusion proteins, oligopeptides and other molecules
that decrease, block, inhibit, abrogate or interfere with signal
transduction resulting from the interaction of PD-1 with PD-L1
and/or PD-L2. In one embodiment, a PD-1 binding antagonist reduces
the negative co-stimulatory signal mediated by or through cell
surface proteins expressed on T lymphocytes mediated signaling
through PD-1 so as render a dysfunctional T-cell less dysfunctional
(e.g., enhancing effector responses to antigen recognition). In
some embodiments, the PD-1 binding antagonist is an anti-PD-1
antibody. In a specific aspect, a PD-1 binding antagonist is MDX-1
106 described herein. In another specific aspect, a PD-1 binding
antagonist is Merck 3745 described herein. In another specific
aspect, a PD-1 binding antagonist is CT-011 described herein.
[0119] The term "PD-L1 binding antagonists" is a molecule that
decreases, blocks, inhibits, abrogates or interferes with signal
transduction resulting from the interaction of PD-L1 with either
one or more of its binding partners, such as PD-1, B7-1. In some
embodiments, a PD-L1 binding antagonist is a molecule that inhibits
the binding of PD-L1 to its binding partners. In a specific aspect,
the PD-L1 binding antagonist inhibits binding of PD-L1 to PD-1
and/or B7-1. In some embodiments, the PD-L1 binding antagonists
include anti-PD-L1 antibodies, antigen binding fragments thereof,
immunoadhesins, fusion proteins, oligopeptides and other molecules
that decrease, block, inhibit, abrogate or interfere with signal
transduction resulting from the interaction of PD-L1 with one or
more of its binding partners, such as PD-1, B7-1. In one
embodiment, a PD-L1 binding antagonist reduces the negative
co-stimulatory signal mediated by or through cell surface proteins
expressed on T lymphocytes mediated signaling through PD-L1 so as
to render a dysfunctional T-cell less dysfunctional (e.g.,
enhancing effector responses to antigen recognition). In some
embodiments, a PD-L1 binding antagonist is an anti-PD-L1 antibody.
In a specific aspect, an anti-PD-L1 antibody is YW243.55.S70
described herein. In another specific aspect, an anti-PD-L1
antibody is MDX-1 105 described herein. In still another specific
aspect, an anti-PD-L1 antibody is MPDL3280A described herein.
[0120] The term "PD-L2 binding antagonists" is a molecule that
decreases, blocks, inhibits, abrogates or interferes with signal
transduction resulting from the interaction of PD-L2 with either
one or more of its binding partners, such as PD-1. In some
embodiments, a PD-L2 binding antagonist is a molecule that inhibits
the binding of PD-L2 to its binding partners. In a specific aspect,
the PD-L2 binding antagonist inhibits binding of PD-L2 to PD-1. In
some embodiments, the PD-L2 antagonists include anti-PD-L2
antibodies, antigen binding fragments thereof, immunoadhesins,
fusion proteins, oligopeptides and other molecules that decrease,
block, inhibit, abrogate or interfere with signal transduction
resulting from the interaction of PD-L2 with either one or more of
its binding partners, such as PD-1. In one embodiment, a PD-L2
binding antagonist reduces the negative co-stimulatory signal
mediated by or through cell surface proteins expressed on T
lymphocytes mediated signaling through PD-L2 so as render a
dysfunctional T-cell less dysfunctional (e.g., enhancing effector
responses to antigen recognition). In some embodiments, a PD-L2
binding antagonist is an immunoadhesin.
[0121] The term "phagocytosis" means the internalization of cells
or particulate matter by cells. In some embodiments, the phagocytic
cells or phagocytes are macrophages or neutrophils. In some
embodiments, the cells are cells that express human OX40. Methods
for assaying phagocytosis are known in the art and include use of
microscopy to detect the presence of cells internalized within
another cells. In other embodiments, phagocytosis is detected using
FACS, e.g., by detecting presence of a detectably labeled cell
within another cell (which may be detectably labeled, e.g., with a
different label than the first cell).
[0122] The phrase "does not possess substantial activity" or
"substantially no activity" with respect to an antibody, as used
herein, means the antibody does not exhibit an activity that is
above background level (in some embodiments, that is above
background level that is statistically significant). The phrase
"little to no activity" with respect to an antibody, as used
herein, means the antibody does not display a biologically
meaningful amount of a function. The function can be measured or
detected according to any assay or technique known in the art,
including, e.g., those described herein. In some embodiments,
antibody function is stimulation of effector T cell proliferation
and/or cytokine secretion.
[0123] The term "biomarker" or "marker" as used herein refers
generally to a molecule, including a gene, mRNA, protein,
carbohydrate structure, or glycolipid, the expression of which in
or on a tissue or cell or secreted can be detected by known methods
(or methods disclosed herein) and is predictive or can be used to
predict (or aid prediction) for a cell, tissue, or patient's
responsiveness to treatment regimes. In some embodiments, a
biomarker may refer to a gene or protein, e.g., the level of
expression of the gene or protein detected in one or more cells. In
some embodiments, a biomarker may refer to a cell type of interest,
e.g., the number of a cell type of interest detected in one or more
samples.
[0124] By "patient sample" is meant a collection of cells or fluids
obtained from a cancer patient. The source of the tissue or cell
sample may be solid tissue as from a fresh, frozen and/or preserved
organ or tissue sample or biopsy or aspirate; blood or any blood
constituents; bodily fluids such as cerebrospinal fluid, amniotic
fluid, peritoneal fluid, or interstitial fluid; cells from any time
in gestation or development of the subject. The tissue sample may
contain compounds which are not naturally intermixed with the
tissue in nature such as preservatives, anticoagulants, buffers,
fixatives, nutrients, antibiotics, or the like. Examples of tumor
samples herein include, but are not limited to, tumor biopsy, fine
needle aspirate, bronchiolar lavage, pleural fluid, sputum, urine,
a surgical specimen, circulating tumor cells, serum, plasma,
circulating plasma proteins, ascitic fluid, primary cell cultures
or cell lines derived from tumors or exhibiting tumor-like
properties, as well as preserved tumor samples, such as
formalin-fixed, paraffin-embedded tumor samples or frozen tumor
samples.
[0125] The phrase "based on expression of" when used herein means
that information about expression level or presence or absence of
expression (e.g., presence or absence or prevalence of (e.g.,
percentage of cells displaying) of the one or more biomarkers
herein (e.g., presence or absence of or amount or prevalence of
FcR-expressing cells, or e.g., presence or absence or amount or
prevalence of human effector cells) is used to inform a treatment
decision, information provided on a package insert, or
marketing/promotional guidance etc.
[0126] A cancer or biological sample which "has human effector
cells" is one which, in a diagnostic test, has human effector cells
present in the sample (e.g., infiltrating human effector
cells).
[0127] A cancer or biological sample which "has FcR-expressing
cells" is one which, in a diagnostic test, has FcR-expressing
present in the sample (e.g., infiltrating FcR-expressing cells). In
some embodiments, FcR is Fc.gamma.R. In some embodiments, FcR is an
activating Fc.gamma.R.
[0128] The phrase "recommending a treatment" as used herein refers
to using the information or data generated relating to the level or
presence of c-met in a sample of a patient to identify the patient
as suitably treated or not suitably treated with a therapy. In some
embodiments the therapy may comprise c-met antibody (e.g.,
onartuzumab). In some embodiments, the therapy may comprise VEGF
antagonist (e.g., bevacizumab). In some embodiments, the therapy
may comprise anti-human OX40 agonist antibody. The information or
data may be in any form, written, oral or electronic. In some
embodiments, using the information or data generated includes
communicating, presenting, reporting, storing, sending,
transferring, supplying, transmitting, delivering, dispensing, or
combinations thereof. In some embodiments, communicating,
presenting, reporting, storing, sending, transferring, supplying,
transmitting, delivering, dispensing, or combinations thereof are
performed by a computing device, analyzer unit or combination
thereof. In some further embodiments, communicating, presenting,
reporting, storing, sending, transferring, supplying, transmitting,
dispensing, or combinations thereof are performed by an individual
(e.g., a laboratory or medical professional). In some embodiments,
the information or data includes a comparison of the amount or
prevalence of FcR expressing cells to a reference level. In some
embodiments, the information or data includes a comparison of the
amount or prevalence of human effector cells to a reference level.
In some embodiments, the information or data includes an indication
that human effector cells or FcR-expressing cells are present or
absent in the sample. In some embodiments, the information or data
includes an indication that FcR-expressing cells and/or human
effector cells are present in a particular percentage of cells
(e.g., high prevalence). In some embodiments, the information or
data includes an indication that the patient is suitably treated or
not suitably treated with a therapy comprising anti-human OX40
agonist antibody.
[0129] The term "detection" includes any means of detecting,
including direct and indirect detection.
[0130] The "amount" or "level" of a biomarker associated with an
increased clinical benefit to an individual is a detectable level
in a biological sample. These can be measured by methods known to
one skilled in the art and also disclosed herein. The expression
level or amount of biomarker assessed can be used to determine the
response to the treatment.
[0131] "Elevated expression," "elevated expression levels," or
"elevated levels" refers to an increased expression or increased
levels of a biomarker in an individual relative to a control, such
as an individual or individuals who are not suffering from the
disease or disorder (e.g., cancer), a tumor with a known
responsiveness to a treatment (e.g., with an OX40 agonist), an
internal control (e.g., housekeeping biomarker), or a reference
number (e.g., a set threshold amount, such as a threshold based on
clinical outcome data).
[0132] "Reduced expression," "reduced expression levels," or
"reduced levels" refers to a decrease expression or decreased
levels of a biomarker in an individual relative to a control, such
as an individual or individuals who are not suffering from the
disease or disorder (e.g., cancer), a tumor with a known
responsiveness to a treatment (e.g., with an OX40 agonist), an
internal control (e.g., housekeeping biomarker), or a reference
number (e.g., a set threshold amount, such as a threshold based on
clinical outcome data). In some embodiments, reduced expression is
little or no expression.
[0133] The term "diagnosis" is used herein to refer to the
identification or classification of a molecular or pathological
state, disease or condition (e.g., cancer). For example,
"diagnosis" may refer to identification of a particular type of
cancer. "Diagnosis" may also refer to the classification of a
particular subtype of cancer, e.g., by histopathological criteria,
or by molecular features (e.g., a subtype characterized by
expression of one or a combination of biomarkers (e.g., particular
genes or proteins encoded by said genes)).
[0134] The term "aiding diagnosis" is used herein to refer to
methods that assist in making a clinical determination regarding
the presence, or nature, of a particular type of symptom or
condition of a disease or disorder (e.g., cancer). For example, a
method of aiding diagnosis of a disease or condition (e.g., cancer)
can comprise measuring certain biomarkers in a biological sample
from an individual.
[0135] The term "sample," as used herein, refers to a composition
that is obtained or derived from a subject and/or individual of
interest that contains a cellular and/or other molecular entity
that is to be characterized and/or identified, for example based on
physical, biochemical, chemical and/or physiological
characteristics. For example, the phrase "disease sample" and
variations thereof refers to any sample obtained from a subject of
interest that would be expected or is known to contain the cellular
and/or molecular entity that is to be characterized. Samples
include, but are not limited to, primary or cultured cells or cell
lines, cell supernatants, cell lysates, platelets, serum, plasma,
vitreous fluid, lymph fluid, synovial fluid, follicular fluid,
seminal fluid, amniotic fluid, milk, whole blood, blood-derived
cells, urine, cerebrospinal fluid, saliva, sputum, tears,
perspiration, mucus, tumor lysates, and tissue culture medium,
tissue extracts such as homogenized tissue, tumor tissue, cellular
extracts, and combinations thereof.
[0136] By "tissue sample" or "cell sample" is meant a collection of
similar cells obtained from a tissue of a subject or individual.
The source of the tissue or cell sample may be solid tissue as from
a fresh, frozen and/or preserved organ, tissue sample, biopsy,
and/or aspirate; blood or any blood constituents such as plasma;
bodily fluids such as cerebral spinal fluid, amniotic fluid,
peritoneal fluid, or interstitial fluid; cells from any time in
gestation or development of the subject. The tissue sample may also
be primary or cultured cells or cell lines. Optionally, the tissue
or cell sample is obtained from a disease tissue/organ. The tissue
sample may contain compounds which are not naturally intermixed
with the tissue in nature such as preservatives, anticoagulants,
buffers, fixatives, nutrients, antibiotics, or the like.
[0137] As used herein, a "section" of a tissue sample is meant a
single part or piece of a tissue sample, e.g. a thin slice of
tissue or cells cut from a tissue sample. It is understood that
multiple sections of tissue samples may be taken and subjected to
analysis according to the present invention, provided that it is
understood that the present invention comprises a method whereby
the same section of tissue sample is analyzed at both morphological
and molecular levels, or is analyzed with respect to protein or
nucleic acid.
[0138] By "correlate" or "correlating" is meant comparing, in any
way, the performance and/or results of a first analysis or protocol
with the performance and/or results of a second analysis or
protocol. For example, one may use the results of a first analysis
or protocol in carrying out a second protocols and/or one may use
the results of a first analysis or protocol to determine whether a
second analysis or protocol should be performed. With respect to
the embodiment of polypeptide analysis or protocol, one may use the
results of the polypeptide expression analysis or protocol to
determine whether a specific therapeutic regimen should be
performed. With respect to the embodiment of polynucleotide
analysis or protocol, one may use the results of the polynucleotide
expression analysis or protocol to determine whether a specific
therapeutic regimen should be performed.
[0139] "Individual response" or "response" can be assessed using
any endpoint indicating a benefit to the individual, including,
without limitation, (1) inhibition, to some extent, of disease
progression (e.g., cancer progression), including slowing down and
complete arrest; (2) a reduction in tumor size; (3) inhibition
(i.e., reduction, slowing down or complete stopping) of cancer cell
infiltration into adjacent peripheral organs and/or tissues; (4)
inhibition (i.e. reduction, slowing down or complete stopping) of
metastasis; (5) relief, to some extent, of one or more symptoms
associated with the disease or disorder (e.g., cancer); (6)
increase or extend in the length of survival, including overall
survival and progression free survival; and/or (9) decreased
mortality at a given point of time following treatment.
[0140] An "effective response" of a patient or a patient's
"responsiveness" to treatment with a medicament and similar wording
refers to the clinical or therapeutic benefit imparted to a patient
at risk for, or suffering from, a disease or disorder, such as
cancer. In one embodiment, such benefit includes any one or more
of: extending survival (including overall survival and progression
free survival); resulting in an objective response (including a
complete response or a partial response); or improving signs or
symptoms of cancer.
[0141] By "extending survival" is meant increasing overall or
progression free survival in a treated patient relative to an
untreated patient (i.e. relative to a patient not treated with the
medicament), or relative to a patient who does not express a
biomarker at the designated level, and/or relative to a patient
treated with an approved anti-tumor agent. An objective response
refers to a measurable response, including complete response (CR)
or partial response (PR).
III. OX40 Agonists
[0142] Provided herein are methods for predicting responsiveness of
a subject having cancer to an OX40 agonist treatment. These methods
are based in part on the discovery described herein that the number
of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing cancer
cells and lymphocytes obtained from a subject having cancer may be
used to classify the subject as responsive or non-responsive to an
OX40 agonist treatment. It is a further discovery of the present
disclosure that the number of CD4+ OX40+ Foxp3+ lymphocytes in a
sample containing cancer cells and lymphocytes obtained from a
subject having cancer may also be used to determine prognosis of
the subject and/or select a subject for treatment with an OX40
agonist of the present disclosure. It is a further discovery of the
present disclosure that the number of CD4+, OX40+, CD4+ OX40+
Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in a sample containing
metastatic cancer cells and lymphocytes obtained from a subject
having cancer may also be used to determine prognosis of the
subject and/or select a subject for treatment with an OX40 agonist
of the present disclosure. Additionally, as described herein, OX40
agonist antibodies may further find use in methods for quantifying
OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in a
sample comprising cancer cells (including primary and metastatic
cancer cells) and lymphocytes obtained from a subject.
[0143] Antibodies suitable for use in the methods of the invention
include antibodies that bind to human OX40. In some embodiments,
the anti-OX40 antibody is an agonist antibody. Descriptions of
anti-OX40 antibodies (e.g., anti-human OX40 agonist antibodies) may
be found in US PG Pub. No. US2015/0307617 and International
Publication No. WO/2015/153513, which are each incorporated by
reference herein in their entirety.
[0144] In some embodiments, the anti-human OX40 agonist antibody
binds human OX40 with an affinity of less than or equal to about
0.45 nM. In some embodiments, the anti-human OX40 antibody binds
human OX40 with an affinity of less than or equal to about 0.4 nM.
In some embodiments, the anti-human OX40 antibody binds human OX40
with an affinity of less than or equal to about 0.5 nM. In some
embodiments, the binding affinity is determined using
radioimmunoassay.
[0145] In some embodiments, the anti-human OX40 agonist antibody
binds human OX40 and cynomolgus OX40. In some embodiments, binding
is determined using a FACS assay. In some embodiments, binding to
human OX40 has an EC50 of about 0.2 ug/ml. In some embodiments,
binding to human OX40 has an EC50 of about 0.3 ug/ml or lower. In
some embodiments, binding to cynomolgus OX40 has an EC50 of about
1.5 ug/ml. In some embodiments, binding to cynomolgus OX40 has an
EC50 of about 1.4 ug/ml.
[0146] In some embodiments, the anti-human OX40 agonist antibody
does not bind to rat OX40 or mouse OX40.
[0147] In some embodiments, the anti-human OX40 agonist antibody is
a depleting anti-human OX40 antibody (e.g., depletes cells that
express human OX40). In some embodiments, the human OX40 expressing
cells are CD4+ effector T cells. In some embodiments, the human
OX40 expressing cells are Treg cells. In some embodiments,
depleting is by ADCC and/or phagocytosis. In some embodiments, the
antibody mediates ADCC by binding Fc.gamma.R expressed by a human
effector cell and activating the human effector cell function. In
some embodiments, the antibody mediates phagocytosis by binding
Fc.gamma.R expressed by a human effector cell and activating the
human effector cell function. Exemplary human effector cells
include, e.g., macrophage, natural killer (NK) cells, monocytes,
neutrophils. In some embodiments, the human effector cell is
macrophage. In some embodiments, the human effector cell is NK
cells. In some embodiments, depletion is not by apoptosis.
[0148] In some embodiments, the anti-human OX40 agonist antibody
has a functional Fc region. In some embodiments, effector function
of a functional Fc region is ADCC. In some embodiments, effector
function of a functional Fc region is phagocytosis. In some
embodiments, effector function of a functional Fc region is ADCC
and phagocytosis. In some embodiments, the Fc region is human IgG1.
In some embodiments, the Fc region is human IgG4.
[0149] In some embodiments, the anti-human OX40 agonist antibody
does not induce apoptosis in OX40-expressing cells (e.g., Treg). In
some embodiments, apoptosis is assayed using an antibody
concentration of 30 ug/ml, e.g., by determining whether apoptosis
has occurred using annexin V and proprodium iodide stained
Treg.
[0150] In some embodiments, the anti-human OX40 agonist antibody
enhances CD4+ effector T cell function, for example, by increasing
CD4+ effector T cell proliferation and/or increasing gamma
interferon production by the CD4+ effector T cell (for example, as
compared to proliferation and/or cytokine production prior to
treatment with anti-human OX40 agonist antibody). In some
embodiments, the cytokine is gamma interferon. In some embodiments,
the anti-human OX40 agonist antibody increases number of
intratumoral (infiltrating) CD4+ effector T cells (e.g., total
number of CD4+ effector T cells, or e.g., percentage of CD4+ cells
in CD45+ cells), e.g., as compared to number of intratumoral
(infiltrating) CD4+ T cells prior to treatment with anti-human OX40
agonist antibody. In some embodiments, the anti-human OX40 agonist
antibody increases number of intratumoral (infiltrating) CD4+
effector T cells that express gamma interferon (e.g., total gamma
interferon expressing CD4+ cells, or e.g., percentage of gamma
interferon expressing CD4+ cells in total CD4+ cells), e.g., as
compared to number of intratumoral (infiltrating) CD4+ T cells that
express gamma interferon prior to treatment with anti-human OX40
agonist antibody.
[0151] In some embodiments, the anti-human OX40 agonist antibody
increases number of intratumoral (infiltrating) CD8+ effector T
cells (e.g., total number of CD8+ effector T cells, or e.g.,
percentage of CD8+ in CD45+ cells), e.g., as compared to number of
intratumoral (infiltrating) CD8+ T effector cells prior to
treatment with anti-human OX40 agonist antibody. In some
embodiments, the anti-human OX40 agonist antibody increases number
of intratumoral (infiltrating) CD8+ effector T cells that express
gamma interferon (e.g., percentage of CD8+ cells that express gamma
interferon in total CD8+ cells), e.g., compared to number of
intratumoral (infiltrating) CD8+ T cells that express gamma
interferon prior to treatment with anti-human OX40 agonist
antibody.
[0152] In some embodiments, the anti-human OX40 agonist antibody
enhances memory T cell function, for example by increasing memory T
cell proliferation and/or increasing cytokine production by the
memory cell. In some embodiments, the cytokine is gamma
interferon.
[0153] In some embodiments, the anti-human OX40 agonist antibody
inhibits Treg function, for example, by decreasing Treg suppression
of effector T cell function (e.g., effector T cell proliferation
and/or effector T cell cytokine secretion). In some embodiments,
the effector T cell is a CD4+ effector T cell. In some embodiments,
the anti-human OX40 agonist antibody reduces the number of
intratumoral (infiltrating) Treg (e.g., total number of Treg or
e.g., percentage of Fox3p+ cells in CD4+ cells).
[0154] In some embodiments, the anti-human OX40 agonist antibody is
engineered to increase effector function (e.g., compared to
effector function in a wild-type IgG1). In some embodiments, the
antibody has increased binding to a Fc.gamma. receptor. In some
embodiments, the antibody lacks fucose attached (directly or
indirectly) to the Fc region. For example, the amount of fucose in
such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65%
or from 20% to 40%. In some embodiments, the Fc region comprises
bisected oligosaccharides, e.g., in which a biantennary
oligosaccharide attached to the Fc region of the antibody is
bisected by GlcNAc. In some embodiments, the antibody comprises an
Fc region with one or more amino acid substitutions which improve
ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the
Fc region (EU numbering of residues).
[0155] In some embodiments, the anti-human OX40 agonist antibody
increases OX40 signal transduction in a target cell that expresses
OX40. In some embodiments, OX40 signal transduction is detected by
monitoring NFkB downstream signaling.
[0156] In some embodiments, the anti-human OX40 agonist antibody is
stable after treatment at 40 C for two weeks.
[0157] In some embodiments, the anti-human OX40 agonist antibody
binds human effector cells, e.g., binds Fc.gamma.R (e.g., an
activating Fc.gamma.R) expressed by human effector cells. In some
embodiments, the human effector cell performs (is capable of
performing) ADCC effector function. In some embodiments, the human
effector cell performs (is capable of performing) phagocytosis
effector function.
[0158] In some embodiments, the anti-human OX40 agonist antibody
comprising a variant IgG1 Fc polypeptide comprising a mutation that
eliminates binding to human effector cells (e.g., a DANA mutation)
has diminished activity (e.g., CD4+ effector T cell function, e.g.,
proliferation), relative to anti-human OX40 agonist antibody
comprising native sequence IgG1 Fc portion. In some embodiment, the
anti-human OX40 agonist antibody comprising a variant IgG1 Fc
polypeptide comprising a mutation that eliminates binding to human
effector cells (e.g., a DANA mutation) does not possess substantial
activity (e.g., CD4+ effector T cell function, e.g.,
proliferation).
[0159] In some embodiments, antibody cross-linking is required for
anti-human OX40 agonist antibody function. In some embodiments,
function is stimulation of CD4+ effector T cell proliferation. In
some embodiments, antibody cross-linking is determined by providing
anti-human OX40 agonist antibody adhered on a solid surface (e.g.,
a cell culture plate). In some embodiments, antibody cross-linking
is determined by introducing a mutation in the antibody's IgG1 Fc
portion (e.g., a DANA mutation) and testing function of the mutant
antibody.
[0160] In some embodiments, the anti-human OX40 agonist antibody
competes for binding to human OX40 with OX40L. In some embodiments,
addition of OX40L does not enhance anti-human OX40 antibody
function in an in vitro assay.
[0161] According to another embodiment, the anti-human OX40 agonist
antibodies include any one, any combination, or all of the
following properties: (1) binds human OX40 with an affinity of less
than or equal to about 0.45 nM, in some embodiments, binds human
OX40 with an affinity of less than or equal to about 0.4 nM, in
some embodiments, binds human OX40 with an affinity of less than or
equal to about 0.5 nM, in some embodiments, the binding affinity is
determined using radioimmunoassay; (2) binds human OX40 and
cynomolgus OX40, in some embodiments, binding is determined using a
FACS assay, (3) binds human OX40 with an EC50 of about 0.2 ug/ml,
in some embodiments, binds to human OX40 has an EC50 of about 0.3
ug/ml or lower, in some embodiments, binds to cynomolgus OX40 with
an EC50 of about 1.5 ug/ml, in some embodiments, binds to
cynomolgus OX40 has an EC50 of about 1.4 ug/ml, (4) does not
substantially bind to rat OX40 or mouse OX40, (6) is a depleting
anti-human OX40 antibody (e.g., depletes cells that express human
OX40), in some embodiments, the cells are CD4+ effector T cells
and/or Treg cells, (7) enhances CD4+ effector T cell function, for
example, by increasing CD4+ effector T cell proliferation and/or
increasing gamma interferon production by the CD4+ effector T cell
(for example, as compared to proliferation and/or cytokine
production prior to treatment with anti-human OX40 agonist
antibody), (8) enhances memory T cell function, for example by
increasing memory T cell proliferation and/or increasing cytokine
production by the memory cell, (9) inhibits Treg function, for
example, by decreasing Treg suppression of effector T cell function
(e.g., effector T cell proliferation and/or effector T cell
cytokine secretion). In some embodiments, the effector T cell is a
CD4+ effector T cell, (10) increases OX40 signal transduction in a
target cell that expresses OX40 (in some embodiments, OX40 signal
transduction is detected by monitoring NFkB downstream signaling),
(11) is stable after treatment at 40 C for two weeks, (12) binds
human effector cells, e.g., binds Fc.gamma.R expressed by human
effector cells, (13) anti-human OX40 agonist antibody comprising a
variant IgG1 Fc polypeptide comprising a mutation that eliminates
binding to human effector cells (e.g., N297G) has diminished
activity (e.g., CD4+ effector T cell function, e.g.,
proliferation), relative to anti-human OX40 agonist antibody
comprising native sequence IgG1 Fc portion, in some embodiment, the
anti-human OX40 agonist antibody comprising a variant IgG1 Fc
polypeptide comprising a mutation that eliminates binding to human
effector cells (e.g., N297G) does not possess substantial activity
(e.g., CD4+ effector T cell function, e.g., proliferation), (14)
antibody cross-linking (e.g., by Fc receptor binding) is required
for anti-human OX40 agonist antibody function.
[0162] In one aspect, the invention provides an anti-human OX40
agonist antibody comprising at least one, two, three, four, five,
or six HVRs selected from (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:2; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:3; (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO:4; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:7.
[0163] In one aspect, the invention provides an anti-human OX40
agonist antibody comprising at least one, at least two, or all
three VH HVR sequences selected from (a) HVR-H1 comprising the
amino acid sequence of SEQ ID NO:2; (b) HVR-H2 comprising the amino
acid sequence of SEQ ID NO:3; and (c) HVR-H3 comprising the amino
acid sequence of SEQ ID NO:4. In one embodiment, the antibody
comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO:4.
In another embodiment, the antibody comprises HVR-H3 comprising the
amino acid sequence of SEQ ID NO:4 and HVR-L3 comprising the amino
acid sequence of SEQ ID NO:7. In a further embodiment, the antibody
comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO:4,
HVR-L3 comprising the amino acid sequence of SEQ ID NO:7, and
HVR-H2 comprising the amino acid sequence of SEQ ID NO:3. In a
further embodiment, the antibody comprises (a) HVR-H1 comprising
the amino acid sequence of SEQ ID NO:2; (b) HVR-H2 comprising the
amino acid sequence of SEQ ID NO:3; and (c) HVR-H3 comprising the
amino acid sequence of SEQ ID NO:4.
[0164] In another aspect, the invention provides an anti-human OX40
agonist antibody comprising at least one, at least two, or all
three VL HVR sequences selected from (a) HVR-L1 comprising the
amino acid sequence of SEQ ID NO:5; (b) HVR-L2 comprising the amino
acid sequence of SEQ ID NO:6; and (c) HVR-L3 comprising the amino
acid sequence of SEQ ID NO:7. In one embodiment, the antibody
comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID
NO:5; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:6;
and (c) HVR-L3 comprising the amino acid sequence of SEQ ID
NO:7.
[0165] In another aspect, an anti-human OX40 agonist antibody of
the invention comprises (a) a VH domain comprising at least one, at
least two, or all three VH HVR sequences selected from (i) HVR-H1
comprising the amino acid sequence of SEQ ID NO:2, (ii) HVR-H2
comprising the amino acid sequence of SEQ ID NO:3, and (iii) HVR-H3
comprising an amino acid sequence selected from SEQ ID NO:4; and
(b) a VL domain comprising at least one, at least two, or all three
VL HVR sequences selected from (i) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5, (ii) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6, and (c) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:7.
[0166] In another aspect, the invention provides an anti-human OX40
agonist antibody comprising (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:2; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:3; (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO:4; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising an amino acid
sequence selected from SEQ ID NO:7.
[0167] In one aspect, the invention provides an anti-human OX40
agonist antibody comprising at least one, two, three, four, five,
or six HVRs selected from (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:2; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:3; (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO:4; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:26.
[0168] In another embodiment, the antibody comprises HVR-H3
comprising the amino acid sequence of SEQ ID NO:4 and HVR-L3
comprising the amino acid sequence of SEQ ID NO:26. In a further
embodiment, the antibody comprises HVR-H3 comprising the amino acid
sequence of SEQ ID NO:4, HVR-L3 comprising the amino acid sequence
of SEQ ID NO:26, and HVR-H2 comprising the amino acid sequence of
SEQ ID NO:3.
[0169] In another aspect, an antibody of the invention comprises
(a) a VH domain comprising at least one, at least two, or all three
VH HVR sequences selected from (i) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:2, (ii) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:3, and (iii) HVR-H3 comprising an amino acid
sequence selected from SEQ ID NO:4; and (b) a VL domain comprising
at least one, at least two, or all three VL HVR sequences selected
from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:5,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:6, and
(c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:26.
[0170] In another aspect, the invention provides an antibody
comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO:2; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:3;
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:4; (d)
HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (e)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (f)
HVR-L3 comprising an amino acid sequence selected from SEQ ID
NO:26.
[0171] In one aspect, the invention provides an anti-human OX40
agonist antibody comprising at least one, two, three, four, five,
or six HVRs selected from (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:2; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:3; (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO:4; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:27.
[0172] In another embodiment, the antibody comprises HVR-H3
comprising the amino acid sequence of SEQ ID NO:4 and HVR-L3
comprising the amino acid sequence of SEQ ID NO:27. In a further
embodiment, the antibody comprises HVR-H3 comprising the amino acid
sequence of SEQ ID NO:4, HVR-L3 comprising the amino acid sequence
of SEQ ID NO:27, and HVR-H2 comprising the amino acid sequence of
SEQ ID NO:3.
[0173] In another aspect, an antibody of the invention comprises
(a) a VH domain comprising at least one, at least two, or all three
VH HVR sequences selected from (i) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:2, (ii) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:3, and (iii) HVR-H3 comprising an amino acid
sequence selected from SEQ ID NO:4; and (b) a VL domain comprising
at least one, at least two, or all three VL HVR sequences selected
from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:5,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:6, and
(c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:27.
[0174] In another aspect, the invention provides an antibody
comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO:2; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:3;
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:4; (d)
HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (e)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (f)
HVR-L3 comprising an amino acid sequence selected from SEQ ID
NO:27.
[0175] In one aspect, the invention provides an anti-human OX40
agonist antibody comprising at least one, two, three, four, five,
or six HVRs selected from (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:2, 8 or 9; (b) HVR-H2 comprising the amino
acid sequence of SEQ ID NO:3, 10, 11, 12, 13 or 14; (c) HVR-H3
comprising the amino acid sequence of SEQ ID NO:4, 15, or 19; (d)
HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (e)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (f)
HVR-L3 comprising the amino acid sequence of SEQ ID NO:7, 22, 23,
24, 25, 26, 27, or 28.
[0176] In one aspect, the invention provides an antibody comprising
at least one, at least two, or all three VH HVR sequences selected
from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 2,
8 or 9; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
3, 10, 11, 12, 13 or 14; and (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO: 4, 15, or 19. In one embodiment, the
antibody comprises HVR-H3 comprising the amino acid sequence of SEQ
ID NO: 4, 15, or 19. In another embodiment, the antibody comprises
HVR-H3 comprising the amino acid sequence of SEQ ID NO:4, 15, or 19
and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 7, 22,
23, 24, 25, 26, 27, or 28. In a further embodiment, the antibody
comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO:
4, 15, or 19, HVR-L3 comprising the amino acid sequence of SEQ ID
NO: 7, 22, 23, 24, 25, 26, 27, or 28, and HVR-H2 comprising the
amino acid sequence of SEQ ID NO: 3, 10, 11, 12, 13 or 14. In a
further embodiment, the antibody comprises (a) HVR-H1 comprising
the amino acid sequence of SEQ ID NO: 2, 8 or 9; (b) HVR-H2
comprising the amino acid sequence of SEQ ID NO: 3, 10, 11, 12, 13
or 14; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO: 4, 15, or 19.
[0177] In another aspect, the invention provides an antibody
comprising at least one, at least two, or all three VL HVR
sequences selected from (a) HVR-L1 comprising the amino acid
sequence of SEQ ID NO: 5; (b) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (c) HVR-L3 comprising the amino acid
sequence of SEQ ID NO: 7, 22, 23, 24, 25, 26, 27, or 28. In one
embodiment, the antibody comprises (a) HVR-L1 comprising the amino
acid sequence of SEQ ID NO:5; (b) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (c) HVR-L3 comprising the amino acid
sequence of SEQ ID NO: 7, 22, 23, 24, 25, 26, 27, or 28.
[0178] In another aspect, an antibody of the invention comprises
(a) a VH domain comprising at least one, at least two, or all three
VH HVR sequences selected from (i) HVR-H1 comprising the amino acid
sequence of SEQ ID NO: 2, 8 or 9, (ii) HVR-H2 comprising the amino
acid sequence of SEQ ID NO: 3, 10, 11, 12, 13 or 14, and (iii)
HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:
4, 15, or 19; and (b) a VL domain comprising at least one, at least
two, or all three VL HVR sequences selected from (i) HVR-L1
comprising the amino acid sequence of SEQ ID NO:5, (ii) HVR-L2
comprising the amino acid sequence of SEQ ID NO:6, and (c) HVR-L3
comprising the amino acid sequence of SEQ ID NO: 7, 22, 23, 24, 25,
26, 27, or 28.
[0179] In another aspect, the invention provides an antibody
comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO: 2, 8 or 9; (b) HVR-H2 comprising the amino acid sequence of SEQ
ID NO: 3, 10, 11, 12, 13 or 14; (c) HVR-H3 comprising the amino
acid sequence of SEQ ID NO: 4, 15, or 19; (d) HVR-L1 comprising the
amino acid sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino
acid sequence of SEQ ID NO:6; and (f) HVR-L3 comprising an amino
acid sequence selected from SEQ ID NO: 7, 22, 23, 24, 25, 26, 27,
or 28.
[0180] In one aspect, the invention provides an anti-human OX40
agonist antibody comprising at least one, two, three, four, five,
or six HVRs selected from (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:172; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:173; (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO:174; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:175. In some embodiment, HVR-H2 is not
DMYPDAAAASYNQKFRE (SEQ ID NO:222). In some embodiments, HVR-H3 is
not APRWAAAA (SEQ ID NO:223). In some embodiments, HVR-L3 is not
QAAAAAAAT (SEQ ID NO:224).
[0181] In one aspect, the invention provides an antibody comprising
at least one, at least two, or all three VH HVR sequences selected
from (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO:172; (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO:173; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:174. In one embodiment, the antibody comprises HVR-H3 comprising
the amino acid sequence of SEQ ID NO:174. In another embodiment,
the antibody comprises HVR-H3 comprising the amino acid sequence of
SEQ ID NO:174 and HVR-L3 comprising the amino acid sequence of SEQ
ID NO:175. In a further embodiment, the antibody comprises HVR-H3
comprising the amino acid sequence of SEQ ID NO:174, HVR-L3
comprising the amino acid sequence of SEQ ID NO:175, and HVR-H2
comprising the amino acid sequence of SEQ ID NO:173. In a further
embodiment, the antibody comprises (a) HVR-H1 comprising the amino
acid sequence of SEQ ID NO:172; (b) HVR-H2 comprising the amino
acid sequence of SEQ ID NO:173; and (c) HVR-H3 comprising the amino
acid sequence of SEQ ID NO:174. In some embodiment, HVR-H2 is not
DMYPDAAAASYNQKFRE (SEQ ID NO:222). In some embodiments, HVR-H3 is
not APRWAAAA (SEQ ID NO:223). In some embodiments, HVR-L3 is not
QAAAAAAAT (SEQ ID NO:224).
[0182] In another aspect, the invention provides an antibody
comprising (a) HVR-L1 comprising the amino acid sequence of SEQ ID
NO:5; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO:6;
and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:175.
In some embodiments, HVR-L3 is not QAAAAAAAT (SEQ ID NO:224).
[0183] In another aspect, an antibody of the invention comprises
(a) a VH domain comprising at least one, at least two, or all three
VH HVR sequences selected from (i) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:172, (ii) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:173, and (iii) HVR-H3 comprising an amino
acid sequence selected from SEQ ID NO:174; and (b) a VL domain
comprising at least one, at least two, or all three VL HVR
sequences selected from (i) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5, (ii) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6, and (c) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:175.
[0184] In another aspect, the invention provides an antibody
comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO:172; (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO:173; (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:174; (d) HVR-L1 comprising the amino acid sequence of SEQ ID
NO:5; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:6;
and (f) HVR-L3 comprising an amino acid sequence selected from SEQ
ID NO:175. In some embodiment, HVR-H2 is not DMYPDAAAASYNQKFRE (SEQ
ID NO:222). In some embodiments, HVR-H3 is not APRWAAAA (SEQ ID
NO:223). In some embodiments, HVR-L3 is not QAAAAAAAT (SEQ ID
NO:224).
[0185] All possible combinations of the above substitutions are
encompassed by the consensus sequences of SEQ ID NO:172, 173, 174
and 175.
[0186] In one aspect, the invention provides an anti-human OX40
agonist antibody comprising at least one, two, three, four, five,
or six HVRs selected from (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:29; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:30; (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO:33; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:37; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:39; and (f) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:42.
[0187] In one aspect, the invention provides an antibody comprising
at least one, at least two, or all three VH HVR sequences selected
from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:29;
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:30; and
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:33. In
one embodiment, the antibody comprises HVR-H3 comprising the amino
acid sequence of SEQ ID NO:33. In another embodiment, the antibody
comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO:33
and HVR-L3 comprising the amino acid sequence of SEQ ID NO:42. In a
further embodiment, the antibody comprises HVR-H3 comprising the
amino acid sequence of SEQ ID NO:33, HVR-L3 comprising the amino
acid sequence of SEQ ID NO:42, and HVR-H2 comprising the amino acid
sequence of SEQ ID NO:30. In a further embodiment, the antibody
comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO:29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO:30; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:33.
[0188] In another aspect, the invention provides an antibody
comprising at least one, at least two, or all three VL HVR
sequences selected from (a) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:37; (b) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:39; and (c) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:42. In one embodiment, the antibody comprises
(a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:37; (b)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:39; and (c)
HVR-L3 comprising the amino acid sequence of SEQ ID NO:42.
[0189] In another aspect, an antibody of the invention comprises
(a) a VH domain comprising at least one, at least two, or all three
VH HVR sequences selected from (i) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:29, (ii) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:30, and (iii) HVR-H3 comprising an amino acid
sequence selected from SEQ ID NO:33; and (b) a VL domain comprising
at least one, at least two, or all three VL HVR sequences selected
from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:37,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:39, and
(c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:42.
[0190] In another aspect, the invention provides an antibody
comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO:29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO:30; (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:33; (d) HVR-L1 comprising the amino acid sequence of SEQ ID
NO:37; (e) HVR-L2 comprising the amino acid sequence of SEQ ID
NO:39; and (f) HVR-L3 comprising an amino acid sequence selected
from SEQ ID NO:42.
[0191] In one aspect, the invention provides an anti-human OX40
agonist antibody comprising at least one, two, three, four, five,
or six HVRs selected from (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:29; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:30; (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO:33; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:37; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:40; and (f) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:42.
[0192] In another aspect, the invention provides an antibody
comprising at least one, at least two, or all three VL HVR
sequences selected from (a) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:37; (b) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:40; and (c) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:42. In one embodiment, the antibody comprises
(a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:37; (b)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:40; and (c)
HVR-L3 comprising the amino acid sequence of SEQ ID NO:42.
[0193] In another aspect, an antibody of the invention comprises
(a) a VH domain comprising at least one, at least two, or all three
VH HVR sequences selected from (i) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:29, (ii) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:30, and (iii) HVR-H3 comprising an amino acid
sequence selected from SEQ ID NO:33; and (b) a VL domain comprising
at least one, at least two, or all three VL HVR sequences selected
from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:37,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:40, and
(c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:42.
[0194] In another aspect, the invention provides an antibody
comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO:29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO:30; (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:33; (d) HVR-L1 comprising the amino acid sequence of SEQ ID
NO:37; (e) HVR-L2 comprising the amino acid sequence of SEQ ID
NO:40; and (f) HVR-L3 comprising an amino acid sequence selected
from SEQ ID NO:42.
[0195] In one aspect, the invention provides an anti-human OX40
agonist antibody comprising at least one, two, three, four, five,
or six HVRs selected from (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:29; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:30, 31, or 32; (c) HVR-H3 comprising the
amino acid sequence of SEQ ID NO:33; (d) HVR-L1 comprising the
amino acid sequence of SEQ ID NO:37; (e) HVR-L2 comprising the
amino acid sequence of SEQ ID NO:39, 40 or 41; and (f) HVR-L3
comprising the amino acid sequence of SEQ ID NO:42, 43, or 44.
[0196] In one aspect, the invention provides an antibody comprising
at least one, at least two, or all three VH HVR sequences selected
from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:29;
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30, 31,
or 32; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:33. In another embodiment, the antibody comprises HVR-H3
comprising the amino acid sequence of SEQ ID NO:33 and HVR-L3
comprising the amino acid sequence of SEQ ID NO: 42, 43, or 44. In
a further embodiment, the antibody comprises HVR-H3 comprising the
amino acid sequence of SEQ ID NO:33, HVR-L3 comprising the amino
acid sequence of SEQ ID NO: 42, 43, or 44, and HVR-H2 comprising
the amino acid sequence of SEQ ID NO: 39, 40 or 41. In a further
embodiment, the antibody comprises (a) HVR-H1 comprising the amino
acid sequence of SEQ ID NO:29; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:30, 31, or 32; and (c) HVR-H3 comprising the
amino acid sequence of SEQ ID NO:33.
[0197] In another aspect, the invention provides an antibody
comprising at least one, at least two, or all three VL HVR
sequences selected from (a) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:37; (b) HVR-L2 comprising the amino acid
sequence of SEQ ID NO: 39, 40 or 41; and (c) HVR-L3 comprising the
amino acid sequence of SEQ ID NO: 42, 43, or 44. In one embodiment,
the antibody comprises (a) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:37; (b) HVR-L2 comprising the amino acid
sequence of SEQ ID NO: 39, 40 or 41; and (c) HVR-L3 comprising the
amino acid sequence of SEQ ID NO: 42, 43, or 44.
[0198] In another aspect, an antibody of the invention comprises
(a) a VH domain comprising at least one, at least two, or all three
VH HVR sequences selected from (i) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:29, (ii) HVR-H2 comprising the amino acid
sequence of SEQ ID NO: 30, 31, or 32, and (iii) HVR-H3 comprising
an amino acid sequence selected from SEQ ID NO:33; and (b) a VL
domain comprising at least one, at least two, or all three VL HVR
sequences selected from (i) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:37, (ii) HVR-L2 comprising the amino acid
sequence of SEQ ID NO: 39, 40 or 41, and (c) HVR-L3 comprising the
amino acid sequence of SEQ ID NO: 42, 43, or 44.
[0199] In another aspect, the invention provides an antibody
comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO:29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
30, 31, or 32; (c) HVR-H3 comprising the amino acid sequence of SEQ
ID NO:33; (d) HVR-L1 comprising the amino acid sequence of SEQ ID
NO:37; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
39, 40 or 41; and (f) HVR-L3 comprising an amino acid sequence
selected from SEQ ID NO: 42, 43, or 44.
[0200] In one aspect, the invention provides an anti-human OX40
agonist antibody comprising at least one, two, three, four, five,
or six HVRs selected from (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:29; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:175; (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO:33; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:37; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:177; and (f) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:178.
[0201] In one aspect, the invention provides an antibody comprising
at least one, at least two, or all three VH HVR sequences selected
from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:29;
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:175; and
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:33. In
another embodiment, the antibody comprises HVR-H3 comprising the
amino acid sequence of SEQ ID NO:33 and HVR-L3 comprising the amino
acid sequence of SEQ ID NO:177. In a further embodiment, the
antibody comprises HVR-H3 comprising the amino acid sequence of SEQ
ID NO:33, HVR-L3 comprising the amino acid sequence of SEQ ID
NO:178, and HVR-H2 comprising the amino acid sequence of SEQ ID
NO:176. In a further embodiment, the antibody comprises (a) HVR-H1
comprising the amino acid sequence of SEQ ID NO:29; (b) HVR-H2
comprising the amino acid sequence of SEQ ID NO:176; and (c) HVR-H3
comprising the amino acid sequence of SEQ ID NO:33.
[0202] In another aspect, the invention provides an antibody
comprising at least one, at least two, or all three VL HVR
sequences selected from (a) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:37; (b) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:177; and (c) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:177. In one embodiment, the antibody
comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID
NO:37; (b) HVR-L2 comprising the amino acid sequence of SEQ ID
NO:177; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID
NO:178.
[0203] In another aspect, an antibody of the invention comprises
(a) a VH domain comprising at least one, at least two, or all three
VH HVR sequences selected from (i) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:29, (ii) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:176, and (iii) HVR-H3 comprising an amino
acid sequence selected from SEQ ID NO:33; and (b) a VL domain
comprising at least one, at least two, or all three VL HVR
sequences selected from (i) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:37, (ii) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:177, and (c) HVR-L3 comprising the amino acid
sequence of SEQ ID NO:178.
[0204] In another aspect, the invention provides an antibody
comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO:29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO:176; (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:33; (d) HVR-L1 comprising the amino acid sequence of SEQ ID
NO:37; (e) HVR-L2 comprising the amino acid sequence of SEQ ID
NO:177; and (f) HVR-L3 comprising an amino acid sequence selected
from SEQ ID NO:178.
[0205] In any of the above embodiments, an anti-OX40 agonist
antibody is humanized. In one embodiment, an anti-OX40 antibody
comprises HVRs as in any of the above embodiments or for any of the
embodiments in FIG. 11, and further comprises an acceptor human
framework, e.g. a human immunoglobulin framework or a human
consensus framework. In another embodiment, an anti-OX40 antibody
comprises HVRs as in any of the above embodiments, and further
comprises a VH and/or VL comprising an FR sequence shown in FIG.
11.
[0206] In another aspect, an anti-human OX40 agonist antibody
comprises a heavy chain variable domain (VH) sequence having at
least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to the amino acid sequence of SEQ ID NO:56, 58,
60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92,
94, 96, 98, 100, 108, 114 or 116. In certain embodiments, a VH
sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, or 99% identity contains substitutions (e.g., conservative
substitutions), insertions, or deletions relative to the reference
sequence, but an anti-human OX40 agonist antibody comprising that
sequence retains the ability to bind to OX40. In certain
embodiments, a total of 1 to 10 amino acids have been substituted,
inserted and/or deleted in SEQ ID NO:56, 58, 60, 62, 64, 66, 68,
70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100,
108, 114 or 116. In certain embodiments, substitutions, insertions,
or deletions occur in regions outside the HVRs (i.e., in the FRs).
Optionally, the anti-human OX40 agonist antibody comprises the VH
sequence in SEQ ID NO:56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76,
78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 108, 114 or 116,
including post-translational modifications of that sequence. In a
particular embodiment, the VH comprises one, two or three HVRs
selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ
ID NO:2, (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO:3, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:4.
[0207] In another aspect, an anti-human OX40 agonist antibody is
provided, wherein the antibody comprises a light chain variable
domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to the amino acid sequence of
SEQ ID NO:57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83,
85, 87, 89, 91, 93, 95, 97, 99, 101, 109, 115 or 117. In certain
embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g.,
conservative substitutions), insertions, or deletions relative to
the reference sequence, but an anti-human OX40 agonist antibody
comprising that sequence retains the ability to bind to OX40. In
certain embodiments, a total of 1 to 10 amino acids have been
substituted, inserted and/or deleted in SEQ ID NO: 57, 59, 61, 63,
65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97,
99, 101, 109, 115 or 117. In certain embodiments, the
substitutions, insertions, or deletions occur in regions outside
the HVRs (i.e., in the FRs). Optionally, the anti-human OX40
agonist antibody comprises the VL sequence in SEQ ID NO: 57, 59,
61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93,
95, 97, 99, 101, 109, 115 or 117, including post-translational
modifications of that sequence. In a particular embodiment, the VL
comprises one, two or three HVRs selected from (a) HVR-L1
comprising the amino acid sequence of SEQ ID NO:5; (b) HVR-L2
comprising the amino acid sequence of SEQ ID NO:6; and (c) HVR-L3
comprising the amino acid sequence of SEQ ID NO:7.
[0208] In another aspect, an anti-human OX40 agonist antibody
comprises a heavy chain variable domain (VH) sequence having at
least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to the amino acid sequence of SEQ ID NO:56. In
certain embodiments, a VH sequence having at least 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains
substitutions (e.g., conservative substitutions), insertions, or
deletions relative to the reference sequence, but an anti-human
OX40 agonist antibody comprising that sequence retains the ability
to bind to OX40. In certain embodiments, a total of 1 to 10 amino
acids have been substituted, inserted and/or deleted in SEQ ID
NO:56. In certain embodiments, substitutions, insertions, or
deletions occur in regions outside the HVRs (i.e., in the FRs).
Optionally, the anti-human OX40 agonist antibody comprises the VH
sequence in SEQ ID NO:56, including post-translational
modifications of that sequence. In a particular embodiment, the VH
comprises one, two or three HVRs selected from: (a) HVR-H1
comprising the amino acid sequence of SEQ ID NO:2, (b) HVR-H2
comprising the amino acid sequence of SEQ ID NO:3, and (c) HVR-H3
comprising the amino acid sequence of SEQ ID NO:4.
[0209] In another aspect, an anti-human OX40 agonist antibody is
provided, wherein the antibody comprises a light chain variable
domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to the amino acid sequence of
SEQ ID NO:57. In certain embodiments, a VL sequence having at least
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity
contains substitutions (e.g., conservative substitutions),
insertions, or deletions relative to the reference sequence, but an
anti-human OX40 agonist antibody comprising that sequence retains
the ability to bind to OX40. In certain embodiments, a total of 1
to 10 amino acids have been substituted, inserted and/or deleted in
SEQ ID NO: 57. In certain embodiments, the substitutions,
insertions, or deletions occur in regions outside the HVRs (i.e.,
in the FRs). Optionally, the anti-human OX40 agonist antibody
comprises the VL sequence in SEQ ID NO: 57, including
post-translational modifications of that sequence. In a particular
embodiment, the VL comprises one, two or three HVRs selected from
(a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (b)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (c)
HVR-L3 comprising the amino acid sequence of SEQ ID NO:7.
[0210] In another aspect, an anti-human OX40 agonist antibody
comprises a heavy chain variable domain (VH) sequence having at
least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to the amino acid sequence of SEQ ID NO:94. In
certain embodiments, a VH sequence having at least 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains
substitutions (e.g., conservative substitutions), insertions, or
deletions relative to the reference sequence, but an anti-human
OX40 agonist antibody comprising that sequence retains the ability
to bind to OX40. In certain embodiments, a total of 1 to 10 amino
acids have been substituted, inserted and/or deleted in SEQ ID
NO:94. In certain embodiments, substitutions, insertions, or
deletions occur in regions outside the HVRs (i.e., in the FRs).
Optionally, the anti-human OX40 agonist antibody comprises the VH
sequence in SEQ ID NO:94, including post-translational
modifications of that sequence. In a particular embodiment, the VH
comprises one, two or three HVRs selected from: (a) HVR-H1
comprising the amino acid sequence of SEQ ID NO:2, (b) HVR-H2
comprising the amino acid sequence of SEQ ID NO:3, and (c) HVR-H3
comprising the amino acid sequence of SEQ ID NO:4.
[0211] In another aspect, an anti-human OX40 agonist antibody is
provided, wherein the antibody comprises a light chain variable
domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to the amino acid sequence of
SEQ ID NO:95. In certain embodiments, a VL sequence having at least
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity
contains substitutions (e.g., conservative substitutions),
insertions, or deletions relative to the reference sequence, but an
anti-human OX40 agonist antibody comprising that sequence retains
the ability to bind to OX40. In certain embodiments, a total of 1
to 10 amino acids have been substituted, inserted and/or deleted in
SEQ ID NO:95. In certain embodiments, the substitutions,
insertions, or deletions occur in regions outside the HVRs (i.e.,
in the FRs). Optionally, the anti-human OX40 agonist antibody
comprises the VL sequence in SEQ ID NO:95, including
post-translational modifications of that sequence. In a particular
embodiment, the VL comprises one, two or three HVRs selected from
(a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (b)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (c)
HVR-L3 comprising the amino acid sequence of SEQ ID NO:26.
[0212] In another aspect, an anti-human OX40 agonist antibody
comprises a heavy chain variable domain (VH) sequence having at
least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to the amino acid sequence of SEQ ID NO:96. In
certain embodiments, a VH sequence having at least 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains
substitutions (e.g., conservative substitutions), insertions, or
deletions relative to the reference sequence, but an anti-human
OX40 agonist antibody comprising that sequence retains the ability
to bind to OX40. In certain embodiments, a total of 1 to 10 amino
acids have been substituted, inserted and/or deleted in SEQ ID
NO:96. In certain embodiments, substitutions, insertions, or
deletions occur in regions outside the HVRs (i.e., in the FRs).
Optionally, the anti-human OX40 agonist antibody comprises the VH
sequence in SEQ ID NO:96, including post-translational
modifications of that sequence. In a particular embodiment, the VH
comprises one, two or three HVRs selected from: (a) HVR-H1
comprising the amino acid sequence of SEQ ID NO:2, (b) HVR-H2
comprising the amino acid sequence of SEQ ID NO:3, and (c) HVR-H3
comprising the amino acid sequence of SEQ ID NO:4.
[0213] In another aspect, an anti-human OX40 agonist antibody is
provided, wherein the antibody comprises a light chain variable
domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to the amino acid sequence of
SEQ ID NO:97. In certain embodiments, a VL sequence having at least
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity
contains substitutions (e.g., conservative substitutions),
insertions, or deletions relative to the reference sequence, but an
anti-human OX40 agonist antibody comprising that sequence retains
the ability to bind to OX40. In certain embodiments, a total of 1
to 10 amino acids have been substituted, inserted and/or deleted in
SEQ ID NO:97. In certain embodiments, the substitutions,
insertions, or deletions occur in regions outside the HVRs (i.e.,
in the FRs). Optionally, the anti-human OX40 agonist antibody
comprises the VL sequence in SEQ ID NO:97, including
post-translational modifications of that sequence. In a particular
embodiment, the VL comprises one, two or three HVRs selected from
(a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (b)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (c)
HVR-L3 comprising the amino acid sequence of SEQ ID NO:27.
[0214] In another aspect, an anti-human OX40 agonist antibody
comprises a heavy chain variable domain (VH) sequence having at
least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to the amino acid sequence of SEQ ID NO: 118,
120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144,
146, 148. In certain embodiments, a VH sequence having at least
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity
contains substitutions (e.g., conservative substitutions),
insertions, or deletions relative to the reference sequence, but an
anti-human OX40 agonist antibody comprising that sequence retains
the ability to bind to OX40. In certain embodiments, a total of 1
to 10 amino acids have been substituted, inserted and/or deleted in
SEQ ID NO: 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138,
140, 142, 144, 146, 148. In certain embodiments, substitutions,
insertions, or deletions occur in regions outside the HVRs (i.e.,
in the FRs). Optionally, the anti-human OX40 agonist antibody
comprises the VH sequence in SEQ ID NO: 118, 120, 122, 124, 126,
128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, including
post-translational modifications of that sequence. In a particular
embodiment, the VH comprises one, two or three HVRs selected from:
(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29, (b)
HVR-H2 comprising the amino acid sequence of SEQ ID NO:30, and (c)
HVR-H3 comprising the amino acid sequence of SEQ ID NO:33.
[0215] In another aspect, an anti-human OX40 agonist antibody is
provided, wherein the antibody comprises a light chain variable
domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to the amino acid sequence of
SEQ ID NO: 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139,
141, 143, 145, 147, 149. In certain embodiments, a VL sequence
having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity contains substitutions (e.g., conservative substitutions),
insertions, or deletions relative to the reference sequence, but an
anti-human OX40 agonist antibody comprising that sequence retains
the ability to bind to OX40. In certain embodiments, a total of 1
to 10 amino acids have been substituted, inserted and/or deleted in
SEQ ID NO: 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139,
141, 143, 145, 147, 149. In certain embodiments, the substitutions,
insertions, or deletions occur in regions outside the HVRs (i.e.,
in the FRs). Optionally, the anti-human OX40 agonist antibody
comprises the VL sequence in SEQ ID NO: 119, 121, 123, 125, 127,
129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, including
post-translational modifications of that sequence. In a particular
embodiment, the VL comprises one, two or three HVRs selected from
(a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:37; (b)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:39; and (c)
HVR-L3 comprising the amino acid sequence of SEQ ID NO:42.
[0216] In one embodiment, the antibody comprises the VH and VL
sequences in SEQ ID NO:56 and SEQ ID NO:57, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:58 and SEQ ID NO:59, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:60 and SEQ ID NO:61, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:62 and SEQ ID NO:63, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:64 and SEQ ID NO:65, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:66 and SEQ ID NO:67, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:68 and SEQ ID NO:69, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:70 and SEQ ID NO:71, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:72 and SEQ ID NO:73, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:74 and SEQ ID NO:75, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:76 and SEQ ID NO:77, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:78 and SEQ ID NO:79, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:80 and SEQ ID NO:81, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:82 and SEQ ID NO:83, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:84 and SEQ ID NO:85, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:86 and SEQ ID NO:87, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:88 and SEQ ID NO:89, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:90 and SEQ ID NO:91, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:92 and SEQ ID NO:93, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:94 and SEQ ID NO:95, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:96 and SEQ ID NO:97, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:98 and SEQ ID NO:99, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:100 and SEQ ID NO:101, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:108 and SEQ ID NO:109, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:114 and SEQ ID NO:115, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:116 and SEQ ID NO:117, respectively, including
post-translational modifications of those sequences.
[0217] In one embodiment, the antibody comprises the VH and VL
sequences in SEQ ID NO:118 and SEQ ID NO:119, respectively,
including post-translational modifications of those sequences. In
one embodiment, the antibody comprises the VH and VL sequences in
SEQ ID NO:120 and SEQ ID NO:121, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:122 and SEQ ID NO:123, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:124 and SEQ ID NO:125, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:126 and SEQ ID NO:127, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:128 and SEQ ID NO:129, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:130 and SEQ ID NO:131, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:132 and SEQ ID NO:133, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:134 and SEQ ID NO:135, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:136 and SEQ ID NO:137, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:138 and SEQ ID NO:139, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:140 and SEQ ID NO:141, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:142 and SEQ ID NO:143, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:144 and SEQ ID NO:145, respectively, including
post-translational modifications of those sequences. In one
embodiment, the antibody comprises the VH and VL sequences in SEQ
ID NO:146 and SEQ ID NO:147, respectively, including
post-translational modifications of those sequences.
[0218] In another aspect, an anti-human OX40 agonist antibody is
provided, wherein the antibody comprises a VH as in any of the
embodiments provided above, and a VL as in any of the embodiments
provided above.
[0219] In some embodiments, the OX40 agonist antibody is MEDI6469.
In some embodiments, the OX40 agonist antibody is MEDI0562.
[0220] In a further aspect, the invention provides an antibody that
binds to the same epitope as an anti-human OX40 antibody provided
herein. In some embodiments, the antibody is an anti-human OX40
agonist antibody.
[0221] In a further aspect of the invention, an anti-OX40 antibody
according to any of the above embodiments is a monoclonal antibody,
including a chimeric, humanized or human antibody. In one
embodiment, an anti-OX40 antibody is an antibody fragment, e.g., a
Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment. In another
embodiment, the antibody is a full length antibody, e.g., an intact
IgG1 antibody or other antibody class or isotype as defined herein.
In some embodiments, the antibody is a full length intact IgG4
antibody.
[0222] Exemplary amino acid sequences corresponding to OX40
polypeptides and OX40 antibodies are provided below.
TABLE-US-00003 TABLE 2 Amino acid sequences SEQ ID Name SEQUENCE
NO: Human OX40 LHCVGDTYPSNDRCCHECRPGNGMVSRCSRSQNTVCRPCGPGFY 1
(lacking the NDVVSSKPCKPCTWCNLRSGSERKQLCTATQDTVCRCRAGTQPL signal
DSYKPGVDCAPCPPGHFSPGDNQACKPWTNCTLAGKHTLQPASN peptide)
SSDAICEDRDPPATQPQETQGPPARPITVQPTEAWPRTSQGPSTRP
VEVPGGRAVAAILGLGLVLGLLGPLAILLALYLLRRDQRLPPDAH
KPPGGGSFRTPIQEEQADAHSTLAKI HVR-H1- DSYMS 2 1A7.gr.1 1A7.gr.2
1A7.gr.3 1A7.gr.4 1A7.gr.5 1A7.gr.6 1A7.gr.7 1A7.gr.NADS
1A7.gr.NADA 1A7.gr.NGDA 1A7.gr.SGDS 1A7.gr.NGSS 1A7.Ala.1 1A7.Ala.2
1A7.Ala.3 1A7.Ala.4 1A7.Ala.5 1A7.Ala.6 1A7.Ala.7 1A7.Ala.8
1A7.Ala.9 1A7.Ala.10 1A7.Ala.11 1A7.Ala.12 1A7.Ala.13 1A7.Ala.14
1A7.Ala.15 1A7.Ala.16 HVR-H2- DMYPDNGDSSYNQKFRE 3 1A7.gr.1 1A7.gr.2
1A7.gr.3 1A7.gr.4 1A7.gr.5 1A7.gr.6 1A7.gr.7 1A7.gr.DA 1A7.gr.ES
1A7.Ala.1 1A7.Ala.2 1A7.Ala.3 1A7.Ala.4 1A7.Ala.5 1A7.Ala.6
1A7.Ala.7 1A7.Ala.8 1A7.Ala.9 1A7.Ala.10 1A7.Ala.11 1A7.Ala.12
1A7.Ala.13 1A7.Ala.14 1A7.Ala.15 1A7.Ala.16 HVR-H3- APRWYFSV 4
1A7.gr.1 1A7.gr.2 1A7.gr.3 1A7.gr.4 1A7.gr.5 1A7.gr.6 1A7.gr.7
1A7.gr.DA 1A7.gr.ES 1A7.gr.NADS 1A7.gr.NADA 1A7.gr.NGDA 1A7.gr.SGDS
1A7.gr.NGSS 1A7.gr.DANAD A 1A7.Ala.1 1A7.Ala.2 1A7.Ala.3 1A7.Ala.4
1A7.Ala.5 1A7.Ala.6 1A7.Ala.7 1A7-Ala.15 1A7.Ala.16 HVR-L1-
RASQDISNYLN 5 1A7.gr.1 1A7.gr.2 1A7.gr.3 1A7.gr.4 1A7.gr.5 1A7.gr.6
1A7.gr.7 1A7.gr.DA 1A7.gr.ES 1A7.gr.NADS 1A7.gr.NADA 1A7.gr.NGDA
1A7.gr.SGDS 1A7.gr.NGSS 1A7.gr.DANAD A 1A7.Ala.1 1A7.Ala.2
1A7.Ala.3 1A7.Ala.4 1A7.Ala.5 1A7.Ala.6 1A7.Ala.7 1A7.Ala.8
1A7.Ala.9 1A7.Ala.10 1A7.Ala.11 1A7.Ala.12 1A7.Ala.13 1A7.Ala.14
1A7.Ala.15 1A7.Ala.16 HVR-L2- YTSRLRS 6 1A7.gr.1 1A7.gr.2 1A7.gr.3
1A7.gr.4 1A7.gr.5 1A7.gr.6 1A7.gr.7 1A7.gr.DA 1A7.gr.ES 1A7.gr.NADS
1A7.gr.NADA 1A7.gr.NGDA 1A7.gr.SGDS 1A7.gr.NGSS 1A7.gr.DANAD A
1A7.Ala.1 1A7.Ala.2 1A7.Ala.3 1A7.Ala.4 1A7.Ala.5 1A7.Ala.6
1A7.Ala.7 1A7.Ala.8 1A7.Ala.9 1A7.Ala.10 1A7.Ala.11 1A7.Ala.12
1A7.Ala.13 1A7.Ala.14 1A7.Ala.15 1A7.Ala.16 HVR-L3- QQGHTLPPT 7
1A7.gr.1 1A7.gr.2 1A7.gr.3 1A7.gr.4 1A7.gr.5 1A7.gr.6 1A7.gr.7
1A7.gr.DA 1A7.gr.ES 1A7.gr.NADS 1A7.gr.NADA 1A7.gr.NGDA 1A7.gr.SGDS
1A7.gr.NGSS 1A7.gr.DANAD A 1A7.Ala.8 1A7.Ala.9 1A7.Ala.10
1A7.Ala.11 1A7.Ala.12 1A7.Ala.13 1A7.Ala.14 1A7.Ala.15 1A7.Ala.16
HVR-H1- DAYMS 8 1A7.gr.DA HVR-H1- ESYMS 9 1A7.gr.ES 1A7.gr.DANAD A
HVR-H2- DMYPDNADSSYNQKFRE 10 1A7.gr.NADS HVR-H2- DMYPDNADASYNQKFRE
11 1A7.gr.NADA 1A7.gr.DANAD A HVR-H2- DMYPDNGDASYNQKFRE 12
1A7.gr.NGDA HVR-H2- DMYPDSGDSSYNQKFRE 13 1A7.gr.SGDS HVR-H2-
DMYPDNGSSSYNQKFRE 14 1A7.gr.NGSS HVR-H3- APRWYFSA 15 1A7.Ala.8
HVR-H3- APRWYASV 16 1A7.Ala.9 HVR-H3- APRWAFSV 17 1A7.Ala.10
HVR-H3- APAWYFSV 18 1A7.Ala.11 HVR-H3- APRWYFAV 19 1A7.Ala.12
HVR-H3- APRAYFSV 20 1A7.Ala.13 HVR-H3- AARWYFSV 21 1A7.Ala.14
HVR-L3- QQGHTLPAT 22 1A7.Ala.1 HVR-L3- QQGHTAPPT 23 1A7.Ala.2
HVR-L3- QQGATLPPT 24 1A7.Ala.3 HVR-L3- QQGHALPPT 25 1A7.Ala.4
HVR-L3- QQAHTLPPT 26 1A7.Ala.5 HVR-L3- QQGHTLAPT 27 1A7.Ala.6
HVR-L3- QAGHTLPPT 28 1A7.Ala.7 HVR-H1- NYLIE 29 3C8.gr.1 3C8.gr.2
3C8.gr.3 3C8.gr.4 3C8.gr.5 3C8.gr.5.SG 3C8.gr.5.EG 3C8.gr.5.QG
3C9.gr.5.DQ 3C8.gr.5.DA 3C8.gr.6 3C8.gr.7 3C8.gr.8 3C8.gr.9
3C8.gr.10 3C8.gr.11 3C8.A.1 3C8.A.2 3C8.A.3 3C8.A.4 3C8.A.5 3C8.A.6
3C8.A.7 3C8.A.8 3C8.A.9 3C8.A.10 HVR-H2- VINPGSGDTYYSEKFKG 30
3C8.gr.1 3C8.gr.2 3C8.gr.3 3C8.gr.4 3C8.gr.5 3C8.gr.5.SG
3C8.gr.5.EG 3C8.gr.5.QG 3C8.gr.6 3C8.gr.7 3C8.gr.8 3C8.gr.9
3C8.gr.10 3C8.gr.11 3C8.A.1 3C8.A.2 3C8.A.3 3C8.A.4 3C8.A.5 3C8.A.6
3C8.A.7 3C8.A.8 3C8.A.9 3C8.A.10 HVR-H2- VINPGSGDAYYSEKFKG 31
3C8.gr.5.DA HVR-H2- VINPGSGDQYYSEKFKG 32 3C8.gr.5.DQ HVR-H3- DRLDY
33 3C8.gr.1 3C8.gr.2 3C8.gr.3 3C8.gr.4 3C8.gr.5 3C8.gr.5.SG
3C8.gr.5.EG 3C8.gr.5.QG 3C8.gr.5.DA 3C8.gr.5.DQ 3C8.gr.6 3C8.gr.7
3C8.gr.8 3C8.gr.9 3C8.gr.10 3C8.gr.11 3C8.A.1 3C8.A.2 3C8.A.3
3C8.A.4 3C8.A.5 3C8.A.6 3C8.A.7 HVR-H3- ARLDY 34 3C8.A.8 HVR-H3-
DALDY 35 3C8.A.9 HVR-H3- DRADY 36 3C8.A.10 HVR-L1- HASQDISSYIV 37
3C8.gr.1 3C8.gr.2 3C8.gr.3 3C8.gr.4 3C8.gr.5 3C8.gr.5.SG
3C8.gr.5.EG 3C8.gr.5.QG 3C8.gr.5.DA 3C8.gr.5.DQ 3C8.gr.6 3C8.gr.7
3C8.gr.8 3C8.gr.9 3C8.gr.10 3C8.gr.11 3C8.A.1 3C8.A.2 3C8.A.3
3C8.A.4 3C8.A.5 3C8.A.6 3C8.A.7 3C8.A.8 3C8.A.9 3C8.A.10 HVR-L2-
HGTNLED 38 3C8.gr.1 3C8.gr.2 3C8.gr.3 3C8.gr.4 3C8.gr.5 3C8.gr.5.DA
3C8.gr.5.DQ 3C8.gr.6 3C8.gr.7 3C8.gr.8 3C8.gr.9 3C8.gr.10 3C8.gr.11
3C8.A.1 3C8.A.2 3C8.A.3 3C8.A.4 3C8.A.5 3C8.A.6 3C8.A.7 3C8.A.8
3C8.A.9 3C8.A.10 HVR-L2- HGTNLES 39 3C8.gr5.SG HVR-L2- HGTNLEE 40
3C8.gr.5.EG HVR-L2- HGTNLEQ 41 3C8.gr.5.QG HVR-L3 VHYAQFPYT 42
3C8.gr.1 3C8.gr.2 3C8.gr.3 3C8.gr.4 3C8.gr.5 3C8.gr.5.SG
3C8.gr.5.EG 3C8.gr.5.QG 3C8.gr.5.DA 3C8.gr.5.DQ 3C8.gr.6 3C8.gr.7
3C8.gr.8 3C8.gr.9 3C8.gr.10 3C8.gr.11 3C8.A.8 3C8.A.9 3C8.A.10
HVR-L3- AHYAQFPYT 43 3C8.A.1 HVR-L3- VAYAQFPYT 44 3C8.A.2 HVR-L3-
VHAAQFPYT 45 3C8.A.3 HVR-L3- VHYAAFPYT 46 3C8.A.4 HVR-L3- VHYAQAPYT
47 3C8.A.5 HVR-L3- VHYAQFAYT 48 3C8.A.6 HVR-L3- VHYAQFPAT 49
3C8.A.7 HVR-H1- DYGVL 50 1D2.gr.1 1D2.gr.2 1D2.gr.3 HVR-H2-
MIWSGGTTDYNAAFIS 51 1D2.gr.1 1D2.gr.2 1D2.gr.3 HVR-H3- EEMDY 52
1D2.gr.1 1D2.gr.2 1D2.gr.3 HVR-L1- RASQDISNFLN 53 1D2.gr.1 1D2.gr.2
1D2.gr.3 HVR-L2- YTSRLHS 54 1D2.gr.1 1D2.gr.2 1D2.gr.3 HVR-L3-
QQGNTLPWT 55 1D2.gr.1 1D2.gr.2 1D2.gr.3 1A7.gr.1
EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 56 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.1
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 57 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.gr.2 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 58 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITVDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.2
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 59
V.sub.L LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG
HTLPPTFGQGTKVEIK 1A7.gr.3
EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 60 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTLTVDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.3
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 61 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.gr.4 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 62 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITVDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.4
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKTVK 63 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.gr.5 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 64 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITVDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.5
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKTVK 65 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.gr.6 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 66 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITVDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.6
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKTVK 67 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGKDYTLTISSLQPEDFATYFCQQG HTLPPTFGQGTKVEIK
1A7.gr.7 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 68 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITVDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.7
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKTVK 69 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGKDYTLTISSLQPEDFATYFCQQG HTLPPTFGQGTKVEIK
1A7.gr.DA EVQLVQSGAEVKKPGASVKVSCKASGYTFTDAYMSWVRQAPGQ 70 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.DA
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 71 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.gr.ES EVQLVQSGAEVKKPGASVKVSCKASGYTFTESYMSWVRQAPGQ 72 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.ES
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 73 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.gr.NADS EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 74 V.sub.H
GLEWIGDMYPDNADSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.NADS
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 75 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.gr.NADA EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 76 V.sub.H
GLEWIGDMYPDNADASYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.NADA
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 77 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.gr.NGDA EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 78 V.sub.H
GLEWIGDMYPDNGDASYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.NGDA
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 79 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.gr.SGDS EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 80 V.sub.H
GLEWIGDMYPDSGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSE
DTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.SGDS
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 81 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.gr.NGSS EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 82 V.sub.H
GLEWIGDMYPDNGSSSYNQKFRERVTITRDTSTSTAYLELSSLRSE
DTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.NGSS
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 83 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.gr.DANAD EVQLVQSGAEVKKPGASVKVSCKASGYTFTDAYMSWVRQAPGQ 84 A
GLEWIGDMYPDNADASYNQKFRERVTITRDTSTSTAYLELSSLRS V.sub.H
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.DANAD
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 85 A
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG V.sub.L
HTLPPTFGQGTKVEIK 1A7.Ala.1
EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 86 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.Ala.1
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 87 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPATFGQGTKVEIK
1A7.Ala.2 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 88 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.Ala.2
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 89 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTAPPTFGQGTKVEIK
1A7.Ala.3 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 90 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.Ala.3
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 91 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG ATLPPTFGQGTKVEIK
1A7.Ala.4 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 92 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.Ala.4
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 93 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HALPPTFGQGTKVEIK
1A7.Ala.5 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 94 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.Ala.5
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 95 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQA HTLPPTFGQGTKVEIK
1A7.Ala.6 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 96 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.Ala.6
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 97 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLAPTFGQGTKVEIK
1A7.Ala.7 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 98 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSVWGQGTLVTVSS 1A7.Ala.7
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 99 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQAG HTLPPTFGQGTKVEIK
1A7.Ala.8 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 100 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFSAWGQGTLVTVSS 1A7.Ala.8
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 101 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.Ala.9 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 102 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYASVWGQGTLVTVSS 1A7.Ala.9
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 103 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.Ala.10 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 104 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWAFSVWGQGTLVTVSS 1A7.Ala.10
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 105 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.Ala.11 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 106 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPAWYFSVWGQGTLVTVSS 1A7.Ala.11
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 107 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.Ala.12 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 108 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRWYFAVWGQGTLVTVSS 1A7.Ala.12
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 109 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.Ala.13 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 110 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAPRAYFSVWGQGTLVTVSS 1A7.Ala.13
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 111 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.Ala.14 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 112 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVLAARWYFSVWGQGTLVTVSS 1A7.Ala.14
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 113 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.Ala.15 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 114 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCALAPRWYFSVWGQGTLVTVSS 1A7.Ala.15
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 115 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
1A7.Ala.16 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQ 116 V.sub.H
GLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRS
EDTAVYYCVAAPRWYFSVWGQGTLVTVSS 1A7.Ala.16
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPK 117 V.sub.L
LLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG HTLPPTFGQGTKVEIK
3C8.gr.1 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 118 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTITRDTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.1
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKAPK 119 V.sub.L
LLIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHY AQFPYTFGQGTKVEIK
3C8.gr.2 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 120 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTITADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.2
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKAPK 121 V.sub.L
LLIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHY AQFPYTFGQGTKVEIK
3C8.gr.3 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 122 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.3
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKAPK 123 V.sub.L
LLIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHY AQFPYTFGQGTKVEIK
3C8.gr.4 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 124 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.4
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 125 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFPYTFGQGTKVEIK
3C8.gr.5 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 126 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.5
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 127 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFPYTFGQGTKVEIK
3C8.gr.5.SG EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 128 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.5.SG
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 129 V.sub.L
LIYHGTNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFPYTFGQGTKVEIK
3C8.gr.5.EG EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 130 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.5.EG
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 131 V.sub.L
LIYHGTNLEEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFPYTFGQGTKVEIK
3C8.gr.5.QG EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 132 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.5.QG
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 133 V.sub.L
LIYHGTNLEQGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFPYTFGQGTKVEIK
3C8.gr.6 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 134 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTITADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.6
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 135 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGADYTLTISSLQPEDFATYYCVHY AQFPYTFGQGTKVEIK
3C8.gr.7 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 136 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.7
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 137 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGADYTLTISSLQPEDFATYYCVHY AQFPYTFGQGTKVEIK
3C8.gr.8 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 138 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTRDTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.8
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 139 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFPYTFGQGTKVEIK
3C8.gr.9 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 140 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTRDTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.9
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSPKL 141 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFPYTFGQGTKVEIK
3C8.gr.10 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 142 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTRDTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.10
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKAFK 143 V.sub.L
LLIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHY AQFPYTFGQGTKVEIK
3C8.gr.11 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 144 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTRDTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.gr.11
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKAPK 145 V.sub.L
GLIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHY AQFPYTFGQGTKVEIK
3C8.A.1 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 146 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.A.1
DIQMTQSPSSLSASVDGRVTITCHASQDISSYIVWYQQKPGKSFKG 147 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCAHYA QFPYTFGQGTKVEIK
3C8.A.2 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 148 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.A.2
DIQMTQSPSSLSASVDGRVTITCHASQDISSYIVWYQQKPGKSFKG 149 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVAYA QFPYTFGQGTKVEIK
3C8.A.3 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 150 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.A.3
DIQMTQSPSSLSASVDGRVTITCHASQDISSYIVWYQQKPGKSFKG 151 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHAA QFPYTFGQGTKVEIK
3C8.A.4 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 152 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.A.4
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 153 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA AFPYTFGQGTKVEIK
3C8.A.5 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 154 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.A.5
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 155 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QAPYTFGQGTKVEIK
3C8.A.6 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 156 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.A.6
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 157 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFAYTFGQGTKVEIK
3C8.A.7 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 158 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRLDYWGQGTLVTVSS 3C8.A.7
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 159 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFPATFGQGTKVEIK
3C8.A.8 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 160 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARARLDYWGQGTLVTVSS 3C8.A.8
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 161 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFPYTFGQGTKVEIK
3C8.A.9 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 162 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDALDYWGQGTLVTVSS 3C8.A.9
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 163 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFPYTFGQGTKVEIK
3C8.A.10 EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQ 164 V.sub.H
GLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSE
DTAVYYCARDRADYWGQGTLVTVSS 3C8.A.10
DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKG 165 V.sub.L
LIYHGTNLEDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYA QFPYTFGQGTKVEIK
1D2.gr.1 EVQLVESGPGLVKPSETLSLTCTVSGFSLTDYGVLWIRQPPGKGL 166 V.sub.H
EWIGMIWSGGTTDYNAAFISRVTISVDTSKNQFSLKLSSVTAADT
AVYYCVREEMDYWGQGTLVTVSS 1D2.gr.1
DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAPK 167 V.sub.L
LLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG NTLPWTFGQGTKVEIK
1D2.gr.2 EVQLVESGPGLVKPSETLSLTCTVSGFSLTDYGVLWIRQPPGKGL 168 V.sub.H
EWIGMIWSGGTTDYNAAFISRVTISKDTSKNQVSLKLSSVTAADT
AVYYCVREEMDYWGQGTLVTVSS 1D2.gr.2
DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAPK 169 V.sub.L
LLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG NTLPWTFGQGTKVEIK
1D2.gr.3 EVQLVESGPGLVKPSETLSLTCTVSGFSLTDYGVLWVRQPPGKGL 170 V.sub.H
EWLGMIWSGGTTDYNAAFISRLTISKDTSKNQVSLKLSSVTAADT
AVYYCVREEMDYWGQGTLVTVSS 1D2.gr.3
DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAPK 171 V.sub.L
LLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQG NTLPWTFGQGTKVEIK
CON1 X.sub.1X.sub.2YMS, wherein X.sub.1 is D or E, and X.sub.2 is S
or A 172 (1A7)HVR-H1 CON1 (1A7)
DMYPDX.sub.1X.sub.2X.sub.3X.sub.4SYNQKFRE, wherein X.sub.1 is N or
S, X.sub.1 173 HVR-H2 is A or G, X.sub.3 is D or S, and X.sub.4 is
A or S CON1 (1A7) APRWX.sub.1X.sub.2X.sub.3X.sub.4, wherein X.sub.1
is Y or A, X.sub.2 is A or 174 HVR-H3 F, X.sub.3 is S or A, and
X.sub.4 is A or V. CON1 (1A7)
QX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7T, wherein
X.sub.1 is A or Q, X.sub.2 is A 175 HVR-L3 or G, X.sub.3 is A or H,
X.sub.4 is A or T, X.sub.5 is A or L, X.sub.6 is A or P, and
X.sub.7 is A or P. CON2 (3C8) VINPGSGDX.sub.1YYSEKFKG, wherein
X.sub.1 is T, A or Q. 176 HVR-H2 CON2 (3C8) HGTNLEX.sub.1, wherein
X.sub.1 is S, E, or Q. 177 HVR-L2 CON2 (3C8)
X.sub.1X.sub.2YAQFPYX.sub.3, wherein X.sub.1 is V or A, X.sub.2 is
H or 178 HVR-L3 A, and X.sub.3 is Y or A. 1A7 V.sub.L
DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLL 179
IYYTSRLRSGVPSRFSGSGSGKDYFLTISNLEQEDVAAYFCQQGHTLP PTFGGGTKLEIK 1A7
V.sub.H EVQLQQSGPELVKPGASVKISCKASGYTFTDSYMSWVKQSHGKTLE 180
WIGDMYPDNGDSSYNQKFREKVTLTVDKSSTTAYMEFRSLTSEDSA
VYYCVLAPRWYFSVWGTGTTVTVSS 3C8 V.sub.L
DILMTQSPSSMSVSLGDTVSITCHASQDISSYIVWLQQKPGKSFRGLI 181
YHGTNLEDGIPSRFSGSGSGADYSLTISSLESEDFADYYCVHYAQFPY TFGGGTKLEIK 3C8
V.sub.H QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLE 182
WIGVINPGSGDTYYSEKFKGKVTLTADKSSSTAYMQLSSLTSEDSAV
YFCARDRLDYWGQGTTLTVSS 1A7.gr.5'
EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGL 225 V.sub.H
EWIGDMYPDNGDSSYNQKFRERVTLTVDTSTSTAYLELSSLRSEDTA
VYYCVLAPRWYFSVWGQGTLVTVSS 1A7.gr.7'
EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGL 226 V.sub.H
EWIGDMYPDNGDSSYNQKFRERVTLTVDTSTSTAYLELSSLRSEDTA
VYYCVLAPRWYFSVWGQGTLVTVSS
[0223] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in U.S. Pat. No. 7,550,140. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain comprising the sequence of
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYTMNWVRQAPGKGLEWVSAISGSGGSTYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRYSQVHYALDYWGQGTLVTVS
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:183)
and/or a light chain comprising the sequence of
DIVMTQSPDSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKAGQSPQLLIYLGSNRASGV
PDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQYYNHPTTFGQGTKLEIKRTVAAPSVFIFPPS
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS
KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:184). In some
embodiments, the antibody comprises at least one, two, three, four,
five or six hypervariable region (HVR) sequences of antibody 008 as
described in U.S. Pat. No. 7,550,140. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody 008 as described
in U.S. Pat. No. 7,550,140.
[0224] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in U.S. Pat. No. 7,550,140. In some
embodiments, the agonist anti-human OX40 antibody comprises the
sequence of
MAEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYTMNWVRQAPGKGLEWVSAISGSGGST
YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRYSQVHYALDYWGQGT
LVTVLEGTGGSGGTGSGTGTSELDIQMTQSPDSLPVTPGEPASISCRSSQSLLHSNGYNYL
DWYLQKAGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQY
YNHPTTFGQGTKLEIKRAA (SEQ ID NO:185). In some embodiments, the
antibody comprises at least one, two, three, four, five or six
hypervariable region (HVR) sequences of antibody SC02008 as
described in U.S. Pat. No. 7,550,140. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody SC02008 as
described in U.S. Pat. No. 7,550,140.
[0225] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in U.S. Pat. No. 7,550,140. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain comprising the sequence of
EVQLVESGGGLVHPGGSLRLSCAGSGFTFSSYAMHWVRQAPGKGLEWVSAIGTGGGTYYA
DSVMGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYDNVMGLYWFDYWGQGTLVTVS
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:186) and/or a light chain
comprising the sequence of
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFS
GSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS
GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEK
HKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:187). In some embodiments,
the antibody comprises at least one, two, three, four, five or six
hypervariable region (HVR) sequences of antibody 023 as described
in U.S. Pat. No. 7,550,140. In some embodiments, the antibody
comprises a heavy chain variable region sequence and/or a light
chain variable region sequence of antibody 023 as described in U.S.
Pat. No. 7,550,140.
[0226] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in U.S. Pat. No. 7,960,515. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIDYAD
SVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARESGWYLFDYWGQGTLVTVSS (SEQ ID
NO:188) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFS
GSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGGGTKVEIK (SEQ ID NO:189). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
11D4 as described in U.S. Pat. No. 7,960,515. In some embodiments,
the antibody comprises a heavy chain variable region sequence
and/or a light chain variable region sequence of antibody 11D4 as
described in U.S. Pat. No. 7,960,515.
[0227] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in U.S. Pat. No. 7,960,515. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain comprising the sequence of
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGY
ADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDQSTADYYFYYGMDVWGQGTT
VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRV
VSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQV
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFS
CSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:190) and/or a light chain
comprising the sequence of
EIVVTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFS
GSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG
TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH
KVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:191). In some embodiments, the
antibody comprises at least one, two, three, four, five or six
hypervariable region (HVR) sequences of antibody 18D8 as described
in U.S. Pat. No. 7,960,515. In some embodiments, the antibody
comprises a heavy chain variable region sequence and/or a light
chain variable region sequence of antibody 18D8 as described in
U.S. Pat. No. 7,960,515.
[0228] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2012/027328. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGSELKKPGASVKVSCKASGYTFTDYSMHWVRQAPGQGLKWMGWINTETGEPT
YADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCANPYYDYVSYYAMDYWGQGTTVT VSS
(SEQ ID NO:192) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYLYTGVPSRF
SGSGSGTDFTFTISSLQPEDIATYYCQQHYSTPRTFGQGTKLEIK (SEQ ID NO:193). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
hu106-222 as described in WO2012/027328. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody hu106-222 as
described in WO2012/027328.
[0229] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2012/027328. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
EVQLVESGGGLVQPGGSLRLSCAASEYEFPSHDMSWVRQAPGKGLELVAAINSDGGSTYYP
DTMERRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHYDDYYAWFAYWGQGTMVTVSS (SEQ ID
NO:194) and/or a light chain variable region comprising the
sequence of
EIVLTQSPATLSLSPGERATLSCRASKSVSTSGYSYMHWYQQKPGQAPRLLIYLASNLESGVP
ARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRELPLTFGGGTKVEIK (SEQ ID NO:195).
In some embodiments, the antibody comprises at least one, two,
three, four, five or six hypervariable region (HVR) sequences of
antibody Hu119-122 as described in WO2012/027328. In some
embodiments, the antibody comprises a heavy chain variable region
sequence and/or a light chain variable region sequence of antibody
Hu119-122 as described in WO2012/027328.
[0230] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2013/028231. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain comprising the sequence of
MYLGLNYVFIVFLLNGVQSEVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSP
EKGLEWVaEIRSKANNHATYYAESVNGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTWGE
VFYFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYITCNVNHKPSNTKVDKKVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:196) and/or a
light chain comprising the sequence of
MRPSIQFLGLLLFWLHGAQCDIQMTQSPSSLSASLGGKVTITCKSSQDINKYIAWYQHKPGK
GPRLLIHYTSTLQPGIPSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDNLLTFGAGTKLELK
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:197). In
some embodiments, the anti-human OX40 agonist antibody comprises a
heavy chain variable region comprising the sequence of
MYLGLNYVFIVFLLNGVQSEVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKG
LEWVAEIRSKANNHATYYAESVNGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTWGEVFYFDY
WGQGTTLTVSS (SEQ ID NO:198) and/or a light chain variable region
comprising the sequence of
MRPSIQFLGLLLFWLHGAQCDIQMTQSPSSLSASLGGKVTITCKSSQDINKYIAWYQHKPGKGPR
LLIHYTSTLQPGIPSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDNLLTFGAGTKLELK (SEQ
ID NO:199). In some embodiments, the antibody comprises at least
one, two, three, four, five or six hypervariable region (HVR)
sequences of antibody Mab CH 119-43-1 as described in
WO2013/028231. In some embodiments, the antibody comprises a heavy
chain variable region sequence and/or a light chain variable region
sequence of antibody Mab CH 119-43-1 as described in
WO2013/028231.
[0231] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2013038191. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNDGTKY
NEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCANYYGSSLSMDYWGQGTSVTVSS (SEQ ID
NO:200) and/or a light chain variable region comprising the
sequence of
DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFS
GSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIKR (SEQ ID NO:201). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 20E5 as described in WO2013038191. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 20E5 as
described in WO2013038191.
[0232] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2013038191. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
EVQLQQSGPELVKPGASVKISCKTSGYTFKDYTMHWVKQSHGKSLEWIGGIYPNNGGSTYN
QNFKDKATLTVDKSSSTAYMEFRSLTSEDSAVYYCARMGYHGPHLDFDVWGAGTTVTVSP (SEQ
ID NO:202) and/or a light chain variable region comprising the
sequence of
DIVMTQSHKFMSTSLGDRVSITCKASQDVGAAVaWYQQKPGQSPKLLIYWASTRHTGVPDR
FTGGGSGTDFTLTISNVQSEDLTDYFCQQYINYPLTFGGGTKLEIKR (SEQ ID NO:203). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 12H3 as described in WO2013038191. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 12H3 as
described in WO2013038191.
[0233] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQRLEWMGYINPYNDGTK
YNEKFKGRVTITSDTSASTAYMELSSLRSEDTAVYYCANYYGSSLSMDYWGQGTLVTVSS (SEQ
ID NO:204) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFS
GSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKR (SEQ ID NO:205). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 20E5 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 20E5 as
described in WO2014148895A1.
[0234] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQRLEWMGYINPYNDGTK
YNEKFKGRVTITSDTSASTAYMELSSLRSEDTAVYYCANYYGSSLSMDYWGQGTLVTVSS (SEQ
ID NO:204) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAVKLLIYYTSRLHSGVPSRFS
GSGSGTDYTLTISSLQPEDFATYFCQQGNTLPWTFGQGTKVEIKR (SEQ ID NO:206). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 20E5 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 20E5 as
described in WO2014148895A1.
[0235] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQRLEWIGYINPYNDGTK
YNEKFKGRATITSDTSASTAYMELSSLRSEDTAVYYCANYYGSSLSMDYWGQGTLVTVSS (SEQ
ID NO:207) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFS
GSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKR (SEQ ID NO:205). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 20E5 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 20E5 as
described in WO2014148895A1.
[0236] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQRLEWIGYINPYNDGTK
YNEKFKGRATITSDTSASTAYMELSSLRSEDTAVYYCANYYGSSLSMDYWGQGTLVTVSS (SEQ
ID NO:207) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAVKLLIYYTSRLHSGVPSRFS
GSGSGTDYTLTISSLQPEDFATYFCQQGNTLPWTFGQGTKVEIKR (SEQ ID NO:206). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 20E5 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 20E5 as
described in WO2014148895A1.
[0237] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQRLEWIGYINPYNDGTK
YNEKFKGRATLTSDKSASTAYMELSSLRSEDTAVYYCANYYGSSLSMDYWGQGTLVTVSS (SEQ
ID NO:208) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFS
GSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKR (SEQ ID NO:205). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 20E5 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 20E5 as
described in WO2014148895A1.
[0238] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQRLEWIGYINPYNDGTK
YNEKFKGRATLTSDKSASTAYMELSSLRSEDTAVYYCANYYGSSLSMDYWGQGTLVTVSS (SEQ
ID NO:208) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAVKLLIYYTSRLHSGVPSRFS
GSGSGTDYTLTISSLQPEDFATYFCQQGNTLPWTFGQGTKVEIKR (SEQ ID NO:206). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 20E5 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 20E5 as
described in WO2014148895A1.
[0239] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGSSVKVSCKASGYTFKDYTMHWVRQAPGQGLEWMGGIYPNNGGST
YNQNFKDRVTITADKSTSTAYMELSSLRSEDTAVYYCARMGYHGPHLDFDVWGQGTTVTV SS
(SEQ ID NO:209) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCKASQDVGAAVaWYQQKPGKAPKLLIYWASTRHTGVPSRF
SGSGSGTDFTLTISSLQPEDFATYYCQQYINYPLTFGGGTKVEIKR (SEQ ID NO:210). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 12H3 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 12H3 as
described in WO2014148895A1.
[0240] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGSSVKVSCKASGYTFKDYTMHWVRQAPGQGLEWMGGIYPNNGGST
YNQNFKDRVTITADKSTSTAYMELSSLRSEDTAVYYCARMGYHGPHLDFDVWGQGTTVTV SS
(SEQ ID NO:209) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCKASQDVGAAVaWYQQKPGKAPKLLIYWASTRHTGVPDR
FSGGGSGTDFTLTISSLQPEDFATYYCQQYINYPLTFGGGTKVEIKR (SEQ ID NO:211). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 12H3 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 12H3 as
described in WO2014148895A1.
[0241] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGSSVKVSCKASGYTFKDYTMHWVRQAPGQGLEWIGGIYPNNGGSTY
NQNFKDRVTLTADKSTSTAYMELSSLRSEDTAVYYCARMGYHGPHLDFDVWGQGTTVTVS S (SEQ
ID NO:212) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCKASQDVGAAVaWYQQKPGKAPKLLIYWASTRHTGVPSRF
SGSGSGTDFTLTISSLQPEDFATYYCQQYINYPLTFGGGTKVEIKR (SEQ ID NO:210). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 12H3 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 12H3 as
described in WO2014148895A1.
[0242] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGSSVKVSCKASGYTFKDYTMHWVRQAPGQGLEWIGGIYPNNGGSTY
NQNFKDRVTLTADKSTSTAYMELSSLRSEDTAVYYCARMGYHGPHLDFDVWGQGTTVTVS S (SEQ
ID NO:212) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCKASQDVGAAVaWYQQKPGKAPKLLIYWASTRHTGVPDR
FSGGGSGTDFTLTISSLQPEDFATYYCQQYINYPLTFGGGTKVEIKR (SEQ ID NO:211). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 12H3 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 12H3 as
described in WO2014148895A1.
[0243] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGSSVKVSCKASGYTFKDYTMHWVRQAPGQGLEWIGGIYPNNGGSTY
NQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARMGYHGPHLDFDVWGQGTTVTVS S (SEQ
ID NO:213) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCKASQDVGAAVaWYQQKPGKAPKLLIYWASTRHTGVPSRF
SGSGSGTDFTLTISSLQPEDFATYYCQQYINYPLTFGGGTKVEIKR (SEQ ID NO:210). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 12H3 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 12H3 as
described in WO2014148895A1.
[0244] In some embodiments, the agonist anti-human OX40 antibody is
an anti-OX40 antibody described in WO2014148895A1. In some
embodiments, the agonist anti-human OX40 antibody comprises a heavy
chain variable region comprising the sequence of
QVQLVQSGAEVKKPGSSVKVSCKASGYTFKDYTMHWVRQAPGQGLEWIGGIYPNNGGSTY
NQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARMGYHGPHLDFDVWGQGTTVTVS S (SEQ
ID NO:213) and/or a light chain variable region comprising the
sequence of
DIQMTQSPSSLSASVGDRVTITCKASQDVGAAVaWYQQKPGKAPKLLIYWASTRHTGVPDR
FSGGGSGTDFTLTISSLQPEDFATYYCQQYINYPLTFGGGTKVEIKR (SEQ ID NO:211). In
some embodiments, the antibody comprises at least one, two, three,
four, five or six hypervariable region (HVR) sequences of antibody
clone 12H3 as described in WO2014148895A1. In some embodiments, the
antibody comprises a heavy chain variable region sequence and/or a
light chain variable region sequence of antibody clone 12H3 as
described in WO2014148895A1.
[0245] In some embodiments, the agonist anti-human OX40 antibody is
L106 BD (Pharmingen Product #340420). In some embodiments, the
antibody comprises at least one, two, three, four, five or six
hypervariable region (HVR) sequences of antibody L106 (BD
Pharmingen Product #340420). In some embodiments, the antibody
comprises a heavy chain variable region sequence and/or a light
chain variable region sequence of antibody L106 (BD Pharmingen
Product #340420).
[0246] In some embodiments, the agonist anti-human OX40 antibody is
ACT35 (Santa Cruz Biotechnology, Catalog #20073). In some
embodiments, the antibody comprises at least one, two, three, four,
five or six hypervariable region (HVR) sequences of antibody ACT35
(Santa Cruz Biotechnology, Catalog #20073). In some embodiments,
the antibody comprises a heavy chain variable region sequence
and/or a light chain variable region sequence of antibody ACT35
(Santa Cruz Biotechnology, Catalog #20073).
[0247] In some embodiments, the agonist anti-human OX40 antibody is
MEDI6469. In some embodiments, the antibody comprises at least one,
two, three, four, five or six hypervariable region (HVR) sequences
of antibody MEDI6469. In some embodiments, the antibody comprises a
heavy chain variable region sequence and/or a light chain variable
region sequence of antibody MEDI6469.
[0248] In some embodiments, the agonist anti-human OX40 antibody is
MEDI0562. In some embodiments, the antibody comprises at least one,
two, three, four, five or six hypervariable region (HVR) sequences
of antibody MEDI0562. In some embodiments, the antibody comprises a
heavy chain variable region sequence and/or a light chain variable
region sequence of antibody MEDI0562.
[0249] Other OX40 Agonists
[0250] OX40 agonists useful for the methods described herein are in
no way intended to be limited to antibodies. Non-antibody OX40
agonists are contemplated and well known in the art.
[0251] As described above, OX40L (also known as CD134L) serves as a
ligand for OX40. As such, agonists that present part or all of
OX40L may serve as OX40 agonists. In some embodiments, an OX40
agonist may include one or more extracellular domains of OX40L.
Examples of extracellular domains of OX40L may include OX40-binding
domains. In some embodiments, an OX40 agonist may be a soluble form
of OX40L that includes one or more extracellular domains of OX40L
but lacks other, insoluble domains of the protein, e.g.,
transmembrane domains. In some embodiments, an OX40 agonist is a
soluble protein that includes one or more extracellular domains of
OX40L able to bind OX40L. In some embodiments, an OX40 agonist may
be linked to another protein domain, e.g., to increase its
effectiveness, half-life, or other desired characteristics. In some
embodiments, an OX40 agonist may include one or more extracellular
domains of OX40L linked to an immunoglobulin Fc domain.
[0252] In some embodiments, an OX40 agonist may be any one of the
OX40 agonists described in U.S. Pat. No. 7,696,175.
[0253] In some embodiments, an OX40 agonist may be an oligomeric or
multimeric molecule. For example, an OX40 agonist may contain one
or more domains (e.g., a leucine zipper domain) that allows
proteins to oligomerize. In some embodiments, an OX40 agonist may
include one or more extracellular domains of OX40L linked to one or
more leucine zipper domains.
[0254] In some embodiments, an OX40 agonist may be any one of the
OX40 agonists described in European Patent No. EP0672141 B1.
[0255] In some embodiments, an OX40 agonist may be a trimeric OX40L
fusion protein. For example, an OX40 agonist may include one or
more extracellular domains of OX40L linked to an immunoglobulin Fc
domain and a trimerization domain (including without limitation an
isoleucine zipper domain).
[0256] In some embodiments, an OX40 agonist may be any one of the
OX40 agonists described in International Publication No.
WO2006/121810. In some embodiments, the OX40 agonist is
MEDI6383.
[0257] In a further aspect, an anti-OX40 agonist and/or antibody
according to any of the above embodiments may incorporate any of
the features, singly or in combination, as described below.
[0258] 1. Antibody Affinity
[0259] In certain embodiments, an antibody provided herein has a
dissociation constant (Kd) of .ltoreq.1 .mu.M, .ltoreq.100 nM,
.ltoreq.10 nM, .ltoreq.1 nM, .ltoreq.0.1 nM, .ltoreq.0.01 nM, or
.ltoreq.0.001 nM (e.g. 10-8 M or less, e.g. from 10-8 M to 10-13 M,
e.g., from 10-9 M to 10-13 M).
[0260] In one embodiment, Kd is measured by a radiolabeled antigen
binding assay (RIA). In one embodiment, an RIA is performed with
the Fab version of an antibody of interest and its antigen. For
example, solution binding affinity of Fabs for antigen is measured
by equilibrating Fab with a minimal concentration of (125I)-labeled
antigen in the presence of a titration series of unlabeled antigen,
then capturing bound antigen with an anti-Fab antibody-coated plate
(see, e.g., Chen et al., J. Mol. Biol. 293:865-881(1999)). To
establish conditions for the assay, MICROTITER.RTM. multi-well
plates (Thermo Scientific) are coated overnight with 5 .mu.g/ml of
a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium
carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine
serum albumin in PBS for two to five hours at room temperature
(approximately 23.degree. C.). In a non-adsorbent plate (Nunc
#269620), 100 pM or 26 pM [125I]-antigen are mixed with serial
dilutions of a Fab of interest (e.g., consistent with assessment of
the anti-VEGF antibody, Fab-12, in Presta et al., Cancer Res.
57:4593-4599 (1997)). The Fab of interest is then incubated
overnight; however, the incubation may continue for a longer period
(e.g., about 65 hours) to ensure that equilibrium is reached.
Thereafter, the mixtures are transferred to the capture plate for
incubation at room temperature (e.g., for one hour). The solution
is then removed and the plate washed eight times with 0.1%
polysorbate 20 (TWEEN-20.RTM.) in PBS. When the plates have dried,
150 .mu.l/well of scintillant (MICROSCINT-20.TM.; Packard) is
added, and the plates are counted on a TOPCOUNT.TM. gamma counter
(Packard) for ten minutes. Concentrations of each Fab that give
less than or equal to 20% of maximal binding are chosen for use in
competitive binding assays.
[0261] According to another embodiment, Kd is measured using a
BIACORE.RTM. surface plasmon resonance assay. For example, an assay
using a BIACORE.RTM.-2000 or a BIACORE.RTM.-3000 (BIAcore, Inc.,
Piscataway, N.J.) is performed at 25.degree. C. with immobilized
antigen CMS chips at .about.10 response units (RU). In one
embodiment, carboxymethylated dextran biosensor chips (CMS,
BIACORE, Inc.) are activated with
N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC)
and N-hydroxysuccinimide (NHS) according to the supplier's
instructions. Antigen is diluted with 10 mM sodium acetate, pH 4.8,
to 5 .mu.g/ml (.about.0.2 .mu.M) before injection at a flow rate of
5 .mu.l/minute to achieve approximately 10 response units (RU) of
coupled protein. Following the injection of antigen, 1 M
ethanolamine is injected to block unreacted groups. For kinetics
measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM)
are injected in PBS with 0.05% polysorbate 20 (TWEEN-20.TM.)
surfactant (PBST) at 25.degree. C. at a flow rate of approximately
25 .mu.l/min. Association rates (kon) and dissociation rates (koff)
are calculated using a simple one-to-one Langmuir binding model
(BIACORE.RTM. Evaluation Software version 3.2) by simultaneously
fitting the association and dissociation sensorgrams. The
equilibrium dissociation constant (Kd) is calculated as the ratio
koff/kon. See, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999).
If the on-rate exceeds 106 M-1 s-1 by the surface plasmon resonance
assay above, then the on-rate can be determined by using a
fluorescent quenching technique that measures the increase or
decrease in fluorescence emission intensity (excitation=295 nm;
emission=340 nm, 16 nm band-pass) at 25.degree. C. of a 20 nM
anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of
increasing concentrations of antigen as measured in a spectrometer,
such as a stop-flow equipped spectrophometer (Aviv Instruments) or
a 8000-series SLM-AMINCO.TM. spectrophotometer (ThermoSpectronic)
with a stirred cuvette.
[0262] 2. Antibody Fragments
[0263] In certain embodiments, an antibody provided herein is an
antibody fragment. Antibody fragments include, but are not limited
to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, and other
fragments described below. For a review of certain antibody
fragments, see Hudson et al. Nat. Med. 9:129-134 (2003). For a
review of scFv fragments, see, e.g., Pluckthiin, in The
Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and
Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see
also WO 93/16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For
discussion of Fab and F(ab')2 fragments comprising salvage receptor
binding epitope residues and having increased in vivo half-life,
see U.S. Pat. No. 5,869,046.
[0264] Diabodies are antibody fragments with two antigen-binding
sites that may be bivalent or bispecific. See, for example, EP
404,097; WO 1993/01161; Hudson et al., Nat. Med. 9:129-134 (2003);
and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448
(1993). Triabodies and tetrabodies are also described in Hudson et
al., Nat. Med. 9:129-134 (2003).
[0265] Single-domain antibodies are antibody fragments comprising
all or a portion of the heavy chain variable domain or all or a
portion of the light chain variable domain of an antibody. In
certain embodiments, a single-domain antibody is a human
single-domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g.,
U.S. Pat. No. 6,248,516 B1).
[0266] Antibody fragments can be made by various techniques,
including but not limited to proteolytic digestion of an intact
antibody as well as production by recombinant host cells (e.g. E.
coli or phage), as described herein.
[0267] 3. Chimeric and Humanized Antibodies
[0268] In certain embodiments, an antibody provided herein is a
chimeric antibody. Certain chimeric antibodies are described, e.g.,
in U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad.
Sci. USA, 81:6851-6855 (1984)). In one example, a chimeric antibody
comprises a non-human variable region (e.g., a variable region
derived from a mouse, rat, hamster, rabbit, or non-human primate,
such as a monkey) and a human constant region. In a further
example, a chimeric antibody is a "class switched" antibody in
which the class or subclass has been changed from that of the
parent antibody. Chimeric antibodies include antigen-binding
fragments thereof.
[0269] In certain embodiments, a chimeric antibody is a humanized
antibody. Typically, a non-human antibody is humanized to reduce
immunogenicity to humans, while retaining the specificity and
affinity of the parental non-human antibody. Generally, a humanized
antibody comprises one or more variable domains in which HVRs,
e.g., CDRs, (or portions thereof) are derived from a non-human
antibody, and FRs (or portions thereof) are derived from human
antibody sequences. A humanized antibody optionally will also
comprise at least a portion of a human constant region. In some
embodiments, some FR residues in a humanized antibody are
substituted with corresponding residues from a non-human antibody
(e.g., the antibody from which the HVR residues are derived), e.g.,
to restore or improve antibody specificity or affinity.
[0270] Humanized antibodies and methods of making them are
reviewed, e.g., in Almagro and Fransson, Front. Biosci.
13:1619-1633 (2008), and are further described, e.g., in Riechmann
et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad.
Sci. USA 86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337,
7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods
36:25-34 (2005) (describing specificity determining region (SDR)
grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing
"resurfacing"); Dall'Acqua et al., Methods 36:43-60 (2005)
(describing "FR shuffling"); and Osbourn et al., Methods 36:61-68
(2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000)
(describing the "guided selection" approach to FR shuffling).
[0271] Human framework regions that may be used for humanization
include but are not limited to: framework regions selected using
the "best-fit" method (see, e.g., Sims et al. J. Immunol. 151:2296
(1993)); framework regions derived from the consensus sequence of
human antibodies of a particular subgroup of light or heavy chain
variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci.
USA, 89:4285 (1992); and Presta et al. J. Immunol., 151:2623
(1993)); human mature (somatically mutated) framework regions or
human germline framework regions (see, e.g., Almagro and Fransson,
Front. Biosci. 13:1619-1633 (2008)); and framework regions derived
from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem.
272:10678-10684 (1997) and Rosok et al., J. Biol. Chem.
271:22611-22618 (1996)).
[0272] 4. Human Antibodies
[0273] In certain embodiments, an antibody provided herein is a
human antibody. Human antibodies can be produced using various
techniques known in the art. Human antibodies are described
generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:
368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459
(2008).
[0274] Human antibodies may be prepared by administering an
immunogen to a transgenic animal that has been modified to produce
intact human antibodies or intact antibodies with human variable
regions in response to antigenic challenge. Such animals typically
contain all or a portion of the human immunoglobulin loci, which
replace the endogenous immunoglobulin loci, or which are present
extrachromosomally or integrated randomly into the animal's
chromosomes. In such transgenic mice, the endogenous immunoglobulin
loci have generally been inactivated. For review of methods for
obtaining human antibodies from transgenic animals, see Lonberg,
Nat. Biotech. 23:1117-1125 (2005). See also, e.g., U.S. Pat. Nos.
6,075,181 and 6,150,584 describing XENOMOUSE.TM. technology; U.S.
Pat. No. 5,770,429 describing HuMab.RTM. technology; U.S. Pat. No.
7,041,870 describing K-M MOUSE.RTM. technology, and U.S. Patent
Application Publication No. US 2007/0061900, describing
VelociMouse.RTM. technology). Human variable regions from intact
antibodies generated by such animals may be further modified, e.g.,
by combining with a different human constant region.
[0275] Human antibodies can also be made by hybridoma-based
methods. Human myeloma and mouse-human heteromyeloma cell lines for
the production of human monoclonal antibodies have been described.
(See, e.g., Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al.,
Monoclonal Antibody Production Techniques and Applications, pp.
51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J.
Immunol., 147: 86 (1991).) Human antibodies generated via human
B-cell hybridoma technology are also described in Li et al., Proc.
Natl. Acad. Sci. USA, 103:3557-3562 (2006). Additional methods
include those described, for example, in U.S. Pat. No. 7,189,826
(describing production of monoclonal human IgM antibodies from
hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268
(2006) (describing human-human hybridomas). Human hybridoma
technology (Trioma technology) is also described in Vollmers and
Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and
Vollmers and Brandlein, Methods and Findings in Experimental and
Clinical Pharmacology, 27(3):185-91 (2005).
[0276] Human antibodies may also be generated by isolating Fv clone
variable domain sequences selected from human-derived phage display
libraries. Such variable domain sequences may then be combined with
a desired human constant domain. Techniques for selecting human
antibodies from antibody libraries are described below.
[0277] 5. Library-Derived Antibodies
[0278] Antibodies of the invention may be isolated by screening
combinatorial libraries for antibodies with the desired activity or
activities. For example, a variety of methods are known in the art
for generating phage display libraries and screening such libraries
for antibodies possessing the desired binding characteristics. Such
methods are reviewed, e.g., in Hoogenboom et al. in Methods in
Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press,
Totowa, N. J., 2001) and further described, e.g., in the McCafferty
et al., Nature 348:552-554; Clackson et al., Nature 352: 624-628
(1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Marks and
Bradbury, in Methods in Molecular Biology 248:161-175 (Lo, ed.,
Human Press, Totowa, N. J., 2003); Sidhu et al., J. Mol. Biol.
338(2): 299-310 (2004); Lee et al., J. Mol. Biol. 340(5): 1073-1093
(2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472
(2004); and Lee et al., J. Immunol. Methods 284(1-2):
119-132(2004).
[0279] In certain phage display methods, repertoires of VH and VL
genes are separately cloned by polymerase chain reaction (PCR) and
recombined randomly in phage libraries, which can then be screened
for antigen-binding phage as described in Winter et al., Ann. Rev.
Immunol., 12: 433-455 (1994). Phage typically display antibody
fragments, either as single-chain Fv (scFv) fragments or as Fab
fragments. Libraries from immunized sources provide high-affinity
antibodies to the immunogen without the requirement of constructing
hybridomas. Alternatively, the naive repertoire can be cloned
(e.g., from human) to provide a single source of antibodies to a
wide range of non-self and also self antigens without any
immunization as described by Griffiths et al., EMBO J, 12: 725-734
(1993). Finally, naive libraries can also be made synthetically by
cloning unrearranged V-gene segments from stem cells, and using PCR
primers containing random sequence to encode the highly variable
CDR3 regions and to accomplish rearrangement in vitro, as described
by Hoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992).
Patent publications describing human antibody phage libraries
include, for example: U.S. Pat. No. 5,750,373, and US Patent
Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000,
2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and
2009/0002360.
[0280] Antibodies or antibody fragments isolated from human
antibody libraries are considered human antibodies or human
antibody fragments herein.
[0281] 6. Multispecific Antibodies
[0282] In certain embodiments, an antibody provided herein is a
multispecific antibody, e.g. a bispecific antibody. Multispecific
antibodies are monoclonal antibodies that have binding
specificities for at least two different sites. In certain
embodiments, one of the binding specificities is for OX40 and the
other is for any other antigen. In certain embodiments, bispecific
antibodies may bind to two different epitopes of OX40. Bispecific
antibodies may also be used to localize cytotoxic agents to cells
which express OX40. Bispecific antibodies can be prepared as full
length antibodies or antibody fragments.
[0283] Techniques for making multispecific antibodies include, but
are not limited to, recombinant co-expression of two immunoglobulin
heavy chain-light chain pairs having different specificities (see
Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and
Traunecker et al., EMBO J. 10: 3655 (1991)), and "knob-in-hole"
engineering (see, e.g., U.S. Pat. No. 5,731,168). Multi-specific
antibodies may also be made by engineering electrostatic steering
effects for making antibody Fc-heterodimeric molecules (WO
2009/089004A1); cross-linking two or more antibodies or fragments
(see, e.g., U.S. Pat. No. 4,676,980, and Brennan et al., Science,
229: 81 (1985)); using leucine zippers to produce bi-specific
antibodies (see, e.g., Kostelny et al., J. Immunol.,
148(5):1547-1553 (1992)); using "diabody" technology for making
bispecific antibody fragments (see, e.g., Hollinger et al., Proc.
Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and using single-chain
Fv (sFv) dimers (see, e.g. Gruber et al., J. Immunol., 152:5368
(1994)); and preparing trispecific antibodies as described, e.g.,
in Tutt et al. J. Immunol. 147: 60 (1991).
[0284] Engineered antibodies with three or more functional antigen
binding sites, including "Octopus antibodies," are also included
herein (see, e.g. US 2006/0025576A1).
[0285] The antibody or fragment herein also includes a "Dual Acting
FAb" or "DAF" comprising an antigen binding site that binds to OX40
as well as another, different antigen (see, US 2008/0069820, for
example).
[0286] 7. Antibody Variants
[0287] In certain embodiments, amino acid sequence variants of the
antibodies provided herein are contemplated. For example, it may be
desirable to improve the binding affinity and/or other biological
properties of the antibody. Amino acid sequence variants of an
antibody may be prepared by introducing appropriate modifications
into the nucleotide sequence encoding the antibody, or by peptide
synthesis. Such modifications include, for example, deletions from,
and/or insertions into and/or substitutions of residues within the
amino acid sequences of the antibody. Any combination of deletion,
insertion, and substitution can be made to arrive at the final
construct, provided that the final construct possesses the desired
characteristics, e.g., antigen-binding.
[0288] a) Substitution, Insertion, and Deletion Variants
[0289] In certain embodiments, antibody variants having one or more
amino acid substitutions are provided. Sites of interest for
substitutional mutagenesis include the HVRs and FRs. Conservative
substitutions are shown in Table A under the heading of "preferred
substitutions." More substantial changes are provided in Table A
under the heading of "exemplary substitutions," and as further
described below in reference to amino acid side chain classes.
Amino acid substitutions may be introduced into an antibody of
interest and the products screened for a desired activity, e.g.,
retained/improved antigen binding, decreased immunogenicity, or
improved ADCC or CDC.
TABLE-US-00004 TABLE A Original Exemplary Preferred Residue
Substitutions Substitutions Ala (A) Val; Leu; Ile Val Arg (R) Lys;
Gln; Asn Lys Asn (N) Gln; His; Asp, Lys; Arg Gln Asp (D) Glu; Asn
Glu Cys (C) Ser; Ala Ser Gln (Q) Asn; Glu Asn Glu (E) Asp; Gln Asp
Gly (G) Ala Ala His (H) Asn; Gln; Lys; Arg Arg Ile (I) Leu; Val;
Met; Ala; Phe; Norleucine Leu Leu (L) Norleucine; Ile; Val; Met;
Ala; Phe Ile Lys (K) Arg; Gln; Asn Arg Met (M) Leu; Phe; Ile Leu
Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Tyr Pro (P) Ala Ala Ser (S)
Thr Thr Thr (T) Val; Ser Ser Trp (W) Tyr; Phe Tyr Tyr (Y) Trp; Phe;
Thr; Ser Phe Val (V) Ile; Leu; Met; Phe; Ala; Norleucine Leu
[0290] Amino acids may be grouped according to common side-chain
properties:
[0291] (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
[0292] (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
[0293] (3) acidic: Asp, Glu;
[0294] (4) basic: His, Lys, Arg;
[0295] (5) residues that influence chain orientation: Gly, Pro;
[0296] (6) aromatic: Trp, Tyr, Phe.
[0297] Non-conservative substitutions will entail exchanging a
member of one of these classes for another class.
[0298] One type of substitutional variant involves substituting one
or more hypervariable region residues of a parent antibody (e.g. a
humanized or human antibody). Generally, the resulting variant(s)
selected for further study will have modifications (e.g.,
improvements) in certain biological properties (e.g., increased
affinity, reduced immunogenicity) relative to the parent antibody
and/or will have substantially retained certain biological
properties of the parent antibody. An exemplary substitutional
variant is an affinity matured antibody, which may be conveniently
generated, e.g., using phage display-based affinity maturation
techniques such as those described herein. Briefly, one or more HVR
residues are mutated and the variant antibodies displayed on phage
and screened for a particular biological activity (e.g. binding
affinity).
[0299] Alterations (e.g., substitutions) may be made in HVRs, e.g.,
to improve antibody affinity. Such alterations may be made in HVR
"hotspots," i.e., residues encoded by codons that undergo mutation
at high frequency during the somatic maturation process (see, e.g.,
Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and/or residues
that contact antigen, with the resulting variant VH or VL being
tested for binding affinity. Affinity maturation by constructing
and reselecting from secondary libraries has been described, e.g.,
in Hoogenboom et al. in Methods in Molecular Biology 178:1-37
(O'Brien et al., ed., Human Press, Totowa, N.J., (2001).) In some
embodiments of affinity maturation, diversity is introduced into
the variable genes chosen for maturation by any of a variety of
methods (e.g., error-prone PCR, chain shuffling, or
oligonucleotide-directed mutagenesis). A secondary library is then
created. The library is then screened to identify any antibody
variants with the desired affinity. Another method to introduce
diversity involves HVR-directed approaches, in which several HVR
residues (e.g., 4-6 residues at a time) are randomized. HVR
residues involved in antigen binding may be specifically
identified, e.g., using alanine scanning mutagenesis or modeling.
CDR-H3 and CDR-L3 in particular are often targeted.
[0300] In certain embodiments, substitutions, insertions, or
deletions may occur within one or more HVRs so long as such
alterations do not substantially reduce the ability of the antibody
to bind antigen. For example, conservative alterations (e.g.,
conservative substitutions as provided herein) that do not
substantially reduce binding affinity may be made in HVRs. Such
alterations may, for example, be outside of antigen contacting
residues in the HVRs. In certain embodiments of the variant VH and
VL sequences provided above, each HVR either is unaltered, or
contains no more than one, two or three amino acid
substitutions.
[0301] A useful method for identification of residues or regions of
an antibody that may be targeted for mutagenesis is called "alanine
scanning mutagenesis" as described by Cunningham and Wells (1989)
Science, 244:1081-1085. In this method, a residue or group of
target residues (e.g., charged residues such as arg, asp, his, lys,
and glu) are identified and replaced by a neutral or negatively
charged amino acid (e.g., alanine or polyalanine) to determine
whether the interaction of the antibody with antigen is affected.
Further substitutions may be introduced at the amino acid locations
demonstrating functional sensitivity to the initial substitutions.
Alternatively, or additionally, a crystal structure of an
antigen-antibody complex to identify contact points between the
antibody and antigen. Such contact residues and neighboring
residues may be targeted or eliminated as candidates for
substitution. Variants may be screened to determine whether they
contain the desired properties.
[0302] Amino acid sequence insertions include amino- and/or
carboxyl-terminal fusions ranging in length from one residue to
polypeptides containing a hundred or more residues, as well as
intrasequence insertions of single or multiple amino acid residues.
Examples of terminal insertions include an antibody with an
N-terminal methionyl residue. Other insertional variants of the
antibody molecule include the fusion to the N- or C-terminus of the
antibody to an enzyme (e.g. for ADEPT) or a polypeptide which
increases the serum half-life of the antibody.
[0303] b) Glycosylation Variants
[0304] In certain embodiments, an antibody provided herein is
altered to increase or decrease the extent to which the antibody is
glycosylated. Addition or deletion of glycosylation sites to an
antibody may be conveniently accomplished by altering the amino
acid sequence such that one or more glycosylation sites is created
or removed.
[0305] Where the antibody comprises an Fc region, the carbohydrate
attached thereto may be altered. Native antibodies produced by
mammalian cells typically comprise a branched, biantennary
oligosaccharide that is generally attached by an N-linkage to
Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al.
TIBTECH 15:26-32 (1997). The oligosaccharide may include various
carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc),
galactose, and sialic acid, as well as a fucose attached to a
GlcNAc in the "stem" of the biantennary oligosaccharide structure.
In some embodiments, modifications of the oligosaccharide in an
antibody of the invention may be made in order to create antibody
variants with certain improved properties.
[0306] In one embodiment, antibody variants are provided having a
carbohydrate structure that lacks fucose attached (directly or
indirectly) to an Fc region. For example, the amount of fucose in
such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65%
or from 20% to 40%. The amount of fucose is determined by
calculating the average amount of fucose within the sugar chain at
Asn297, relative to the sum of all glycostructures attached to Asn
297 (e. g. complex, hybrid and high mannose structures) as measured
by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for
example. Asn297 refers to the asparagine residue located at about
position 297 in the Fc region (Eu numbering of Fc region residues);
however, Asn297 may also be located about .+-.3 amino acids
upstream or downstream of position 297, i.e., between positions 294
and 300, due to minor sequence variations in antibodies. Such
fucosylation variants may have improved ADCC function. See, e.g.,
US Patent Publication Nos. US 2003/0157108 (Presta, L.); US
2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications
related to "defucosylated" or "fucose-deficient" antibody variants
include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US
2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US
2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO
2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742;
WO2002/031140; Okazaki et al. J. Mol. Biol. 336:1239-1249 (2004);
Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004). Examples of
cell lines capable of producing defucosylated antibodies include
Lec13 CHO cells deficient in protein fucosylation (Ripka et al.
Arch. Biochem. Biophys. 249:533-545 (1986); US Pat Appl No US
2003/0157108 A1, Presta, L; and WO 2004/056312 A1, Adams et al.,
especially at Example 11), and knockout cell lines, such as
alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see,
e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda,
Y. et al., Biotechnol. Bioeng., 94(4):680-688 (2006); and
WO2003/085107).
[0307] Antibodies variants are further provided with bisected
oligosaccharides, e.g., in which a biantennary oligosaccharide
attached to the Fc region of the antibody is bisected by GlcNAc.
Such antibody variants may have reduced fucosylation and/or
improved ADCC function. Examples of such antibody variants are
described, e.g., in WO 2003/011878 (Jean-Mairet et al.); U.S. Pat.
No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al.).
Antibody variants with at least one galactose residue in the
oligosaccharide attached to the Fc region are also provided. Such
antibody variants may have improved CDC function. Such antibody
variants are described, e.g., in WO 1997/30087 (Patel et al.); WO
1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).
[0308] c) Fc Region Variants
[0309] In certain embodiments, one or more amino acid modifications
may be introduced into the Fc region of an antibody provided
herein, thereby generating an Fc region variant. The Fc region
variant may comprise a human Fc region sequence (e.g., a human
IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid
modification (e.g. a substitution) at one or more amino acid
positions.
[0310] In certain embodiments, the invention contemplates an
antibody variant that possesses some but not all effector
functions, which make it a desirable candidate for applications in
which the half life of the antibody in vivo is important yet
certain effector functions (such as complement and ADCC) are
unnecessary or deleterious. In vitro and/or in vivo cytotoxicity
assays can be conducted to confirm the reduction/depletion of CDC
and/or ADCC activities. For example, Fc receptor (FcR) binding
assays can be conducted to ensure that the antibody lacks
Fc.gamma.R binding (hence likely lacking ADCC activity), but
retains FcRn binding ability. The primary cells for mediating ADCC,
NK cells, express Fc(RIII only, whereas monocytes express Fc(RI,
Fc(RII and Fc(RIII. FcR expression on hematopoietic cells is
summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev.
Immunol. 9:457-492 (1991). Non-limiting examples of in vitro assays
to assess ADCC activity of a molecule of interest is described in
U.S. Pat. No. 5,500,362 (see, e.g. Hellstrom, I. et al. Proc. Nat'l
Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc.
Nat'l Acad. Sci. USA 82:1499-1502 (1985); 5,821,337 (see
Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)).
Alternatively, non-radioactive assays methods may be employed (see,
for example, ACTI.TM. non-radioactive cytotoxicity assay for flow
cytometry (CellTechnology, Inc. Mountain View, Calif.; and CytoTox
96.RTM. non-radioactive cytotoxicity assay (Promega, Madison,
Wis.). Useful effector cells for such assays include peripheral
blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
Alternatively, or additionally, ADCC activity of the molecule of
interest may be assessed in vivo, e.g., in a animal model such as
that disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA
95:652-656 (1998). C1q binding assays may also be carried out to
confirm that the antibody is unable to bind C1q and hence lacks CDC
activity. See, e.g., C1q and C3c binding ELISA in WO 2006/029879
and WO 2005/100402. To assess complement activation, a CDC assay
may be performed (see, for example, Gazzano-Santoro et al., J.
Immunol. Methods 202:163 (1996); Cragg, M. S. et al., Blood
101:1045-1052 (2003); and Cragg, M. S. and M. J. Glennie, Blood
103:2738-2743 (2004)). FcRn binding and in vivo clearance/half life
determinations can also be performed using methods known in the art
(see, e.g., Petkova, S. B. et al., Int'l. Immunol. 18(12):1759-1769
(2006)).
[0311] In some embodiments, an antibody includes an Fc region with
a mutation that decreases binding to an Fc receptor. Antibodies
with reduced effector function include without limitation those
with substitution of one or more of Fc region residues 238, 265,
269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc
mutants include Fc mutants with substitutions at two or more of
amino acid positions 265, 269, 270, 297 and 327, including the
so-called "DANA" Fc mutant with substitution of residues 265 and
297 to alanine (U.S. Pat. No. 7,332,581).
[0312] Certain antibody variants with improved or diminished
binding to FcRs are described. (See, e.g., U.S. Pat. No. 6,737,056;
WO 2004/056312, and Shields et al., J. Biol. Chem. 9(2): 6591-6604
(2001).)
[0313] In certain embodiments, an antibody variant comprises an Fc
region with one or more amino acid substitutions which improve
ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the
Fc region (EU numbering of residues).
[0314] In some embodiments, alterations are made in the Fc region
that result in altered (i.e., either improved or diminished) C1q
binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as
described in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie et
al. J. Immunol. 164: 4178-4184 (2000).
[0315] Antibodies with increased half lives and improved binding to
the neonatal Fc receptor (FcRn), which is responsible for the
transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol.
117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)), are
described in US2005/0014934A1 (Hinton et al.). Those antibodies
comprise an Fc region with one or more substitutions therein which
improve binding of the Fc region to FcRn. Such Fc variants include
those with substitutions at one or more of Fc region residues: 238,
256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360,
362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc
region residue 434 (U.S. Pat. No. 7,371,826).
[0316] See also Duncan & Winter, Nature 322:738-40 (1988); U.S.
Pat. No. 5,648,260; U.S. Pat. No. 5,624,821; and WO 94/29351
concerning other examples of Fc region variants.
[0317] d) Cysteine Engineered Antibody Variants
[0318] In certain embodiments, it may be desirable to create
cysteine engineered antibodies, e.g., "thioMAbs," in which one or
more residues of an antibody are substituted with cysteine
residues. In particular embodiments, the substituted residues occur
at accessible sites of the antibody. By substituting those residues
with cysteine, reactive thiol groups are thereby positioned at
accessible sites of the antibody and may be used to conjugate the
antibody to other moieties, such as drug moieties or linker-drug
moieties, to create an immunoconjugate, as described further
herein. In certain embodiments, any one or more of the following
residues may be substituted with cysteine: V205 (Kabat numbering)
of the light chain; A118 (EU numbering) of the heavy chain; and
S400 (EU numbering) of the heavy chain Fc region. Cysteine
engineered antibodies may be generated as described, e.g., in U.S.
Pat. No. 7,521,541.
[0319] e) Antibody Derivatives
[0320] In certain embodiments, an antibody provided herein may be
further modified to contain additional nonproteinaceous moieties
that are known in the art and readily available. The moieties
suitable for derivatization of the antibody include but are not
limited to water soluble polymers. Non-limiting examples of water
soluble polymers include, but are not limited to, polyethylene
glycol (PEG), copolymers of ethylene glycol/propylene glycol,
carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl
pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane,
ethylene/maleic anhydride copolymer, polyaminoacids (either
homopolymers or random copolymers), and dextran or poly(n-vinyl
pyrrolidone)polyethylene glycol, propropylene glycol homopolymers,
prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated
polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.
Polyethylene glycol propionaldehyde may have advantages in
manufacturing due to its stability in water. The polymer may be of
any molecular weight, and may be branched or unbranched. The number
of polymers attached to the antibody may vary, and if more than one
polymer are attached, they can be the same or different molecules.
In general, the number and/or type of polymers used for
derivatization can be determined based on considerations including,
but not limited to, the particular properties or functions of the
antibody to be improved, whether the antibody derivative will be
used in a therapy under defined conditions, etc.
[0321] In another embodiment, conjugates of an antibody and
nonproteinaceous moiety that may be selectively heated by exposure
to radiation are provided. In one embodiment, the nonproteinaceous
moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA
102: 11600-11605 (2005)). The radiation may be of any wavelength,
and includes, but is not limited to, wavelengths that do not harm
ordinary cells, but which heat the nonproteinaceous moiety to a
temperature at which cells proximal to the
antibody-nonproteinaceous moiety are killed.
Recombinant Methods and Compositions
[0322] Antibodies may be produced using recombinant methods and
compositions, e.g., as described in U.S. Pat. No. 4,816,567. In one
embodiment, isolated nucleic acid encoding an anti-OX40 antibody
described herein is provided. Such nucleic acid may encode an amino
acid sequence comprising the VL and/or an amino acid sequence
comprising the VH of the antibody (e.g., the light and/or heavy
chains of the antibody). In a further embodiment, one or more
vectors (e.g., expression vectors) comprising such nucleic acid are
provided. In a further embodiment, a host cell comprising such
nucleic acid is provided. In one such embodiment, a host cell
comprises (e.g., has been transformed with): (1) a vector
comprising a nucleic acid that encodes an amino acid sequence
comprising the VL of the antibody and an amino acid sequence
comprising the VH of the antibody, or (2) a first vector comprising
a nucleic acid that encodes an amino acid sequence comprising the
VL of the antibody and a second vector comprising a nucleic acid
that encodes an amino acid sequence comprising the VH of the
antibody. In one embodiment, the host cell is eukaryotic, e.g. a
Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0,
Sp20 cell). In one embodiment, a method of making an anti-OX40
antibody is provided, wherein the method comprises culturing a host
cell comprising a nucleic acid encoding the antibody, as provided
above, under conditions suitable for expression of the antibody,
and optionally recovering the antibody from the host cell (or host
cell culture medium).
[0323] For recombinant production of an anti-OX40 antibody, nucleic
acid encoding an antibody, e.g., as described above, is isolated
and inserted into one or more vectors for further cloning and/or
expression in a host cell. Such nucleic acid may be readily
isolated and sequenced using conventional procedures (e.g., by
using oligonucleotide probes that are capable of binding
specifically to genes encoding the heavy and light chains of the
antibody).
[0324] Suitable host cells for cloning or expression of
antibody-encoding vectors include prokaryotic or eukaryotic cells
described herein. For example, antibodies may be produced in
bacteria, in particular when glycosylation and Fc effector function
are not needed. For expression of antibody fragments and
polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237,
5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular
Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, N. J.,
2003), pp. 245-254, describing expression of antibody fragments in
E. coli.) After expression, the antibody may be isolated from the
bacterial cell paste in a soluble fraction and can be further
purified.
[0325] In addition to prokaryotes, eukaryotic microbes such as
filamentous fungi or yeast are suitable cloning or expression hosts
for antibody-encoding vectors, including fungi and yeast strains
whose glycosylation pathways have been "humanized," resulting in
the production of an antibody with a partially or fully human
glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414
(2004), and Li et al., Nat. Biotech. 24:210-215 (2006).
[0326] Suitable host cells for the expression of glycosylated
antibody are also derived from multicellular organisms
(invertebrates and vertebrates). Examples of invertebrate cells
include plant and insect cells. Numerous baculoviral strains have
been identified which may be used in conjunction with insect cells,
particularly for transfection of Spodoptera frugiperda cells.
[0327] Plant cell cultures can also be utilized as hosts. See,
e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978,
and 6,417,429 (describing PLANTIBODIES.TM. technology for producing
antibodies in transgenic plants).
[0328] Vertebrate cells may also be used as hosts. For example,
mammalian cell lines that are adapted to grow in suspension may be
useful. Other examples of useful mammalian host cell lines are
monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic
kidney line (293 or 293 cells as described, e.g., in Graham et al.,
J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse
sertoli cells (TM4 cells as described, e.g., in Mather, Biol.
Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African
green monkey kidney cells (VERO-76); human cervical carcinoma cells
(HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL
3A); human lung cells (W138); human liver cells (Hep G2); mouse
mammary tumor (MMT 060562); TRI cells, as described, e.g., in
Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5
cells; and FS4 cells. Other useful mammalian host cell lines
include Chinese hamster ovary (CHO) cells, including DHFR- CHO
cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980));
and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of
certain mammalian host cell lines suitable for antibody production,
see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248
(B.K.C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268
(2003).
Assays
[0329] Anti-OX40 antibodies provided herein may be identified,
screened for, or characterized for their physical/chemical
properties and/or biological activities by various assays known in
the art.
[0330] 1. Binding Assays and Other Assays
[0331] In one aspect, an antibody of the invention is tested for
its antigen binding activity, e.g., by known methods such as ELISA,
Western blot, etc. OX40 binding may be determined using methods
known in the art and exemplary methods are disclosed herein. In one
embodiment, binding is measured using radioimmunoassay. An
exemplary radioimmunassay is exemplified in the Examples. OX40
antibody is iodinated, and competition reaction mixtures are
prepared containing a fixed concentration of iodinated antibody and
decreasing concentrations of serially diluted, unlabeled OZ X40
antibody. Cells expressing OX40 (e.g., BT474 cells stably
transfected with human OX40) are added to the reaction mixture.
Following an incubation, cells are washed to separate the free
iodinated OX40 antibody from the OX40 antibody bound to the cells.
Level of bound iodinated OX40 antibody is determined, e.g., by
counting radioactivity associated with cells, and binding affinity
determined using standard methods. In another embodiment, ability
of OX40 antibody to bind to surface-expressed OX40 (e.g., on T cell
subsets) is assessed using flow cytometry. Peripheral white blood
cells are obtained (e.g., from human, cynomolgus monkey, rat or
mouse) and cells are blocked with serum. Labeled OX40 antibody is
added in serial dilutions, and T cells are also stained to identify
T cell subsets (using methods known in the art). Following
incubation of the samples and washing, the cells are sorted using
flow cytometer, and data analyzed using methods well known in the
art. In another embodiment, OX40 binding may be analyzed using
surface plasmon resonance. An exemplary surface plasmon resonance
method is exemplified in the Examples.
[0332] In another aspect, competition assays may be used to
identify an antibody that competes with any of the anti-OX40
antibodies disclosed herein for binding to OX40. In certain
embodiments, such a competing antibody binds to the same epitope
(e.g., a linear or a conformational epitope) that is bound by any
of the anti-OX40 antibodies disclosed herein. Detailed exemplary
methods for mapping an epitope to which an antibody binds are
provided in Morris (1996) "Epitope Mapping Protocols," in Methods
in Molecular Biology vol. 66 (Humana Press, Totowa, N.J.). A
competition assay is exemplified in the Examples.
[0333] In an exemplary competition assay, immobilized OX40 is
incubated in a solution comprising a first labeled antibody that
binds to OX40 (e.g., mab 1A7.gr.1, mab 3C8.gr5) and a second
unlabeled antibody that is being tested for its ability to compete
with the first antibody for binding to OX40. The second antibody
may be present in a hybridoma supernatant. As a control,
immobilized OX40 is incubated in a solution comprising the first
labeled antibody but not the second unlabeled antibody. After
incubation under conditions permissive for binding of the first
antibody to OX40, excess unbound antibody is removed, and the
amount of label associated with immobilized OX40 is measured. If
the amount of label associated with immobilized OX40 is
substantially reduced in the test sample relative to the control
sample, then that indicates that the second antibody is competing
with the first antibody for binding to OX40. See Harlow and Lane
(1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor
Laboratory, Cold Spring Harbor, N.Y.).
[0334] 2. Activity Assays
[0335] In one aspect, assays are provided for identifying anti-OX40
antibodies thereof having biological activity. Biological activity
may include, e.g., binding OX40 (e.g., binding human and/or
cynomolgus OX40), increasing OX40-mediated signal transduction
(e.g., increasing NFkB-mediated transcription), depleting cells
that express human OX40 (e.g., T cells), depleting cells that
express human OX40 by ADCC and/or phagocytosis, enhancing T
effector cell function (e.g., CD4+ effector T cell), e.g., by
increasing effector T cell proliferation and/or increasing cytokine
production (e.g., gamma interferon) by effector T cells, enhancing
memory T cell function (e.g., CD4+ memory T cell), e.g., by
increasing memory T cell proliferation and/or increasing cytokine
production by memory T cells (e.g., gamma interferon), inhibiting
regulatory T cell function (e.g., by decreasing Treg suppression of
effector T cell function (e.g., CD4+ effector T cell function),
binding human effector cells. Antibodies having such biological
activity in vivo and/or in vitro are also provided.
[0336] In certain embodiments, an antibody of the invention is
tested for such biological activity.
[0337] T cell costimulation may be assayed using methods known in
the art and exemplary methods are disclosed herein. For example, T
cells (e.g., memory or effector T cells) may be obtained from
peripheral white blood cells (e.g., isolated from human whole blood
using Ficoll gradient centrifugation). Memory T cells (e.g., CD4+
memory T cells) or effector T cells (e.g. CD4+ Teff cells) may be
isolated from PBMC using methods known in the art. For example, the
Miltenyi CD4+ memory T cell isolation kit or Miltenyi naive CD4+ T
cell isolation kit may be used. Isolated T cells are cultured in
the presence of antigen presenting cells (e.g., irradiated L cells
that express CD32 and CD80), and activated by addition of anti-CD3
antibody in the presence or absence of OX40 agonist antibody.
Effect of agonist OX40 antibody of T cell proliferation may be
measured using methods well known in the art. For example, the
CellTiter Glo kit (Promega) may be used, and results read on a
Multilabel Reader (Perkin Elmer). Effect of agonist OX40 antibody
on T cell function may also be determined by analysis of cytokines
produced by the T cell. In one embodiment, production of interferon
gamma by CD4+ T cells is determined, e.g., by measurement of
interferon gamma in cell culture supernatant. Methods for measuring
interferon gamma are well-known in the art.
[0338] Treg cell function may be assayed using methods known in the
art and exemplary methods are disclosed herein. In one example, the
ability of Treg to suppress effector T cell proliferation is
assayed. T cells are isolated from human whole blood using methods
known in the art (e.g., isolating memory T cells or naive T cells).
Purified CD4+ naive T cells are labeled (e.g., with CFSE) and
purified Treg cells are labeled with a different reagent.
Irradiated antigen presenting cells (e.g., L cells expressing CD32
and CD80) are co-cultured with the labeled purified naive CD4+ T
cells and purified Tregs. The co-cultures are activated using
anti-CD3 antibody and tested in the presence or absence of agonist
OX40 antibody. Following a suitable time (e.g., 6 days of
coculture), level of CD4+ naive T cell proliferation is tracked by
dye dilution in reduced label staining (e.g., reduced CFSE label
staining) using FACS analysis.
[0339] OX40 signaling may be assayed using methods well known in
the art and exemplary methods are disclosed herein. In one
embodiment, transgenic cells are generated that express human OX40
and a reporter gene comprising the NFkB promoter fused to a
reporter gene (e.g., beta luciferase). Addition of OX40 agonist
antibody to the cells results in increased NFkB transcription,
which is detected using an assay for the reporter gene.
[0340] Phagocytosis may be assayed, e.g., by using monocyte-derived
macrophages, or U937 cells (a human histiocytic lymphoma cells line
with the morphology and characteristics of mature macrophages).
OX40 expressing cells are added to the monocyte-derived macrophages
or U937 cells in the presence or absence of anti-OX40 agonist
antibody. Following culturing of the cells for a suitable period of
time, the percentage of phagocytosis is determined by examining
percentage of cells that double stain for markers of 1) the
macrophage or U937 cell and 2) the OX40 expressing cell, and
dividing this by the total number of cells that show markers of the
OX40 expressing cell (e.g., GFP). Analysis may be done by flow
cytometry. In another embodiment, analysis may be done by
fluorescent microscopy analysis.
[0341] ADCC may be assayed, e.g., using methods well known in the
art. Exemplary methods are described in the definition section and
an exemplary assay is disclosed in the Examples. In some
embodiments, level of OX40 is characterized on an OX40 expressing
cell that is used for testing in an ADCC assay. The cell may be
stained with a detectably labeled anti-OX40 antibody (e.g., PE
labeled), then level of fluorescence determined using flow
cytometry, and results presented as median fluorescence intensity
(MFI). In another embodiment, ADCC may be analyzed by CellTiter Glo
assay kit and cell viability/cytotoxicity may be determined by
chemioluminescence.
[0342] The binding affinities of various antibodies to
Fc.gamma.RIA, Fc.gamma.RIIA, Fc.gamma.RIIB, and two allotypes of
Fc.gamma.RIIIA (F158 and V158) may be measured in ELISA-based
ligand-binding assays using the respective recombinant Fc.gamma.
receptors. Purified human Fc.gamma. receptors are expressed as
fusion proteins containing the extracellular domain of the receptor
.gamma. chain linked to a Gly/6xHis/glutathione S-transferase (GST)
polypeptide tag at the C-terminus. The binding affinities of
antibodies to those human Fc.gamma. receptors are assayed as
follows. For the low-affinity receptors, i.e. Fc.gamma.RIIA
(CD32A), Fc.gamma.RIIB (CD32B), and the two allotypes of
Fc.gamma.RIIIA (CD16), F-158 and V-158, antibodies may be tested as
multimers by cross-linking with a F(ab')2 fragment of goat
anti-human kappa chain (ICN Biomedical; Irvine, Calif.) at an
approximate molar ratio of 1:3 antibody:cross-linking F(ab')2.
Plates are coated with an anti-GST antibody (Genentech) and blocked
with bovine serum albumin (BSA). After washing with
phosphate-buffered saline (PBS) containing 0.05% Tween-20 with an
ELx405.TM. plate washer (Biotek Instruments; Winooski, Vt.),
Fc.gamma. receptors are added to the plate at 25 ng/well and
incubated at room temperature for 1 hour. After the plates are
washed, serial dilutions of test antibodies are added as multimeric
complexes and the plates were incubated at room temperature for 2
hours. Following plate washing to remove unbound antibodies, the
antibodies bound to the Fc.gamma. receptor are detected with
horseradish peroxidase (HRP)-conjugated F(ab')2 fragment of goat
anti-human F(ab')2 (Jackson ImmunoResearch Laboratories; West
Grove, Pa.) followed by the addition of substrate,
tetramethylbenzidine (TMB) (Kirkegaard & Perry Laboratories;
Gaithersburg, Md.). The plates are incubated at room temperature
for 5-20 minutes, depending on the Fc.gamma. receptors tested, to
allow color development. The reaction is terminated with 1 M H3PO4
and absorbance at 450 nm was measured with a microplate reader
(SpectraMax.RTM.190, Molecular Devices; Sunnyvale, Calif.).
Dose-response binding curves are generated by plotting the mean
absorbance values from the duplicates of antibody dilutions against
the concentrations of the antibody. Values for the effective
concentration of the antibody at which 50% of the maximum response
from binding to the Fc.gamma. receptor is detected (EC50) were
determined after fitting the binding curve with a four-parameter
equation using SoftMax Pro (Molecular Devices).
[0343] To select for antibodies which induce cell death, loss of
membrane integrity as indicated by, e.g., propidium iodide (PI),
trypan blue or 7AAD uptake may be assessed relative to control. A
PI uptake assay can be performed in the absence of complement and
immune effector cells. OX40 expressing cells are incubated with
medium alone or medium containing of the appropriate monoclonal
antibody at e.g., about 10 .mu.g/ml. The cells are incubated for a
time period (e.g., 1 or 3 days). Following each treatment, cells
are washed and aliquoted. In some embodiments, cells are aliquoted
into 35 mm strainer-capped 12.times.75 tubes (1 ml per tube, 3
tubes per treatment group) for removal of cell clumps. Tubes then
receive PI (10 .mu.g/ml). Samples may be analyzed using a
FACSCAN.TM. flow cytometer and FACSCONVERT.TM. CellQuest software
(Becton Dickinson).
[0344] Cells for use in any of the above in vitro assays include
cells or cell lines that naturally express OX40 or that have been
engineered to express OX40. Such cells include activated T cells,
Treg cells and activated memory T cells that naturally express
OX40. Such cells also include cell lines that express OX40 and cell
lines that do not normally express OX40 but have been transfected
with nucleic acid encoding OX40. Exemplary cell lines provided
herein for use in any of the above in vitro assays include
transgenic BT474 cells (a human breast cancer cell line) that
express human OX40
[0345] It is understood that any of the above assays may be carried
out using an immunoconjugate of the invention in place of or in
addition to an anti-OX40 antibody.
[0346] It is understood that any of the above assays may be carried
out using anti-OX40 antibody and an additional therapeutic
agent.
Immunoconjugates
[0347] The invention also provides immunoconjugates comprising an
anti-OX40 antibody herein conjugated to one or more cytotoxic
agents, such as chemotherapeutic agents or drugs, growth inhibitory
agents, toxins (e.g., protein toxins, enzymatically active toxins
of bacterial, fungal, plant, or animal origin, or fragments
thereof), or radioactive isotopes.
[0348] In one embodiment, an immunoconjugate is an antibody-drug
conjugate (ADC) in which an antibody is conjugated to one or more
drugs, including but not limited to a maytansinoid (see U.S. Pat.
Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 B1); an
auristatin such as monomethylauristatin drug moieties DE and DF
(MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483 and 5,780,588, and
7,498,298); a dolastatin; a calicheamicin or derivative thereof
(see U.S. Pat. Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285,
5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al.,
Cancer Res. 53:3336-3342 (1993); and Lode et al., Cancer Res.
58:2925-2928 (1998)); an anthracycline such as daunomycin or
doxorubicin (see Kratz et al., Current Med. Chem. 13:477-523
(2006); Jeffrey et al., Bioorganic & Med. Chem. Letters
16:358-362 (2006); Torgov et al., Bioconj. Chem. 16:717-721 (2005);
Nagy et al., Proc. Natl. Acad. Sci. USA 97:829-834 (2000);
Dubowchik et al., Bioorg. & Med. Chem. Letters 12:1529-1532
(2002); King et al., J. Med. Chem. 45:4336-4343 (2002); and U.S.
Pat. No. 6,630,579); methotrexate; vindesine; a taxane such as
docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; a
trichothecene; and CC1065.
[0349] In another embodiment, an immunoconjugate comprises an
antibody as described herein conjugated to an enzymatically active
toxin or fragment thereof, including but not limited to diphtheria
A chain, nonbinding active fragments of diphtheria toxin, exotoxin
A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A
chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins,
dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and
PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria
officinalis inhibitor, gelonin, mitogellin, restrictocin,
phenomycin, enomycin, and the tricothecenes.
[0350] In another embodiment, an immunoconjugate comprises an
antibody as described herein conjugated to a radioactive atom to
form a radioconjugate. A variety of radioactive isotopes are
available for the production of radioconjugates. Examples include
At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 and
radioactive isotopes of Lu. When the radioconjugate is used for
detection, it may comprise a radioactive atom for scintigraphic
studies, for example tc99m or 1123, or a spin label for nuclear
magnetic resonance (NMR) imaging (also known as magnetic resonance
imaging, mri), such as iodine-123 again, iodine-131, indium-111,
fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium,
manganese or iron.
[0351] Conjugates of an antibody and cytotoxic agent may be made
using a variety of bifunctional protein coupling agents such as
N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP),
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC),
iminothiolane (IT), bifunctional derivatives of imidoesters (such
as dimethyl adipimidate HCl), active esters (such as disuccinimidyl
suberate), aldehydes (such as glutaraldehyde), bis-azido compounds
(such as bis(p-azidobenzoyl) hexanediamine), bis-diazonium
derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine),
diisocyanates (such as toluene 2,6-diisocyanate), and bis-active
fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For
example, a ricin immunotoxin can be prepared as described in
Vitetta et al., Science 238:1098 (1987). Carbon-14-labeled
1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid
(MX-DTPA) is an exemplary chelating agent for conjugation of
radionucleotide to the antibody. See WO94/11026. The linker may be
a "cleavable linker" facilitating release of a cytotoxic drug in
the cell. For example, an acid-labile linker, peptidase-sensitive
linker, photolabile linker, dimethyl linker or disulfide-containing
linker (Chari et al., Cancer Res. 52:127-131 (1992); U.S. Pat. No.
5,208,020) may be used.
[0352] The immunuoconjugates or ADCs herein expressly contemplate,
but are not limited to such conjugates prepared with cross-linker
reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS,
LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS,
sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and
sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate) which
are commercially available (e.g., from Pierce Biotechnology, Inc.,
Rockford, Ill., U.S.A).
IV. Predictive and Prognostic Methods
[0353] Provided herein are methods for determining the prognosis of
a subject having cancer by measuring the number of CD4+ OX40+
Foxp3+ lymphocytes in a sample containing cancer cells and
lymphocytes obtained from the subject; and determining the
prognosis of the subject based on the number of CD4+ OX40+ Foxp3+
lymphocytes in the sample, as compared with a reference, wherein an
increased number of CD4+ OX40+ Foxp3+ lymphocytes in the sample
indicates that the subject may have an improved prognosis. These
methods are based in part on the discovery described herein that
increased prevalence of CD4+ OX40+ Foxp3+ lymphocytes (i.e., OX40+
Treg cells) in a tumor sample correlates with improved patient
prognosis. Further provided herein are methods for determining the
prognosis of a subject having cancer by measuring the number of
CD4+, OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in
a sample containing metastatic cancer cells and lymphocytes
obtained from the subject; and determining the prognosis of the
subject based on the number of OX40+, CD4+ OX40+ Foxp3+, or CD4+
OX40+ Foxp3- lymphocytes in the sample, as compared with a
reference, wherein an increased number of OX40+, CD4+ OX40+ Foxp3+,
or CD4+ OX40+ Foxp3- lymphocytes in the sample indicates that the
subject may have an improved prognosis. These methods are based in
part on the discovery described herein that increased prevalence of
CD4+ lymphocytes, total OX40+ lymphocytes, CD4+ OX40+ Foxp3+
lymphocytes (i.e., OX40+ Treg cells), or CD4+ OX40+ Foxp3-
lymphocytes (i.e., OX40+ Teff cells) in a tumor sample correlates
with improved patient prognosis, and that the prevalence of each of
these lymphocyte subtypes is strongly correlated in matched primary
tumor and metastatic samples from a subject.
[0354] Certain aspects of the present disclosure relate to
measuring the number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+
Foxp3- lymphocytes in a sample comprising cancer cells and
lymphocytes obtained from the subject. In some embodiments, a
sample may include cancer cells and lymphocytes. For example, the
sample may be a tumor sample. A tumor sample may include cancer
cells, lymphocytes, leukocytes, stroma, blood vessels, connective
tissue, basal lamina, and any other cell type in association with
the tumor. A sample may be obtained from a subject by any method
known in the art, including without limitation a biopsy, endoscopy,
or surgical procedure. In some embodiments, a sample may be
prepared by methods such as freezing, fixation (e.g., by using
formalin or a similar fixative), and/or embedding in paraffin wax.
In some embodiments, a sample may be sectioned.
[0355] In some embodiments, the number of OX40+, CD4+ OX40+ Foxp3+,
or CD4+ OX40+ Foxp3- lymphocytes in a tumor is measured. In some
embodiments, the number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+
Foxp3- lymphocytes in a metastatic tumor is measured. In any or all
of the above cases, the lymphocytes may be tumor-infiltrating
lymphocytes. As used herein, any lymphocyte associated with a tumor
may be a tumor-infiltrating lymphocyte. In some embodiments, the
tumor-infiltrating lymphocyte may be associated with cancer cells
in the tumor. In some embodiments, the tumor-infiltrating
lymphocyte may be associated with the tumor stroma.
[0356] As used herein, a CD4+ OX40+ Foxp3+ cell (e.g., a lymphocyte
or leukocyte) may refer to any cell that has increased expression
of CD4 as compared with a reference, increased expression of OX40
as compared with a reference, and increased expression of Foxp3 as
compared with a reference. As used herein, a CD4+ OX40+ Foxp3- cell
(e.g., a lymphocyte or leukocyte) may refer to any cell that has
increased expression of CD4 as compared with a reference, increased
expression of OX40 as compared with a reference, and decreased
expression of Foxp3 as compared with a reference. As used herein,
an OX40+ cell (e.g., a lymphocyte or leukocyte) may refer to any
cell that has increased expression of OX40 as compared with a
reference. The phrases "compared with" and "compared to" may be
used interchangeably herein. In some embodiments, expression may
refer to protein expression. In some embodiments, expression may
refer to mRNA expression.
[0357] In some embodiment, tumor may refer to a physical mass
containing a plurality of cancer cells, e.g., cells showing the
characteristics of any of the cancers described herein. Examples of
tumors may include primary tumors of any of the above types of
cancer or metastatic tumors at a second site derived from any of
the above types of cancer. In some embodiments, a tumor may contain
cancer cells as well as tumor stroma.
[0358] In some embodiments, within a tumor section, a region of
interest may be identified. A region of interest may refer to any
subset of a tumor section selected for analysis. In some
embodiments, a region of interest may include a portion of a tumor
section, which may include cancer cells, lymphocytes, and,
optionally, tumor stroma. Lymphocytes may be associated with cancer
cells and/or tumor stroma. In some embodiments, more than one
region of interest from a sample may be analyzed (e.g., if a main
tumor mass and satellite mass are observed).
[0359] The level of expression of CD4, OX40, and/or Foxp3 may be
compared with a reference. Many methods for comparing the
expression level of a gene or protein of interest to a reference
are known in the art. For example, in some embodiments, a reference
may be expression level of a tumor with a known responsiveness to a
treatment (e.g., with an OX40 agonist) or prognosis, a control
(e.g., expression level of a housekeeping biomarker), or a
reference number (e.g., a set threshold level of expression, such
as a threshold based on clinical outcome data). In some
embodiments, a comparison with a reference may refer to a
comparison with a reference number (e.g., a predetermined level of
expression) or a comparison with a reference sample.
[0360] In some embodiments, the expression level of a gene or
protein of interest (e.g., CD4, OX40, and/or Foxp3) in a cell may
be compared with the expression level of the gene of interest in
other cells in the sample. For example, the sample may be assayed
for the expression level of a gene or protein of interest (e.g.,
CD4, OX40, and/or Foxp3), and cells that show increased expression
of the gene or protein of interest relative to other cells in the
sample may be considered "positive" for expression of the gene or
protein of interest. In some embodiments, the sample may be assayed
for the expression level of a gene or protein of interest (e.g.,
CD4, OX40, and/or Foxp3), and a global threshold for expression
level may be applied. Cells that show expression at or above the
global threshold may be considered "positive" for expression of the
gene or protein of interest, whereas cells that show expression
below the global threshold may be considered "negative" for
expression of the gene or protein of interest. In some embodiments,
the expression level of a gene or protein of interest (e.g., CD4,
OX40, and/or Foxp3) in a cell may be compared with the expression
level of the gene of interest in other cells in the region of
interest.
[0361] Many methods for assaying the expression level of a gene or
protein of interest are known in the art. For example, in some
embodiments, expression level may be assayed by immunofluorescence
staining, immunohistochemistry, imaging (e.g., microscopic imaging,
such as fluorescence microscopy), flow cytometry, in situ
hybridization, immunoprecipitation, and the like. In some
embodiments, lymphocytes showing CD4 expression, OX40 expression,
and Foxp3 expression are labeled by immunofluorescence staining
Exemplary methods for immunofluorescence staining are described
herein.
[0362] In some embodiments, expression level may refer to a median
or mean expression level detected for a cell in a sample. In some
embodiments, expression level may refer to the maximum expression
level detected for a cell. For example, if assayed by
immunofluorescence staining and immunofluorescence imaging,
expression level of a gene or protein of interest in a cell may be
based on the median fluorescence intensity detected in the area
corresponding to the cell (e.g., as defined by morphology, membrane
staining, and/or a nuclear staining).
[0363] In some embodiments, an absolute number of cells of interest
(e.g., OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3- cells) may be
measured and used. In some embodiments, a relative number of cells
of interest (e.g., OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3-
cells) may be measured or used. For example, the number of CD4+
OX40+ Foxp3+ cells may be normalized to the total amount of cells
detected in a sample, or in a region of interest from the sample.
In some embodiments, the number of cells of interest may be an
average, mean, or median of number of cells of interest in
different regions of interest of a sample or different samples from
the subject.
[0364] Certain aspects of the present disclosure relate to
determining the prognosis of the subject based on the number of
CD4+ OX40+ Foxp3+ lymphocytes in the sample, as compared with a
reference of the present disclosure. In some embodiments, an
increased number (e.g., absolute or normalized number) of cells of
interest (e.g., e.g., OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+
Foxp3- cells) as compared with a reference of the present
disclosure may indicate an improved prognosis. Certain aspects of
the present disclosure relate to determining the prognosis of the
subject based on the number of CD4+ OX40+ Foxp3- lymphocytes in the
sample, as compared with a reference of the present disclosure. In
some embodiments, an increased number (e.g., absolute or normalized
number) of cells of interest (e.g., CD4+ OX40+ Foxp3- cells) as
compared with a reference of the present disclosure may indicate an
improved prognosis. Certain aspects of the present disclosure
relate to determining the prognosis of the subject based on the
number of OX40+ lymphocytes in the sample, as compared with a
reference of the present disclosure. In some embodiments, an
increased number (e.g., absolute or normalized number) of cells of
interest (e.g., OX40+ cells) as compared with a reference of the
present disclosure may indicate an improved prognosis.
[0365] In some embodiments, prognosis may refer to overall survival
and/or progression-free survival. In some embodiments, an improved
prognosis may predict increased overall survival. In some
embodiments, an improved prognosis may predict increased
progression-free survival. In some embodiments, an improved
prognosis may predict increased overall survival and increased
progression-free survival. In some embodiments, other factors may
additionally be considered to determine a prognosis, including
without limitation, age, the type and/or location of a cancer,
stage, cancer grade, overall health, family history, and so
forth.
[0366] In some embodiments, a reference of the present disclosure
may refer to a number of cells of interest (e.g., OX40+, CD4+ OX40+
Foxp3+, or CD4+ OX40+ Foxp3- cells) in a sample comprising cancer
cells and lymphocytes obtained from a cancer having the same type
and/or stage as the cancer of the subject. For example, if the
subject presents with stage I colorectal cancer, the sample from
the patient may be compared with a reference sample from another
patient or patients with stage I colorectal cancer. An increased
number of CD4+ OX40+ Foxp3+ cells in the patient sample as compared
with the reference sample may indicate an improved prognosis. It is
a discovery of the present disclosure that the numbers of OX40+
Treg and OX40+ Teff are correlated with prognosis (e.g., overall
survival) when the analyses are adjusted for factors such as age,
gender, and cancer stage.
[0367] In some embodiments, the reference is based on the number of
CD4+ OX40+ Foxp3+ lymphocytes in a sample comprising cancer cells
and lymphocytes obtained from a cancer having the same type and/or
stage as the cancer of the subject. In some embodiments, the
reference is based on the number of CD4+ OX40+ Foxp3- lymphocytes
in a sample comprising metastatic cancer cells and lymphocytes
obtained from a cancer having the same type and/or stage as the
cancer of the subject. In some embodiments, the reference is based
on the number of OX40+ lymphocytes in a sample comprising
metastatic cancer cells and lymphocytes obtained from a cancer
having the same type and/or stage as the cancer of the subject. For
example, a set of samples obtained from cancers having a shared
characteristic (e.g., the same cancer type and/or stage) may be
studied from a population, such as with a clinical outcome study.
This set may be used to derive a reference, e.g., a reference
number, to which a subject's sample may be compared. As such, the
number of OX40+, CD4+ OX40+ Foxp3+, or OX40+, CD4+ OX40+ Foxp3-
lymphocytes in a sample may be correlated to clinical outcome.
Therefore, a reference number of OX40+, CD4+ OX40+ Foxp3+, or
OX40+, CD4+ OX40+ Foxp3- lymphocytes may be used for comparison
with a subject's sample to predict responsiveness of a subject to
an OX40 agonist treatment and/or determine the prognosis of a
subject.
[0368] In some embodiments, the reference is the mean number of
OX40+, CD4+ OX40+ Foxp3+, or OX40+, CD4+ OX40+ Foxp3- lymphocytes
in samples obtained from cancers having the same type and/or stage
as the cancer of the subject. In some embodiments, the reference is
the median number of OX40+, CD4+ OX40+ Foxp3+, or OX40+, CD4+ OX40+
Foxp3- lymphocytes in samples obtained from cancers having the same
type and/or stage as the cancer of the subject. In some
embodiments, the reference is the average number of OX40+, CD4+
OX40+ Foxp3+, or OX40+, CD4+ OX40+ Foxp3- lymphocytes in samples
obtained from cancers having the same type and/or stage as the
cancer of the subject.
[0369] Provided herein are methods for predicting responsiveness of
a subject having cancer to an OX40 agonist treatment by measuring
the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing
cancer cells and lymphocytes obtained from the subject; and
classifying the subject as a responsive or non-responsive subject
based on the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample,
as compared with a reference, where an increased number of CD4+
OX40+ Foxp3+ lymphocytes in the sample indicates a responsive
subject, as compared with a subject whose sample has a decreased
number of CD4+ OX40+ Foxp3+ lymphocytes. Further provided herein
are methods for predicting responsiveness of a subject having
cancer to an OX40 agonist treatment by measuring the number of
OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in a
sample containing metastatic cancer cells and lymphocytes obtained
from the subject; and classifying the subject as a responsive or
non-responsive subject based on the number of OX40+, CD4+ OX40+
Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in the sample, as compared
with a reference, where an increased number of OX40+, CD4+ OX40+
Foxp3+, or CD4+ OX40+ Foxp3- lymphocytes in the sample indicates a
responsive subject, as compared with a subject whose sample has a
decreased number of OX40+, CD4+ OX40+ Foxp3+, or CD4+ OX40+ Foxp3-
lymphocytes. Without wishing to be bound to theory, it is thought
that patients having tumors with increased numbers of OX40+, CD4+
OX40+ Foxp3+, and/or CD4+ OX40+ Foxp3- lymphocytes may be more
likely to respond to OX40 agonist treatment, compared to patients
whose tumors have fewer such cells. Predicting a patient's
responsiveness to a treatment may be highly advantageous in
selecting a treatment option with the greatest likelihood of
producing a successful clinical outcome, either by positively
selecting a treatment option that is deemed more likely to work, or
by eliminating a treatment option that is deemed less likely to
work. Any of the methods herein for measuring OX40+, CD4+ OX40+
Foxp3+ or CD4+ OX40+ Foxp3- lymphocytes of the present disclosure
may find use in these methods.
[0370] In some embodiments, a subject is classified as responsive
or non-responsive based on the number of OX40+, CD4+ OX40+ Foxp3+,
or CD4+ OX40+ Foxp3- lymphocytes in a sample, as compared with a
reference. Any of the references described herein may be used. For
example, the number of CD4+ OX40+ Foxp3+ lymphocytes in a patient
sample may be compared to a reference number (e.g., one based on
clinical outcome studies), or a sample with known responsiveness to
treatment.
[0371] In some embodiments, responsiveness to treatment may refer
to any one or more of: extending survival (including overall
survival and progression free survival); resulting in an objective
response (including a complete response or a partial response); or
improving signs or symptoms of cancer. In some embodiments,
responsiveness may refer to improvement of one or more factors
according to the published set of RECIST or Immune-Related Response
Criteria guidelines for determining the status of a tumor in a
cancer patient, i.e., responding, stabilizing, or progressing. For
a more detailed discussion of these guidelines, see Eisenhauer et
al., Eur J Cancer 2009; 45: 228-47; Topalian et al., N Engl J Med
2012; 366:2443-54; Wolchok et al., Clin Can Res 2009; 15:7412-20;
and Therasse, P., et al. J. Natl. Cancer Inst. 92:205-16 (2000). A
responsive subject may refer to a subject whose tumor(s) show
improvement, e.g., according to one or more factors based on RECIST
or Immune-Related Response criteria. A non-responsive subject may
refer to a subject whose tumor(s) do not show improvement, e.g.,
according to one or more factors based on RECIST or Immune-Related
Response criteria. In some embodiments, responsiveness may include
immune activation. In some embodiments, responsiveness may include
treatment efficacy. In some embodiments, responsiveness may include
immune activation and treatment efficacy.
[0372] Conventional response criteria may not be adequate to
characterize the anti-tumor activity of immunotherapeutic agents,
which can produce delayed responses that may be preceded by initial
apparent radiological progression, including the appearance of new
lesions. Therefore, modified response criteria have been developed
that account for the possible appearance of new lesions and allow
radiological progression to be confirmed at a subsequent
assessment. Accordingly, in some embodiments, responsiveness may
refer to improvement of one of more factors according to
immune-related response criteria2(irRC). See, e.g., Wolchok et al.,
Clin Can Res 2009; 15:7412-20. In some embodiments, new lesions are
added into the defined tumor burden and followed, e.g., for
radiological progression at a subsequent assessment. In some
embodiments, presence of non-target lesions are included in
assessment of complete response and not included in assessment of
radiological progression. In some embodiments, radiological
progression may be determined only on the basis of measurable
disease and/or may be confirmed by a consecutive assessment
.gtoreq.4 weeks from the date first documented.
[0373] Certain aspects of the present disclosure relate to methods
for measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a
sample comprising cancer cells and lymphocytes obtained from a
subject. In some embodiments, the methods include: (a) labeling
lymphocytes that show CD4 expression in the sample; (b) labeling
lymphocytes that show OX40 expression in the sample after step (a);
(c) labeling lymphocytes that show Foxp3 expression in the sample
after step (b); and (d) measuring the number of CD4+ OX40+ Foxp3+
lymphocytes in the sample after step (c). These methods may find
use in any of the other methods described herein, e.g., methods for
predicting responsiveness of a subject having cancer to an OX40
agonist treatment, methods for determining the prognosis of a
subject having cancer by measuring the number of CD4+ OX40+ Foxp3+
lymphocytes in a sample containing cancer cells and lymphocytes
obtained from the subject, and/or methods for treating or delaying
progression of cancer in a subject.
[0374] In some embodiments, lymphocytes that show expression of
CD4, OX40, and/or Foxp3 are labeled. Any suitable method known in
the art and/or described herein for labeling a cell that shows
expression of a marker may be used. In some embodiments,
lymphocytes that show expression of CD4, OX40, and/or Foxp3 are
labeled using an antibody that specifically binds to CD4, OX40, or
Foxp3. For example, such antibodies may be used for assays
including without limitation immunofluorescence staining, flow
cytometry, immunoprecipitation, and the like. In some embodiments,
lymphocytes showing CD4 expression, OX40 expression, and Foxp3
expression are labeled by immunofluorescence staining. In some
embodiments, lymphocytes that show expression of CD4, OX40, and/or
Foxp3 are labeled for in situ hybridization using a probe that
specifically binds to CD4, OX40, or Foxp3 transcripts. In some
embodiments, expression of CD4, OX40, and/or Foxp3 may be labeled
using the same technique. In some embodiments, expression of CD4,
OX40, and/or Foxp3 may be labeled using multiple techniques.
[0375] In some embodiments, imaging techniques are used to quantify
expression of CD4, OX40, and/or Foxp3 corresponding to labeled
lymphocytes. For example, fluorescence microscopy may be used to
measure the amount of CD4, OX40, and/or Foxp3 expression in a
sample. Image analysis techniques, such as those described above,
may be used to quantify expression of each marker on a cell-by-cell
basis, enabling the enumeration of cells of interest (e.g., CD4+
OX40+ Foxp3+ lymphocytes).
[0376] In some embodiments, lymphocytes that show CD4 expression in
a sample are labeled first, followed by lymphocytes that show OX40
expression in the sample, followed by lymphocytes that show Foxp3
expression in the sample. In some embodiments, detection of CD4
expression may occur before detection of OX40 expression, and/or
detection of OX40 expression may occur before detection of Foxp3
expression. In some embodiments, each marker may be labeled in
succession, but the detection of all three markers may be performed
at the same time (e.g., by multichannel fluorescence microscopy).
It is to be noted that detection of three separate fluorophores may
not occur simultaneously; rather, "at the same time" may encompass
successive imaging of a sample using a first channel, then a second
channel, then a third channel, to create a composite, three-color
image of a sample showing expression levels of CD4, OX40, and
Foxp3.
[0377] In some embodiments, antigen retrieval techniques are used
between labeling steps. Antigen retrieval techniques are widely
known and used in the art to improve specific binding of antibodies
to antigens. Without wishing to be bound to theory, these
techniques are thought to uncover and/or recover antigenic sites by
breaking cross-linkages or otherwise altering protein conformation.
Antigen retrieval techniques often include heat, chemical, and/or
enzymatic treatment of samples, such as fixed and/or
paraffin-embedded samples.
[0378] In some embodiments, a sample may be treated with a solution
containing an effective amount of an antigen retrieval agent
between labeling lymphocytes that show CD4 expression in the sample
and labeling lymphocytes that show OX40 expression in the sample
and/or between labeling lymphocytes that show OX40 expression in
the sample and labeling lymphocytes that show Foxp3 expression in
the sample. In some embodiments, a sample may be heated while being
treated with an antigen retrieval agent.
[0379] In some embodiments, the antigen retrieval agent contains
EDTA. In some embodiments, the antigen retrieval agent includes an
EDTA buffer. Effective amounts of various antigen retrieval agents
may be determined empirically, such as by assaying the
effectiveness of staining with a particular antibody, and effective
amounts of many antigen retrieval agents are known in the art. For
example, a sample may be treated with 1 mM EDTA buffer. In some
embodiments, the EDTA buffer may be at pH 8.0, pH 8.5, or pH
9.0.
[0380] In some embodiments, the antigen retrieval agent contains a
citrate buffer. For example, DAKO.RTM. Target Retrieval Solution or
sodium citrate buffer may be used. Effective amounts of various
antigen retrieval agents may be determined empirically, such as by
assaying the effectiveness of staining with a particular antibody,
and effective amounts of many antigen retrieval agents are known in
the art. For example, a sample may be treated with 10 mM sodium
citrate buffer. In some embodiments, the citrate buffer may be at
pH 6.0.
[0381] It is known in the art that different primary antibodies
used for immunofluorescence staining may have different effective
dilutions. In some embodiments, an anti-CD4 antibody in
concentrated form may be diluted between 1:50-1:500 for use. In
some embodiments, an anti-CD4 antibody in concentrated form may be
diluted 1:50 for use. In some embodiments, the anti-CD4 antibody
may be clone 4B12 (Fisher Scientific, Waltham, Mass.). In some
embodiments, an anti-OX40 antibody in concentrated form may be
diluted between 1:200-1:600 for use. In some embodiments, an
anti-OX40 antibody in concentrated form may be diluted 1:400 for
use. In some embodiments, the anti-OX40 antibody may be 1A7. In
some embodiments, an anti-Foxp3 antibody in concentrated form may
be diluted between 1:100-1:500 for use. In some embodiments, an
anti-Foxp3 antibody in concentrated form may be diluted 1:100 for
use. In some embodiments, the anti-Foxp3 antibody may be clone
236A/E7 (Abcam, Cambridge, UK).
[0382] Various antibodies known in the art that specifically bind
to OX40 may be used in the detection assays described herein. In
some embodiments, lymphocytes that show expression of OX40 are
labeled by one of the antibodies described herein. In some
embodiments, lymphocytes that show expression of OX40 are labeled
by an antibody comprising (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:2; (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:3; (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO:4; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising an amino acid
sequence selected from SEQ ID NO:7.
[0383] In some embodiments, lymphocytes that show expression of
OX40 are labeled by antibody clone 1A7. In some embodiments,
lymphocytes that show expression of OX40 are labeled by an antibody
comprising a heavy chain variable region comprising the amino acid
sequence of
EVQLQQSGPELVKPGASVKISCKASGYTFTDSYMSWVKQSHGKTLEWIGDMYPDNGDSSY
NQKFREKVTLTVDKSSTTAYMEFRSLTSEDSAVYYCVLAPRWYFSVWGTGTTVTVSS (SEQ ID
NO:) and/or a light chain variable region comprising the amino acid
sequence of
DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLRSGVPSRFS
GSGSGKDYFLTISNLEQEDVAAYFCQQGHTLPPTFGGGTKLEIK (SEQ ID NO:).
[0384] In some embodiments, the anti-OX40 antibody for use in a
method of diagnosis or detection is an anti-human OX40 antibody
comprising at least one, two, three, four, five, or six HVRs
selected from (a) HVR-H1 comprising the amino acid sequence of SEQ
ID NO:2; (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO:3; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:4;
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (e)
HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (f)
HVR-L3 comprising the amino acid sequence of SEQ ID NO:7. In some
embodiments, the anti-OX40 antibody comprises (a) a VH domain
comprising at least one, at least two, or all three VH HVR
sequences selected from (i) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:2, (ii) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:3, and (iii) HVR-H3 comprising an amino acid
sequence selected from SEQ ID NO:4; and (b) a VL domain comprising
at least one, at least two, or all three VL HVR sequences selected
from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:5,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:6, and
(c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:7. In
some embodiments, the OX40 antibody comprises (a) HVR-H1 comprising
the amino acid sequence of SEQ ID NO:2; (b) HVR-H2 comprising the
amino acid sequence of SEQ ID NO:3; (c) HVR-H3 comprising the amino
acid sequence of SEQ ID NO:4; (d) HVR-L1 comprising the amino acid
sequence of SEQ ID NO:5; (e) HVR-L2 comprising the amino acid
sequence of SEQ ID NO:6; and (f) HVR-L3 comprising an amino acid
sequence selected from SEQ ID NO:7. In some embodiments, the
antibody comprises a heavy chain variable domain (VH) sequence
having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,
or 100% sequence identity to the amino acid sequence of SEQ ID
NO:179. In certain embodiments, a VH sequence having at least 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains
substitutions (e.g., conservative substitutions), insertions, or
deletions relative to the reference sequence, but an anti-human
OX40 agonist antibody comprising that sequence retains the ability
to bind to OX40. In certain embodiments, a total of 1 to 10 amino
acids have been substituted, inserted and/or deleted in SEQ ID
NO:179. In certain embodiments, substitutions, insertions, or
deletions occur in regions outside the HVRs (i.e., in the FRs).
Optionally, the anti-human OX40 agonist antibody comprises the VH
sequence in SEQ ID NO:179, including post-translational
modifications of that sequence. In a particular embodiment, the VH
comprises one, two or three HVRs selected from: (a) HVR-H1
comprising the amino acid sequence of SEQ ID NO:2, (b) HVR-H2
comprising the amino acid sequence of SEQ ID NO:3, and (c) HVR-H3
comprising the amino acid sequence of SEQ ID NO:4. In some
embodiments, the antibody comprises a light chain variable domain
(VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID
NO:180. In certain embodiments, a VL sequence having at least 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains
substitutions (e.g., conservative substitutions), insertions, or
deletions relative to the reference sequence, but an anti-human
OX40 agonist antibody comprising that sequence retains the ability
to bind to OX40. In certain embodiments, a total of 1 to 10 amino
acids have been substituted, inserted and/or deleted in SEQ ID NO:
180. In certain embodiments, the substitutions, insertions, or
deletions occur in regions outside the HVRs (i.e., in the FRs).
Optionally, the anti-human OX40 agonist antibody comprises the VL
sequence in SEQ ID NO: 180, including post-translational
modifications of that sequence. In a particular embodiment, the VL
comprises one, two or three HVRs selected from (a) HVR-L1
comprising the amino acid sequence of SEQ ID NO:5; (b) HVR-L2
comprising the amino acid sequence of SEQ ID NO:6; and (c) HVR-L3
comprising the amino acid sequence of SEQ ID NO:7.
[0385] In some embodiments, the anti-OX40 antibody used in the
method of diagnosis or detection is an anti-human OX40 antibody
comprising at least one, two, three, four, five, or six HVRs
selected from (a) HVR-H1 comprising the amino acid sequence of SEQ
ID NO:29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO:30; (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:31; (d) HVR-L1 comprising the amino acid sequence of SEQ ID
NO:37; (e) HVR-L2 comprising the amino acid sequence of SEQ ID
NO:39; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID
NO:42. In some embodiments, the anti-OX40 antibody comprises (a) a
VH domain comprising at least one, at least two, or all three VH
HVR sequences selected from (i) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:29, (ii) HVR-H2 comprising the amino acid
sequence of SEQ ID NO:30, and (iii) HVR-H3 comprising an amino acid
sequence selected from SEQ ID NO:31; and (b) a VL domain comprising
at least one, at least two, or all three VL HVR sequences selected
from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:37,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:39, and
(c) HVR-L3 comprising the amino acid sequence of SEQ ID NO:42. In
some embodiments, the anti-OX40 antibody comprises (a) HVR-H1
comprising the amino acid sequence of SEQ ID NO:29; (b) HVR-H2
comprising the amino acid sequence of SEQ ID NO:30; (c) HVR-H3
comprising the amino acid sequence of SEQ ID NO:31; (d) HVR-L1
comprising the amino acid sequence of SEQ ID NO:37; (e) HVR-L2
comprising the amino acid sequence of SEQ ID NO:39; and (f) HVR-L3
comprising an amino acid sequence selected from SEQ ID NO:42. In
some embodiment, the anti-OX40 antibody comprises a heavy chain
variable domain (VH) sequence having at least 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the
amino acid sequence of SEQ ID NO:181. In certain embodiments, a VH
sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, or 99% identity contains substitutions (e.g., conservative
substitutions), insertions, or deletions relative to the reference
sequence, but an anti-human OX40 agonist antibody comprising that
sequence retains the ability to bind to OX40. In certain
embodiments, a total of 1 to 10 amino acids have been substituted,
inserted and/or deleted in SEQ ID NO:181. In certain embodiments,
substitutions, insertions, or deletions occur in regions outside
the HVRs (i.e., in the FRs). Optionally, the anti-human OX40
agonist antibody comprises the VH sequence in SEQ ID NO:181,
including post-translational modifications of that sequence. In a
particular embodiment, the VH comprises one, two or three HVRs
selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ
ID NO:29, (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO:30, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO:31. In some embodiments, the anti-OX40 antibody comprises a
light chain variable domain (VL) having at least 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the
amino acid sequence of SEQ ID NO:182. In certain embodiments, a VL
sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, or 99% identity contains substitutions (e.g., conservative
substitutions), insertions, or deletions relative to the reference
sequence, but an anti-human OX40 agonist antibody comprising that
sequence retains the ability to bind to OX40. In certain
embodiments, a total of 1 to 10 amino acids have been substituted,
inserted and/or deleted in SEQ ID NO: 182. In certain embodiments,
the substitutions, insertions, or deletions occur in regions
outside the HVRs (i.e., in the FRs). Optionally, the anti-human
OX40 agonist antibody comprises the VL sequence in SEQ ID NO: 182,
including post-translational modifications of that sequence. In a
particular embodiment, the VL comprises one, two or three HVRs
selected from (a) HVR-L1 comprising the amino acid sequence of SEQ
ID NO:37; (b) HVR-L2 comprising the amino acid sequence of SEQ ID
NO:39; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID
NO:42.
[0386] In some embodiments, the anti-OX40 antibody comprises a VH
sequence of SEQ ID NO: 179. In some embodiments, the anti-OX40
antibody comprises a VL sequence of SEQ ID NO: 180. In some
embodiments, the anti-OX40 antibody comprises a VH sequence of SEQ
ID NO:179 and a VL sequence of SEQ ID NO: 180. In some embodiments,
the anti-OX40 antibody comprises a VH sequence of SEQ ID NO: 181.
In some embodiments, the anti-OX40 antibody comprises a VL sequence
of SEQ ID NO: 182. In some embodiments, the anti-OX40 antibody
comprises a VH sequence of SEQ ID NO:181 and a VL sequence of SEQ
ID NO: 182.
V. Methods of Treatment
[0387] In one aspect, provided herein are methods for treating or
delaying progression of cancer in an individual comprising
administering to the individual an effective amount of an OX40
agonist. The methods of this disclosure may find use, inter alia,
in treating conditions where enhanced immunogenicity is desired
such as increasing tumor immunogenicity for the treatment of cancer
or T cell dysfunctional disorders. A variety of cancers may be
treated, or their progression may be delayed, by these methods.
[0388] Certain aspects of the present disclosure relate to methods
for treating or delaying progression of cancer in a subject. In
some embodiments, the methods include measuring the number of CD4+
OX40+ Foxp3+ lymphocytes in a sample containing cancer cells and
lymphocytes obtained from the subject; determining the number of
CD4+ OX40+ Foxp3+ lymphocytes in the sample, as compared with a
reference; and if the number of CD4+ OX40+ Foxp3+ lymphocytes in
the sample is higher than the reference, administering to the
subject an effective amount of an OX40 agonist. In some
embodiments, the methods include administering to the subject an
effective amount of an OX40 agonist, where a sample comprising
cancer cells and lymphocytes obtained from the subject has an
increased number of CD4+ OX40+ Foxp3+ lymphocytes, as compared with
a reference. In some embodiments, the methods include measuring the
number of CD4+ OX40+ Foxp3- lymphocytes in a sample containing
cancer cells (e.g., metastatic cancer cells) and lymphocytes
obtained from the subject; determining the number of CD4+ OX40+
Foxp3- lymphocytes in the sample, as compared with a reference; and
if the number of CD4+ OX40+ Foxp3- lymphocytes in the sample is
higher than the reference, administering to the subject an
effective amount of an OX40 agonist. In some embodiments, the
methods include administering to the subject an effective amount of
an OX40 agonist, where a sample comprising (e.g., metastatic cancer
cells) cancer cells and lymphocytes obtained from the subject has
an increased number of CD4+ OX40+ Foxp3- lymphocytes, as compared
with a reference. In some embodiments, the methods include
measuring the number of OX40+ lymphocytes in a sample containing
metastatic cancer cells and lymphocytes obtained from the subject;
determining the number of OX40+ lymphocytes in the sample, as
compared with a reference; and if the number of OX40+ lymphocytes
in the sample is higher than the reference, administering to the
subject an effective amount of an OX40 agonist. In some
embodiments, the methods include administering to the subject an
effective amount of an OX40 agonist, where a sample comprising
metastatic cancer cells and lymphocytes obtained from the subject
has an increased number of OX40+ lymphocytes, as compared with a
reference. Any of the methods described herein for measuring the
number of OX40+ lymphocytes in a sample may be used.
[0389] In some embodiments, the OX40 agonist is administered to a
subject wherein a sample containing cancer cells (including
metastatic cancer cells) and lymphocytes from the subject have been
detected for having increase number of OX40+, CD4+ OX40+ Foxp3+,
and/or CD4+ OX40+ Foxp3- lymphocytes in the sample as compared to a
reference. In some embodiments, the increase may be one that is
considered increased to a skilled person. For example, such
increase may be at least about 0.5 fold, at least about 1 fold, at
least about 2 fold, or at least about 5 fold relative to the
reference.
[0390] In some embodiments, a cancer to be treated by the methods
of the present disclosure includes, but is not limited to, squamous
cell cancer (e.g., epithelial squamous cell cancer), lung cancer
including small-cell lung cancer, non-small cell lung cancer,
adenocarcinoma of the lung and squamous carcinoma of the lung,
cancer of the peritoneum, hepatocellular cancer, gastric or stomach
cancer including gastrointestinal cancer and gastrointestinal
stromal cancer, pancreatic cancer, glioblastoma, cervical cancer,
ovarian cancer, liver cancer, bladder cancer, cancer of the urinary
tract, hepatoma, breast cancer, colon cancer, rectal cancer,
colorectal cancer, endometrial or uterine carcinoma, salivary gland
carcinoma, kidney or renal cancer, prostate cancer, vulval cancer,
thyroid cancer, hepatic carcinoma, anal carcinoma, penile
carcinoma, melanoma, superficial spreading melanoma, lentigo
maligna melanoma, acral lentiginous melanomas, nodular melanomas,
multiple myeloma and B-cell lymphoma; chronic lymphocytic leukemia
(CLL); acute lymphoblastic leukemia (ALL); hairy cell leukemia;
chronic myeloblastic leukemia; and post-transplant
lymphoproliferative disorder (PTLD), as well as abnormal vascular
proliferation associated with phakomatoses, edema (such as that
associated with brain tumors), Meigs' syndrome, brain, as well as
head and neck cancer, and associated metastases. In some
embodiments, the cancer is colorectal cancer. In some embodiments,
the cancer is selected from non-small cell lung cancer,
glioblastoma, neuroblastoma, renal cell carcinoma, bladder cancer,
ovarian cancer, melanoma, breast carcinoma, gastric cancer, and
hepatocellular carcinoma. In some embodiments, the cancer is
triple-negative breast carcinoma. In some embodiments, the cancer
may be an early stage cancer or a late stage cancer. In some
embodiments, the cancer may be a primary tumor. In some
embodiments, the cancer may be a metastatic tumor at a second site
derived from any of the above types of cancer.
[0391] In some embodiments, examples of cancer further include, but
are not limited to, B-cell lymphoma (including low grade/follicular
non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL;
intermediate grade/follicular NHL; intermediate grade diffuse NHL;
high grade immunoblastic NHL; high grade lymphoblastic NHL; high
grade small non-cleaved cell NHL; bulky disease NHL; mantle cell
lymphoma; AIDS-related lymphoma; and Waldenstrom's
Macroglobulinemia); chronic lymphocytic leukemia (CLL); acute
lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic
myeloblastic leukemia; and post-transplant lymphoproliferative
disorder (PTLD), as well as abnormal vascular proliferation
associated with phakomatoses, edema (such as that associated with
brain tumors), B-cell proliferative disorders, and Meigs' syndrome.
More specific examples include, but are not limited to, relapsed or
refractory NHL, front line low grade NHL, Stage III/IV NHL,
chemotherapy resistant NHL, precursor B lymphoblastic leukemia
and/or lymphoma, small lymphocytic lymphoma, B-cell chronic
lymphocytic leukemia and/or prolymphocytic leukemia and/or small
lymphocytic lymphoma, B-cell prolymphocytic lymphoma, immunocytoma
and/or lymphoplasmacytic lymphoma, lymphoplasmacytic lymphoma,
marginal zone B-cell lymphoma, splenic marginal zone lymphoma,
extranodal marginal zone--MALT lymphoma, nodal marginal zone
lymphoma, hairy cell leukemia, plasmacytoma and/or plasma cell
myeloma, low grade/follicular lymphoma, intermediate
grade/follicular NHL, mantle cell lymphoma, follicle center
lymphoma (follicular), intermediate grade diffuse NHL, diffuse
large B-cell lymphoma, aggressive NHL (including aggressive
front-line NHL and aggressive relapsed NHL), NHL relapsing after or
refractory to autologous stem cell transplantation, primary
mediastinal large B-cell lymphoma, primary effusion lymphoma, high
grade immunoblastic NHL, high grade lymphoblastic NHL, high grade
small non-cleaved cell NHL, bulky disease NHL, Burkitt's lymphoma,
precursor (peripheral) large granular lymphocytic leukemia, mycosis
fungoides and/or Sezary syndrome, skin (cutaneous) lymphomas,
anaplastic large cell lymphoma, angiocentric lymphoma.
[0392] In some embodiments, examples of cancer further include, but
are not limited to, B-cell proliferative disorders, which further
include, but are not limited to, lymphomas (e.g., B-Cell
Non-Hodgkin's lymphomas (NHL)) and lymphocytic leukemias. Such
lymphomas and lymphocytic leukemias include e.g. a) follicular
lymphomas, b) Small Non-Cleaved Cell Lymphomas/Burkitt's lymphoma
(including endemic Burkitt's lymphoma, sporadic Burkitt's lymphoma
and Non-Burkitt's lymphoma), c) marginal zone lymphomas (including
extranodal marginal zone B-cell lymphoma (Mucosa-associated
lymphatic tissue lymphomas, MALT), nodal marginal zone B-cell
lymphoma and splenic marginal zone lymphoma), d) Mantle cell
lymphoma (MCL), e) Large Cell Lymphoma (including B-cell diffuse
large cell lymphoma (DLCL), Diffuse Mixed Cell Lymphoma,
Immunoblastic Lymphoma, Primary Mediastinal B-Cell Lymphoma,
Angiocentric Lymphoma-Pulmonary B-Cell Lymphoma), f) hairy cell
leukemia, g) lymphocytic lymphoma, Waldenstrom's macroglobulinemia,
h) acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia
(CLL)/small lymphocytic lymphoma (SLL), B cell prolymphocytic
leukemia, i) plasma cell neoplasms, plasma cell myeloma, multiple
myeloma, plasmacytoma, and/or j) Hodgkin's disease.
[0393] In some embodiments of any of the methods, the cancer is a
B-cell proliferative disorder. In some embodiments, the B-cell
proliferative disorder is lymphoma, non-Hodgkins lymphoma (NHL),
aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL,
refractory NHL, refractory indolent NHL, chronic lymphocytic
leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell
leukemia (HCL), acute lymphocytic leukemia (ALL), or mantle cell
lymphoma. In some embodiments, the B-cell proliferative disorder is
NHL, such as indolent NHL and/or aggressive NHL. In some
embodiments, the B-cell proliferative disorder is indolent
follicular lymphoma or diffuse large B-cell lymphoma.
[0394] It is a discovery of the present disclosure that the OX40+
status of immune infiltrates found on primary tumors and metastases
are strongly correlated. That is to say, matched samples
representing a primary tumor and a metastatic site from the same
patient strongly correlate with respect to the number of OX40+
cells present (e.g., CD4+ OX40+ Foxp3+ Treg or CD4+ OX40+ Foxp3-
Teff cells). Advantageously, this allows a clinician to sample a
metastatic lesion for OX40+ status and determine the likely OX40+
status of the primary tumor, or vice versa. Certain aspects of the
present disclosure relate to samples comprising cancer cells and
lymphocytes. Therefore, in some embodiments, the cancer cells may
be from a primary tumor, while in other embodiments, the cancer
cells may be from a metastasis.
[0395] In some embodiments, the individual has cancer or is at risk
of developing cancer. In some embodiments, the treatment results in
a sustained response in the individual after cessation of the
treatment. In some embodiments, the individual has cancer that may
be at early stage or late stage. In some embodiments, the
individual is a human. In some embodiments, the individual is a
mammal, such as domesticated animals (e.g., cows, sheep, cats,
dogs, and horses), primates (e.g., humans and non-human primates
such as monkeys), rabbits, and rodents (e.g., mice and rats).
[0396] In some embodiments, provided is a method for treating or
delaying progression of cancer in an individual comprising
administering to the individual an effective amount of an OX40
agonist, and further comprising administering an additional
therapy. The additional therapy may be radiation therapy, surgery
(e.g., lumpectomy and a mastectomy), chemotherapy, gene therapy,
DNA therapy, viral therapy, RNA therapy, immunotherapy, bone marrow
transplantation, nanotherapy, monoclonal antibody therapy, or a
combination of the foregoing. The additional therapy may be in the
form of adjuvant or neoadjuvant therapy. In some embodiments, the
additional therapy is the administration of small molecule
enzymatic inhibitor or anti-metastatic agent. In some embodiments,
the additional therapy is the administration of side-effect
limiting agents (e.g., agents intended to lessen the occurrence
and/or severity of side effects of treatment, such as anti-nausea
agents, etc.). In some embodiments, the additional therapy is
radiation therapy. In some embodiments, the additional therapy is
surgery. In some embodiments, the additional therapy is a
combination of radiation therapy and surgery. In some embodiments,
the additional therapy is gamma irradiation. In some embodiments,
the additional therapy is therapy targeting PI3K/AKT/mTOR pathway,
HSP90 inhibitor, tubulin inhibitor, apoptosis inhibitor, and/or
chemopreventative agent. The additional therapy may be one or more
of the chemotherapeutic agents described hereabove.
[0397] Such combination therapies noted above encompass combined
administration (where two or more therapeutic agents are included
in the same or separate formulations), and separate administration,
in which case, administration of the OX40 agonist of the invention
can occur prior to, simultaneously, and/or following,
administration of the additional therapeutic agent or agents. In
one embodiment, administration of the OX40 agonist and
administration of an additional therapeutic agent occur within
about one month, or within about one, two or three weeks, or within
about one, two, three, four, five, or six days, of each other. OX40
agonists of the invention can also be used in combination with
radiation therapy.
[0398] In some embodiments, an anti-human OX40 agonist may be
administered in conjunction with a chemotherapy or chemotherapeutic
agent. In some embodiments, an anti-human OX40 agonist may be
administered in conjunction with a radiation therapy or
radiotherapeutic agent. In some embodiments, an anti-human OX40
agonist may be administered in conjunction with a targeted therapy
or targeted therapeutic agent. In some embodiments, an anti-human
OX40 agonist may be administered in conjunction with an
immunotherapy or immunotherapeutic agent, for example a monoclonal
antibody.
[0399] In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with in
combination with a PD-1 axis binding antagonist. A PD-1 axis
binding antagonist includes but is not limited to a PD-1 binding
antagonist, a PD-L1 binding antagonist and a PD-L2 binding
antagonist. Alternative names for "PD-1" include CD279 and SLEB2.
Alternative names for "PD-L1" include B7-H 1, B7-4, CD274, and
B7-H. Alternative names for "PD-L2" include B7-DC, Btdc, and CD273.
In some embodiments, PD-1, PD-L1, and PD-L2 are human PD-1, PD-L1
and PD-L2. In some embodiments, the PD-1 binding antagonist is a
molecule that inhibits the binding of PD-1 to its ligand binding
partners. In a specific aspect the PD-1 ligand binding partners are
PD-L1 and/or PD-L2. In another embodiment, a PD-L1 binding
antagonist is a molecule that inhibits the binding of PD-L1 to its
binding partners. In a specific aspect, PD-L1 binding partners are
PD-1 and/or B7-1. In another embodiment, the PD-L2 binding
antagonist is a molecule that inhibits the binding of PD-L2 to its
binding partners. In a specific aspect, a PD-L2 binding partner is
PD-1. The antagonist may be an antibody, an antigen binding
fragment thereof, an immunoadhesin, a fusion protein, or
oligopeptide. In some embodiment, the PD-1 binding antagonist is an
anti-PD-1 antibody (e.g., a human antibody, a humanized antibody,
or a chimeric antibody). In some embodiments, the anti-PD-1
antibody is selected from the group consisting of MDX-1 106, Merck
3475 and CT-011. In some embodiments, the PD-1 binding antagonist
is an immunoadhesin (e.g., an immunoadhesin comprising an
extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a
constant region (e.g., an Fc region of an immunoglobulin sequence).
In some embodiments, the PD-1 binding antagonist is AMP-224. In
some embodiments, the PD-L1 binding antagonist is an anti-PD-L1
antibody. In some embodiments, the anti-PD-L1 binding antagonist is
selected from the group consisting of YW243.55.S70, MPDL3280A
(atezolizumab), MEDI4736 (durvalumab), MDX-1105, and MSB0010718C
(avelumab). MDX-1 105, also known as BMS-936559, is an anti-PD-L1
antibody described in WO2007/005874. Antibody YW243.55.S70 (heavy
and light chain variable region sequences shown in SEQ ID Nos. 20
and 21, respectively) is an anti-PD-L1 described in WO 2010/077634
A1. MDX-1 106, also known as MDX-1 106-04, ONO-4538 or BMS-936558,
is an anti-PD-1 antibody described in WO2006/121168. Merck 3745,
also known as MK-3475, SCH-900475, pembrolizumab, and
KEYTRUDA.RTM., is an anti-PD-1 antibody described in WO2009/114335.
CT-011, also known as hBAT, hBAT-1, and pidilizumab, is an
anti-PD-1 antibody described in WO2009/101611. AMP-224, also known
as B7-DCIg, is a PD-L2-Fc fusion soluble receptor described in
WO2010/027827 and WO2011/066342. In some embodiments, the anti-PD-1
antibody is MDX-1 106. Alternative names for "MDX-1106" include
MDX-1 106-04, ONO-4538, BMS-936558, Nivolumab, or OPDIVO.RTM.. In
some embodiments, the anti-PD-1 antibody is Nivolumab (CAS Registry
Number: 946414-94-4). In some embodiments, the anti-PD-1 antibody
is selected from the group consisting of MDX-1106 (nivolumab,
OPDIVO.RTM.), Merck 3475 (MK-3475, pembrolizumab, KEYTRUDA.RTM.),
CT-011 (Pidilizumab), MEDI-0680 (AMP-514), PDR001, REGN2810,
BGB-108, and BGB-A317.
[0400] In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with an
antagonist directed against CTLA-4 (also known as CD152), e.g., a
blocking antibody. In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with ipilimumab (also known as MDX-010, MDX-101, or
Yervoy.RTM.). In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with tremelimumab (also known as ticilimumab or
CP-675,206). In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with an antagonist directed against B7-H3 (also known
as CD276), e.g., a blocking antibody. In some embodiments, an OX40
agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with MGA271. In some embodiments, an
OX40 agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with an antagonist directed against a
TGF beta, e.g., metelimumab (also known as CAT-192), fresolimumab
(also known as GC1008), or LY2157299.
[0401] In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with a
treatment comprising adoptive transfer of a T cell (e.g., a
cytotoxic T cell or CTL) expressing a chimeric antigen receptor
(CAR). In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with a
treatment comprising adoptive transfer of a T cell comprising a
dominant-negative TGF beta receptor, e.g, a dominant-negative TGF
beta type II receptor. In some embodiments, an OX40 agonist (e.g.,
an anti-human OX40 agonist antibody) may be administered in
conjunction with a treatment comprising a HERCREEM protocol (see,
e.g., ClinicalTrials.gov Identifier NCT00889954).
[0402] In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with an
agonist directed against CD137 (also known as TNFRSF9, 4-1BB, or
ILA), e.g., an activating antibody. In some embodiments, an OX40
agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with urelumab (also known as
BMS-663513). In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with an agonist directed against CD40, e.g., an
activating antibody. In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with CP-870893. In some embodiments, an OX40 agonist
(e.g., an anti-human OX40 agonist antibody) may be administered in
conjunction with an agonist directed against OX40 (also known as
CD134), e.g., an activating antibody. In some embodiments, an OX40
agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with a different anti-OX40 antibody
(e.g., AgonOX). In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with an agonist directed against CD27, e.g., an
activating antibody. In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with CDX-1127. In some embodiments, an OX40 agonist
(e.g., an anti-human OX40 agonist antibody) may be administered in
conjunction with an antagonist directed against
indoleamine-2,3-dioxygenase (IDO). In some embodiments, with the
IDO antagonist is 1-methyl-D-tryptophan (also known as 1-D-MT).
[0403] In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with an
antibody-drug conjugate. In some embodiments, the antibody-drug
conjugate comprises mertansine or monomethyl auristatin E (MMAE).
In some embodiments, an OX40 agonist (e.g., an anti-human OX40
agonist antibody) may be administered in conjunction with and
anti-NaPi2b antibody-MMAE conjugate (also known as DNIB0600A or
RG7599). In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with
trastuzumab emtansine (also known as T-DM1, ado-trastuzumab
emtansine, or KADCYLA.RTM., Genentech). In some embodiments, an
OX40 agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with DMUC5754A. In some embodiments, an
OX40 agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with an antibody-drug conjugate
targeting the endothelin B receptor (EDNBR), e.g., an antibody
directed against EDNBR conjugated with MMAE.
[0404] In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with an
angiogenesis inhibitor. In some embodiments, an OX40 agonist (e.g.,
an anti-human OX40 agonist antibody) may be administered in
conjunction with an antibody directed against a VEGF, e.g., VEGF-A.
In some embodiments, an OX40 agonist (e.g., an anti-human OX40
agonist antibody) may be administered in conjunction with
bevacizumab (also known as AVASTIN.RTM., Genentech). In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with an antibody
directed against angiopoietin 2 (also known as Ang2). In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with MEDI3617.
[0405] In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with an
antineoplastic agent. In some embodiments, an OX40 agonist (e.g.,
an anti-human OX40 agonist antibody) may be administered in
conjunction with an agent targeting CSF-1R (also known as M-CSFR or
CD115). In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with
anti-CSF-1R (also known as IMC-CS4). In some embodiments, an OX40
agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with an interferon, for example
interferon alpha or interferon gamma. In some embodiments, an OX40
agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with Roferon-A (also known as
recombinant Interferon alpha-2a). In some embodiments, an OX40
agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with GM-CSF (also known as recombinant
human granulocyte macrophage colony stimulating factor, rhu GM-CSF,
sargramostim, or Leukine.RTM.). In some embodiments, an OX40
agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with IL-2 (also known as aldesleukin or
Proleukin.RTM.). In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with IL-12. In some embodiments, an OX40 agonist (e.g.,
an anti-human OX40 agonist antibody) may be administered in
conjunction with an antibody targeting CD20. In some embodiments,
the antibody targeting CD20 is obinutuzumab (also known as GA101 or
Gazyva.RTM.) or rituximab. In some embodiments, an OX40 agonist
(e.g., an anti-human OX40 agonist antibody) may be administered in
conjunction with an antibody targeting GITR. In some embodiments,
the antibody targeting GITR is TRX518.
[0406] In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with a
cancer vaccine. In some embodiments, the cancer vaccine is a
peptide cancer vaccine, which in some embodiments is a personalized
peptide vaccine. In some embodiments the peptide cancer vaccine is
a multivalent long peptide, a multi-peptide, a peptide cocktail, a
hybrid peptide, or a peptide-pulsed dendritic cell vaccine (see,
e.g., Yamada et al., Cancer Sci, 104:14-21, 2013). In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with an adjuvant. In
some embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with a treatment
comprising a TLR agonist, e.g., Poly-ICLC (also known as
Hiltonol.RTM.), LPS, MPL, or CpG ODN. In some embodiments, an OX40
agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with tumor necrosis factor (TNF) alpha.
In some embodiments, an OX40 agonist (e.g., an anti-human OX40
agonist antibody) may be administered in conjunction with IL-1. In
some embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with HMGB1. In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with an IL-10
antagonist. In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with an IL-4 antagonist. In some embodiments, an OX40
agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with an IL-13 antagonist. In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with an HVEM
antagonist. In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with an ICOS agonist, e.g., by administration of
ICOS-L, or an agonistic antibody directed against ICOS. In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with a treatment
targeting CX3CL1. In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with a treatment targeting CXCL9. In some embodiments,
an OX40 agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with a treatment targeting CXCL10. In
some embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with a treatment
targeting CCL5. In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with an LFA-1 or ICAM1 agonist. In some embodiments, an
OX40 agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with a Selectin agonist.
[0407] In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with a
targeted therapy. In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with an inhibitor of B-Raf. In some embodiments, an
OX40 agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with vemurafenib (also known as
Zelboraf.RTM.). In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with dabrafenib (also known as Tafinlar.RTM.). In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with erlotinib (also
known as Tarceva.RTM.). In some embodiments, an OX40 agonist (e.g.,
an anti-human OX40 agonist antibody) may be administered in
conjunction with an inhibitor of a MEK, such as MEK1 (also known as
MAP2K1) or MEK2 (also known as MAP2K2). In some embodiments, an
OX40 agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with cobimetinib (also known as
GDC-0973 or XL-518). In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with trametinib (also known as Mekinist.RTM.). In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with an inhibitor of
K-Ras. In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with an
inhibitor of c-Met. In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with onartuzumab (also known as MetMAb). In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with an inhibitor of
Alk. In some embodiments, an OX40 agonist (e.g., an anti-human OX40
agonist antibody) may be administered in conjunction with AF802
(also known as CH5424802 or alectinib). In some embodiments, an
OX40 agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with an inhibitor of a
phosphatidylinositol 3-kinase (PI3K). In some embodiments, an OX40
agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with BKM120. In some embodiments, an
OX40 agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with idelalisib (also known as GS-1101
or CAL-101). In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with perifosine (also known as KRX-0401). In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with an inhibitor of
an Akt. In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with
MK2206. In some embodiments, an OX40 agonist (e.g., an anti-human
OX40 agonist antibody) may be administered in conjunction with
GSK690693. In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with GDC-0941. In some embodiments, an OX40 agonist
(e.g., an anti-human OX40 agonist antibody) may be administered in
conjunction with an inhibitor of mTOR. In some embodiments, an OX40
agonist (e.g., an anti-human OX40 agonist antibody) may be
administered in conjunction with sirolimus (also known as
rapamycin). In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with temsirolimus (also known as CCI-779 or
Torisel.RTM.). In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with everolimus (also known as RAD001). In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with ridaforolimus
(also known as AP-23573, MK-8669, or deforolimus). In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with OSI-027. In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with AZD8055. In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with INK128. In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with a dual PI3K/mTOR
inhibitor. In some embodiments, an OX40 agonist (e.g., an
anti-human OX40 agonist antibody) may be administered in
conjunction with XL765. In some embodiments, an OX40 agonist (e.g.,
an anti-human OX40 agonist antibody) may be administered in
conjunction with GDC-0980. In some embodiments, an OX40 agonist
(e.g., an anti-human OX40 agonist antibody) may be administered in
conjunction with BEZ235 (also known as NVP-BEZ235). In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with BGT226. In some
embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with GSK2126458. In
some embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with PF-04691502. In
some embodiments, an OX40 agonist (e.g., an anti-human OX40 agonist
antibody) may be administered in conjunction with PF-05212384 (also
known as PKI-587).
[0408] An OX40 agonist of the invention (and any additional
therapeutic agent) can be administered by any suitable means,
including parenteral, intrapulmonary, and intranasal, and, if
desired for local treatment, intralesional administration.
Parenteral infusions include intramuscular, intravenous,
intraarterial, intraperitoneal, or subcutaneous administration.
Dosing can be by any suitable route, e.g. by injections, such as
intravenous or subcutaneous injections, depending in part on
whether the administration is brief or chronic. Various dosing
schedules including but not limited to single or multiple
administrations over various time-points, bolus administration, and
pulse infusion are contemplated herein.
[0409] OX40 agonists of the invention would be formulated, dosed,
and administered in a fashion consistent with good medical
practice. Factors for consideration in this context include the
particular disorder being treated, the particular mammal being
treated, the clinical condition of the individual patient, the
cause of the disorder, the site of delivery of the agent, the
method of administration, the scheduling of administration, and
other factors known to medical practitioners. The antibody need not
be, but is optionally formulated with one or more agents currently
used to prevent or treat the disorder in question. The effective
amount of such other agents depends on the amount of antibody
present in the formulation, the type of disorder or treatment, and
other factors discussed above. These are generally used in the same
dosages and with administration routes as described herein, or
about from 1 to 99% of the dosages described herein, or in any
dosage and by any route that is empirically/clinically determined
to be appropriate.
[0410] For the prevention or treatment of disease, the appropriate
dosage of an OX40 agonist of the invention (when used alone or in
combination with one or more other additional therapeutic agents)
will depend on the type of disease to be treated, the type of
antibody, the severity and course of the disease, whether the
antibody is administered for preventive or therapeutic purposes,
previous therapy, the patient's clinical history and response to
the antibody, and the discretion of the attending physician. The
antibody is suitably administered to the patient at one time or
over a series of treatments. Depending on the type and severity of
the disease, about 1 .mu.g/kg to 40 mg/kg of antibody can be an
initial candidate dosage for administration to the patient,
whether, for example, by one or more separate administrations, or
by continuous infusion. One typical daily dosage might range from
about 1 .mu.g/kg to 100 mg/kg or more, depending on the factors
mentioned above. For repeated administrations over several days or
longer, depending on the condition, the treatment would generally
be sustained until a desired suppression of disease symptoms
occurs. Such doses may be administered intermittently, e.g. every
week or every three weeks (e.g. such that the patient receives from
about two to about twenty, or e.g. about six doses of the
antibody). An initial higher loading dose, followed by one or more
lower doses may be administered. However, other dosage regimens may
be useful. The progress of this therapy is easily monitored by
conventional techniques and assays.
[0411] In some embodiments of the methods of the present
disclosure, the cancer has elevated levels of T cell infiltration.
As used herein, T cell infiltration of a cancer may refer to the
presence of T cells, such as tumor-infiltrating lymphocytes (TILs),
within or otherwise associated with the cancer tissue. It is known
in the art that T cell infiltration may be associated with improved
clinical outcome in certain cancers (see, e.g., Zhang et al., N.
Engl. J. Med. 348(3):203-213 (2003)). In some embodiments, the TILs
may be OX40+. In some embodiments, the TILs may be CD4+ OX40+
Foxp3+ Treg or CD4+ OX40+ Foxp3- Teff cells.
[0412] The specification is considered to be sufficient to enable
one skilled in the art to practice the invention. Various
modifications of the invention in addition to those shown and
described herein will become apparent to those skilled in the art
from the foregoing description and fall within the scope of the
appended claims.
VI. Kits and Articles of Manufacture
[0413] For use in the methods described above and herein, kits or
articles of manufacture are also provided. Such kits may comprise
at least one reagent specific for detecting CD4+, OX40+,
CD4+OX40+Foxp3+, or CD4+OX40+Foxp3- lymphocytes in a sample
comprising cancer cells and lymphocytes from a subject. In some
embodiments, kits or articles of manufacture comprises an antibody
that binds to human CD4 (e.g., NeoMarkers clone 4B12), an antibody
that binds to human OX40 (e.g., antibody 1A7), and/or an antibody
that binds to FoxP3 (e.g., Abcam clone 236A/E7). In some
embodiments, the kits or articles of manufacture further comprise
an OX40 agonist (e.g., an anti-OX40 agonist antibody) described
herein. In some embodiments, the kits or articles of manufacture
further comprise other reagents and/or buffers, such as
bacteriostatic water for injection (BWFI), phosphate-buffered
saline, Ringer's solution and dextrose solution. It may further
include other materials desirable from a commercial and user
standpoint, including other buffers, diluents, filters, needles,
and syringes. The reagents and antibodies may be in a container.
Suitable containers include, for example, bottles, vials, syringes,
IV solution bags, etc. The containers may be formed from a variety
of materials such as glass or plastic. In some embodiments, the
kits and article of manufactures further comprise a label or
packages insert (that may be on or associated with a container)
providing instructions to use the reagents and/or antibodies in
methods described herein.
[0414] All publications, patents, and patent applications cited
herein are hereby incorporated by reference in their entirety for
all purposes.
EXAMPLES
[0415] The invention can be further understood by reference to the
following examples, which are provided by way of illustration and
are not meant to be limiting.
Example 1
Inverse Correlation Between T-Cell Subsets and Cancer Stage
[0416] Increased numbers of OX40+ T cells in the tumor
microenvironment of colorectal cancer (CRC) patients have been
associated with improved outcome (Petty, J. K., et al. (2002) Am.
J. Surg. 183(5):512-8). However, the OX40+ T cell population is
heterogeneous and includes, among others, CD4+Foxp3+ regulatory T
cells (Tregs) as well as CD4+Foxp3- effector T cells (Teff).
[0417] To study the functional significance of these T cell
subsets, a multiplex immunofluorescence assay was developed to
evaluate the expression of OX40 in certain CD4+ T cell subsets.
This assay was utilized to determine whether OX40+ cell subsets and
clinical outcome are associated in colorectal cancer (CRC)
patients.
[0418] Materials and Methods
Case Selection
[0419] Formalin-fixed paraffin-embedded (FFPE) CRC specimens
including primary site (n=48) and matched metastases (n=19) were
included from a collection annotated with treatment histories and
survival outcomes. Patient ages ranged from 26-85 yrs. and Stage I
(4), Stage II (12), Stage III (17) and Stage IV (8) disease were
represented. Cases were included well- or moderately-differentiated
adenocarcinoma (n=36) with additional cases with either
poorly-differentiated (n=4) or mucinous features (8).
Immunofluorescence Staining
[0420] A sequential approach was followed for all immunolabelings,
including the double and triple round of immunofluorescence
staining. CD4 (NeoMarkers clone 4B12), FoxP3 (Abcam clone 236A/E7),
and OX40 (Clone 1A7) antibodies were used.
[0421] Formalin fixed, paraffin embedded human tissue sections were
cut at 4 um, deparaffinized and rehydrated through a graded series
of alcohols. Sections were then pre-treated for antigen retrieval
by incubation in a PT Module (Thermo Scientific, Waltham, Mass.)
using EDTA Retrieval (Lab Vision, Fremont, Calif.) at 65.degree. C.
Sections were then heated to 99.degree. C. for 20 minutes, followed
by 20 minutes of cooling. After pretreatment with EDTA Retrieval,
endogenous peroxidase activity was quenched by incubating sections
in 3% H.sub.2O.sub.2 at room temperature for 4 minutes.
[0422] Sections were then stained using antigen retrieval
techniques. As such, sections were stained first using the anti-CD4
primary antibody (diluted 1:50 in 10% normal horse serum, NHS),
then the anti-OX40 primary antibody (diluted to 10 .mu.g/mL in 10%
NHS), and finally the anti-Foxp3 primary antibody (diluted to 10
.mu.g/mL in 10% NHS). Sections were treated with antigen retrieval
agent between anti-CD4 and anti-OX40 incubation, as well as between
anti-OX40 and anti-Foxp3 incubation, as described below.
[0423] For each primary antibody staining step, sections were
blocked for avidin/biotin using an Avidin/Biotin Blocking Kit
(Vector Laboratories, Burlingame, Calif.) according to
manufacturer's instructions. Sections were then rinsed and
subsequently blocked for non-specific binding sites with 10% Horse
serum/3% BSA/PBS. Sections were incubated in primary antibody
solution for 60 minutes at room temperature, followed by incubation
with a biotinylated horse-anti-mouse (Vector Labs). Sections were
subsequently incubated with Vector Elite ABC-HRP reagent (Vector
Labs). After rinsing, sections were stained with secondary antibody
solution per manufacturer's instructions. The following secondary
antibodies were used: Alexa 488-tyramide conjugate (CD4), Alexa
555-tyramide conjugate (Foxp3), or Alexa 647-tyramide conjugate
(OX40) (Life Technologies, Grand Island, N.Y.).
[0424] Between primary antibody staining steps, after incubation
with secondary antibody solution, sections were incubated in EDTA
buffer (Thermo Scientific, Waltham, Mass.) or DAKO target retrieval
solution (Dako North America, Carpinteria, Calif.) per
manufacturer's instructions at 99.degree. C. for 20 minutes,
followed by 20 minutes cooling. After the last secondary antibody
incubation, slides were counterstained with DAPI and cover-slipped
with ProLong Gold Antifade Mountant (Life Technologies). For
negative controls, sections were incubated with appropriate naive
isotype controls for each marker in place of the primary
antibody.
Digital Imaging and Analysis
[0425] Images were acquired by the Ariol SL-50 automated slide
scanning platform (Leica Microsystems, Buffalo Grove, Ill.) at
100.times. final magnification using standard fluorescence filters.
The entire tiled image was exported and analyzed in the Matlab
software package (ver. R2012b, Mathworks, Natick, Mass.).
[0426] For each tumor section, at least one region of interest was
manually identified and subjected to analysis. For some tumors,
multiple regions of interest were selected (e.g., if both a main
tumor mass and satellite mass were observed on the slide). Within
each region of interest, individual cell nuclei were segmented
using a radial symmetry based method applied to the DAPI channel
(Veta, M., et al. (2013) PLoS ONE 8(7):e70221), and then scored by
the presence of signal above a global intensity threshold in the
nucleus (FoxP3), or the area immediately surrounding each nucleus
(CD4 and OX40). The global threshold for each marker was determined
empirically such that false positive calls of obviously negative
cells, in samples with and without being exposed to the primary
labeling antibody, were less than 0.5% of all cells identified.
Statistical Analysis
[0427] Overall survival was calculated from the date of diagnosis
to the date of death from any cause; data for patients still alive
were censored at the date the patient was last known to be alive.
Association between level of tumor-associated T cell subsets
(dichotomized by median) and overall survival was evaluated using
log-rank tests. To assess the association between tumor-associated
T cell subsets and TNM stage at diagnosis, Kruskal-Wallis tests
were employed. No multiple testing correction was applied.
[0428] A multivariate Cox regression model was employed to assess
the strength of association between overall survival and OX40
expression (dichotomized at median) adjusted for age (>=60 vs
<60), gender (male vs female) and stage (IV vs III vs I/II).
[0429] Results
[0430] Tumors from 48 CRC patients including primary site (n=48)
and matched metastases (n=19) were stained and digitally
imaged.
[0431] FIGS. 1A-1C show representative immunofluorescence images of
stage I CRC samples that were stained for expression of CD4, OX40,
and Foxp3. These images demonstrate the presence of CD4+ OX40+
Foxp3+ Treg cells as well as CD4+ OX40+ Foxp3- Teff cells.
Representative immunofluorescence images of stage II (FIGS. 2A-2C),
stage III (FIGS. 3A-3C), and stage IV (FIGS. 4A-4C) CRC samples
were also captured. To summarize these data, decreased numbers of
total OX40+ cells, as well as CD4+ OX40+ Foxp3+ Treg cells, were
observed in stage IV samples, compared to stage I-III samples.
[0432] From these images, tumor-associated T cell subsets were
enumerated. The correlation between the number of cells
corresponding to specific tumor-associated T cell subsets and tumor
stage was analyzed as described above. FIGS. 5A-6D show the results
of these correlation analyses, with the T cell subsets selected for
study provided as follows: CD4+ (FIG. 5A), Foxp3+ (FIG. 5B), OX40+
(FIG. 5C), OX40+ CD4+ (FIG. 6A), OX40+ CD4- (FIG. 6B), OX40+ CD4+
Foxp3+ (FIG. 6C), and OX40+ CD4+ Foxp3- (FIG. 6D).
[0433] These results indicate statistically significant inverse
correlations of OX40+ cells, OX40+ Treg cells, and OX40+ Teff cells
with increased stage at diagnosis. These associations remained
statistically significant when counts were normalized to total
cells. Total CD4+ or Foxp3+ cells did not show significant
association with stage.
Example 2
Presence of Increased OX40+ Lymphocytes is Associated with Improved
Survival
[0434] Because of the observed correlations between OX40+ T cell
subsets and cancer stage described above, the presence of these T
cell subsets was next analyzed with respect to prognosis.
[0435] The prevalence of T cell subsets in the tumor samples
described above was analyzed to determine potential association
with patient prognosis (e.g., overall survival). FIGS. 7A-8D show
the results of these correlation analyses, with the T cell subsets
selected for study provided as follows: CD4+ (FIG. 7A), Foxp3+
(FIG. 7B), OX40+ (FIG. 7C), OX40+ CD4+ (FIG. 8A), OX40+ CD4- (FIG.
8B), OX40+ CD4+ Foxp3+ (FIG. 8C), and OX40+ CD4+ Foxp3- (FIG. 8D).
Overall survival was plotted for patients whose samples showed
expression of the labeled marker(s) above or below the median of
all samples, as indicated in each plot.
[0436] These analyses indicated that increased prevalence of CD4+
(p=0.019), total OX40+ (p=0.046), and OX40+ Treg (p=0.022) cells
correlated with improved overall survival. Higher prevalence of
OX40+ Teff cells also showed a trend of improved overall survival,
but did not reach statistical significance. When normalized to
total number of cells, CD4+ (p=0.02) and total OX40+ (p=0.041)
cells remained statistically significant. Treg number showed a
closer correlation to survival than did Teff (p=0.265), though
neither achieved statistical significance.
[0437] Importantly, CD4, OX40, and Foxp3 IHC staining remained
significantly associated with overall survival in a multivariate
Cox PH model, adjusting for age, gender and stage. FIGS. 11A-11D
provide the results of these analyses of CD4 expression (FIG. 11A),
OX40 expression (FIG. 11B), Foxp3 expression (FIG. 11C), and the
ratio of OX40+ Teff cells to OX40+ Treg cells (FIG. 11D). These
results indicate that these markers remain prognostic even after
adjusting for baseline characteristics (e.g., age, gender, and
stage).
[0438] These results demonstrate that higher numbers of total OX40+
cells and OX40+ Treg cells are associated with improved prognosis
in CRC.
Example 3
Correlation Between OX40+ Status of Immune Infiltrates of Primary
Tumors and Metastases
[0439] Given the correlations observed between OX40+ cells found in
tumor samples and tumor stage and patient survival, OX40+ T cell
subsets were next analyzed in paired primary and metastatic tumor
samples.
[0440] FIGS. 9A-10D show the results of these correlation analyses,
with the T cell subsets selected for study provided as follows:
CD4+ (FIG. 9A), Foxp3+ (FIG. 9B), OX40+ (FIG. 9C), OX40+ CD4+ (FIG.
10A), OX40+ CD4- (FIG. 10B), OX40+ CD4+ Foxp3+ (FIG. 10C), and
OX40+ CD4+ Foxp3- (FIG. 10D).
[0441] Analysis of paired primary and metastatic samples (n=19)
showed strong correlations between positive cell counts for CD4
(r=0.75), total OX40+ (r=0.84), OX40+ Treg (0.52), and OX40+ Teff
(r=0.85) subsets in primary and metastatic samples. These
associations remained strong when counts were normalized to total
cells. These results show that the OX40+ status of immune
infiltrates of primary tumors and metastases are strongly
correlated.
[0442] Taken together, these results demonstrate that higher
numbers of total OX40+ cells and OX40+ Treg cells are associated
with improved prognosis in CRC. The triple immunofluorescence assay
described herein may be useful in characterizing associations
between OX40+ Treg and Teff cell subsets and clinical outcome in
multiple solid tumor types. Moreover, incorporating this assay into
clinical trials may help identify patients and indications that are
likely to respond to therapeutics targeting OX40.
[0443] All patents, patent applications, documents, and articles
cited herein are herein incorporated by reference in their
entireties.
Sequence CWU 1
1
2261249PRTHomo sapiens 1Leu His Cys Val Gly Asp Thr Tyr Pro Ser Asn
Asp Arg Cys Cys His1 5 10 15 Glu Cys Arg Pro Gly Asn Gly Met Val
Ser Arg Cys Ser Arg Ser Gln 20 25 30 Asn Thr Val Cys Arg Pro Cys
Gly Pro Gly Phe Tyr Asn Asp Val Val 35 40 45 Ser Ser Lys Pro Cys
Lys Pro Cys Thr Trp Cys Asn Leu Arg Ser Gly 50 55 60 Ser Glu Arg
Lys Gln Leu Cys Thr Ala Thr Gln Asp Thr Val Cys Arg65 70 75 80 Cys
Arg Ala Gly Thr Gln Pro Leu Asp Ser Tyr Lys Pro Gly Val Asp 85 90
95 Cys Ala Pro Cys Pro Pro Gly His Phe Ser Pro Gly Asp Asn Gln Ala
100 105 110 Cys Lys Pro Trp Thr Asn Cys Thr Leu Ala Gly Lys His Thr
Leu Gln 115 120 125 Pro Ala Ser Asn Ser Ser Asp Ala Ile Cys Glu Asp
Arg Asp Pro Pro 130 135 140 Ala Thr Gln Pro Gln Glu Thr Gln Gly Pro
Pro Ala Arg Pro Ile Thr145 150 155 160 Val Gln Pro Thr Glu Ala Trp
Pro Arg Thr Ser Gln Gly Pro Ser Thr 165 170 175 Arg Pro Val Glu Val
Pro Gly Gly Arg Ala Val Ala Ala Ile Leu Gly 180 185 190 Leu Gly Leu
Val Leu Gly Leu Leu Gly Pro Leu Ala Ile Leu Leu Ala 195 200 205 Leu
Tyr Leu Leu Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys 210 215
220 Pro Pro Gly Gly Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln
Ala225 230 235 240 Asp Ala His Ser Thr Leu Ala Lys Ile 245
25PRTArtificial SequenceSynthetic Construct 2Asp Ser Tyr Met Ser1 5
317PRTArtificial SequenceSynthetic Construct 3Asp Met Tyr Pro Asp
Asn Gly Asp Ser Ser Tyr Asn Gln Lys Phe Arg1 5 10 15
Glu48PRTArtificial SequenceSynthetic Construct 4Ala Pro Arg Trp Tyr
Phe Ser Val1 5 511PRTArtificial SequenceSynthetic Construct 5Arg
Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn1 5 10 67PRTArtificial
SequenceSynthetic Construct 6Tyr Thr Ser Arg Leu Arg Ser1 5
79PRTArtificial SequenceSynthetic Construct 7Gln Gln Gly His Thr
Leu Pro Pro Thr1 5 85PRTArtificial SequenceSynthetic Construct 8Asp
Ala Tyr Met Ser1 5 95PRTArtificial SequenceSynthetic Construct 9Glu
Ser Tyr Met Ser1 5 1017PRTArtificial SequenceSynthetic Construct
10Asp Met Tyr Pro Asp Asn Ala Asp Ser Ser Tyr Asn Gln Lys Phe Arg1
5 10 15 Glu1117PRTArtificial SequenceSynthetic Construct 11Asp Met
Tyr Pro Asp Asn Ala Asp Ala Ser Tyr Asn Gln Lys Phe Arg1 5 10 15
Glu1217PRTArtificial SequenceSynthetic Construct 12Asp Met Tyr Pro
Asp Asn Gly Asp Ala Ser Tyr Asn Gln Lys Phe Arg1 5 10 15
Glu1317PRTArtificial SequenceSynthetic Construct 13Asp Met Tyr Pro
Asp Ser Gly Asp Ser Ser Tyr Asn Gln Lys Phe Arg1 5 10 15
Glu1417PRTArtificial SequenceSynthetic Construct 14Asp Met Tyr Pro
Asp Asn Gly Ser Ser Ser Tyr Asn Gln Lys Phe Arg1 5 10 15
Glu158PRTArtificial SequenceSynthetic Construct 15Ala Pro Arg Trp
Tyr Phe Ser Ala1 5 168PRTArtificial SequenceSynthetic Construct
16Ala Pro Arg Trp Tyr Ala Ser Val1 5 178PRTArtificial
SequenceSynthetic Construct 17Ala Pro Arg Trp Ala Phe Ser Val1 5
188PRTArtificial SequenceSynthetic Construct 18Ala Pro Ala Trp Tyr
Phe Ser Val1 5 198PRTArtificial SequenceSynthetic Construct 19Ala
Pro Arg Trp Tyr Phe Ala Val1 5 208PRTArtificial SequenceSynthetic
Construct 20Ala Pro Arg Ala Tyr Phe Ser Val1 5 218PRTArtificial
SequenceSynthetic Construct 21Ala Ala Arg Trp Tyr Phe Ser Val1 5
229PRTArtificial SequenceSynthetic Construct 22Gln Gln Gly His Thr
Leu Pro Ala Thr1 5 239PRTArtificial SequenceSynthetic Construct
23Gln Gln Gly His Thr Ala Pro Pro Thr1 5 249PRTArtificial
SequenceSynthetic Construct 24Gln Gln Gly Ala Thr Leu Pro Pro Thr1
5 259PRTArtificial SequenceSynthetic Construct 25Gln Gln Gly His
Ala Leu Pro Pro Thr1 5 269PRTArtificial SequenceSynthetic Construct
26Gln Gln Ala His Thr Leu Pro Pro Thr1 5 279PRTArtificial
SequenceSynthetic Construct 27Gln Gln Gly His Thr Leu Ala Pro Thr1
5 289PRTArtificial SequenceSynthetic Construct 28Gln Ala Gly His
Thr Leu Pro Pro Thr1 5 295PRTArtificial SequenceSynthetic Construct
29Asn Tyr Leu Ile Glu1 5 3017PRTArtificial SequenceSynthetic
Construct 30Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe Lys1 5 10 15 Gly3117PRTArtificial SequenceSynthetic Construct
31Val Ile Asn Pro Gly Ser Gly Asp Ala Tyr Tyr Ser Glu Lys Phe Lys1
5 10 15 Gly3217PRTArtificial SequenceSynthetic Construct 32Val Ile
Asn Pro Gly Ser Gly Asp Gln Tyr Tyr Ser Glu Lys Phe Lys1 5 10 15
Gly335PRTArtificial SequenceSynthetic Construct 33Asp Arg Leu Asp
Tyr1 5 345PRTArtificial SequenceSynthetic Construct 34Ala Arg Leu
Asp Tyr1 5 355PRTArtificial SequenceSynthetic Construct 35Asp Ala
Leu Asp Tyr1 5 365PRTArtificial SequenceSynthetic Construct 36Asp
Arg Ala Asp Tyr1 5 3711PRTArtificial SequenceSynthetic Construct
37His Ala Ser Gln Asp Ile Ser Ser Tyr Ile Val1 5 10
387PRTArtificial SequenceSynthetic Construct 38His Gly Thr Asn Leu
Glu Asp1 5 397PRTArtificial SequenceSynthetic Construct 39His Gly
Thr Asn Leu Glu Ser1 5 407PRTArtificial SequenceSynthetic Construct
40His Gly Thr Asn Leu Glu Glu1 5 417PRTArtificial SequenceSynthetic
Construct 41His Gly Thr Asn Leu Glu Gln1 5 429PRTArtificial
SequenceSynthetic Construct 42Val His Tyr Ala Gln Phe Pro Tyr Thr1
5 439PRTArtificial SequenceSynthetic Construct 43Ala His Tyr Ala
Gln Phe Pro Tyr Thr1 5 449PRTArtificial SequenceSynthetic Construct
44Val Ala Tyr Ala Gln Phe Pro Tyr Thr1 5 459PRTArtificial
SequenceSynthetic Construct 45Val His Ala Ala Gln Phe Pro Tyr Thr1
5 469PRTArtificial SequenceSynthetic Construct 46Val His Tyr Ala
Ala Phe Pro Tyr Thr1 5 479PRTArtificial SequenceSynthetic Construct
47Val His Tyr Ala Gln Ala Pro Tyr Thr1 5 489PRTArtificial
SequenceSynthetic Construct 48Val His Tyr Ala Gln Phe Ala Tyr Thr1
5 499PRTArtificial SequenceSynthetic Construct 49Val His Tyr Ala
Gln Phe Pro Ala Thr1 5 505PRTArtificial SequenceSynthetic Construct
50Asp Tyr Gly Val Leu1 5 5116PRTArtificial SequenceSynthetic
Construct 51Met Ile Trp Ser Gly Gly Thr Thr Asp Tyr Asn Ala Ala Phe
Ile Ser1 5 10 15 525PRTArtificial SequenceSynthetic Construct 52Glu
Glu Met Asp Tyr1 5 5311PRTArtificial SequenceSynthetic Construct
53Arg Ala Ser Gln Asp Ile Ser Asn Phe Leu Asn1 5 10
547PRTArtificial SequenceSynthetic Construct 54Tyr Thr Ser Arg Leu
His Ser1 5 559PRTArtificial SequenceSynthetic Construct 55Gln Gln
Gly Asn Thr Leu Pro Trp Thr1 5 56117PRTArtificial SequenceSynthetic
Construct 56Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr
Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly
Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly
Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile
Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser
Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu
Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110
Val Thr Val Ser Ser 115 57107PRTArtificial SequenceSynthetic
Construct 57Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp
Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys
Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro 85 90 95 Thr Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 58117PRTArtificial
SequenceSynthetic Construct 58Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met
Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg
Glu Arg Val Thr Ile Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75
80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95 Val Leu Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly
Thr Leu 100 105 110 Val Thr Val Ser Ser 115 59107PRTArtificial
SequenceSynthetic Construct 59Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr
Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
60117PRTArtificial SequenceSynthetic Construct 60Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys
Phe 50 55 60 Arg Glu Arg Val Thr Leu Thr Val Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg Trp Tyr Phe Ser
Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115
61107PRTArtificial SequenceSynthetic Construct 61Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg
Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35
40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly
His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 105 62117PRTArtificial SequenceSynthetic Construct
62Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser
Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Val Asp
Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg
Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val
Ser Ser 115 63107PRTArtificial SequenceSynthetic Construct 63Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Thr Val Lys Leu
Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Gly His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Val Glu Ile Lys 100 105 64117PRTArtificial SequenceSynthetic
Construct 64Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr
Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly
Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly
Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile
Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser
Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu
Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110
Val Thr Val Ser Ser 115 65107PRTArtificial SequenceSynthetic
Construct 65Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp
Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys
Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro 85 90 95 Thr Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 66117PRTArtificial
SequenceSynthetic Construct 66Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20
25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn
Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Val Asp Thr Ser
Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg Trp Tyr
Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser
115 67107PRTArtificial SequenceSynthetic Construct 67Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp
Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25
30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Thr Val Lys Leu Leu Ile
35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe
Ser Gly 50 55 60 Ser Gly Ser Gly Lys Asp Tyr Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln
Gly His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val
Glu Ile Lys 100 105 68117PRTArtificial SequenceSynthetic Construct
68Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser
Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Val Asp
Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg
Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val
Ser Ser 115 69107PRTArtificial SequenceSynthetic Construct 69Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Thr Val Lys Leu
Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Lys Asp Tyr Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys
Gln Gln Gly His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Val Glu Ile Lys 100 105 70117PRTArtificial SequenceSynthetic
Construct 70Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr
Phe Thr Asp Ala 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly
Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly
Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile
Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser
Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu
Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110
Val Thr Val Ser Ser 115 71107PRTArtificial SequenceSynthetic
Construct 71Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp
Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys
Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro 85 90 95 Thr Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 72117PRTArtificial
SequenceSynthetic Construct 72Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Glu Ser 20 25 30 Tyr Met Ser Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met
Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg
Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75
80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95 Val Leu Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly
Thr Leu 100 105 110 Val Thr Val Ser Ser 115 73107PRTArtificial
SequenceSynthetic Construct 73Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr
Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
74117PRTArtificial SequenceSynthetic Construct 74Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Asp Met Tyr Pro Asp Asn Ala Asp Ser Ser Tyr Asn Gln Lys
Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg Trp Tyr Phe Ser
Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115
75107PRTArtificial SequenceSynthetic Construct 75Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg
Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35
40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly
His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 105 76117PRTArtificial SequenceSynthetic Construct
76Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Ala Asp Ala Ser
Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp
Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg
Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val
Ser Ser 115 77107PRTArtificial SequenceSynthetic Construct 77Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Gly His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Val Glu Ile Lys 100 105 78117PRTArtificial SequenceSynthetic
Construct 78Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr
Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly
Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly
Asp Ala Ser Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile
Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser
Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu
Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110
Val Thr Val Ser Ser 115 79107PRTArtificial SequenceSynthetic
Construct 79Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp
Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys
Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro 85 90 95 Thr Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 80117PRTArtificial
SequenceSynthetic Construct 80Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met
Tyr Pro Asp Ser Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg
Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75
80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95 Val Leu Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly
Thr Leu 100 105 110 Val Thr Val Ser Ser 115 81107PRTArtificial
SequenceSynthetic Construct 81Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr
Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
82117PRTArtificial SequenceSynthetic Construct 82Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Asp Met Tyr Pro Asp Asn Gly Ser Ser Ser Tyr Asn Gln Lys
Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg Trp Tyr Phe Ser
Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115
83107PRTArtificial SequenceSynthetic Construct 83Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg
Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35
40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly
His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 105 84117PRTArtificial SequenceSynthetic Construct
84Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Ala 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Ala Asp Ala Ser
Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp
Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg
Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val
Ser Ser 115 85107PRTArtificial SequenceSynthetic Construct 85Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Gly His Thr
Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 86117PRTArtificial SequenceSynthetic Construct 86Glu Val
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20
25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn
Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp Thr Ser
Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg Trp Tyr
Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser
115 87107PRTArtificial SequenceSynthetic Construct 87Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp
Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25
30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe
Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Gly His Thr Leu Pro Ala 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val
Glu Ile Lys 100 105 88117PRTArtificial SequenceSynthetic Construct
88Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser
Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp
Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg
Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val
Ser Ser 115 89107PRTArtificial SequenceSynthetic Construct 89Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Gly His Thr Ala Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Val Glu Ile Lys 100 105 90117PRTArtificial SequenceSynthetic
Construct 90Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr
Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly
Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly
Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile
Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser
Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu
Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110
Val Thr Val Ser Ser 115 91107PRTArtificial SequenceSynthetic
Construct 91Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp
Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys
Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Gly Ala Thr Leu Pro Pro 85 90 95 Thr Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 92117PRTArtificial
SequenceSynthetic Construct 92Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met
Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg
Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75
80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95 Val Leu Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly
Thr Leu 100 105 110 Val Thr Val Ser Ser 115 93107PRTArtificial
SequenceSynthetic Construct 93Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr
Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly His Ala Leu Pro Pro
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
94117PRTArtificial SequenceSynthetic Construct 94Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys
Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg Trp Tyr Phe Ser
Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115
95107PRTArtificial SequenceSynthetic Construct 95Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg
Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35
40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala
His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 105 96117PRTArtificial SequenceSynthetic Construct
96Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser
Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp
Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg
Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val
Ser Ser 115 97107PRTArtificial SequenceSynthetic Construct 97Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Gly His Thr Leu Ala Pro 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Val Glu Ile Lys 100 105 98117PRTArtificial SequenceSynthetic
Construct 98Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr
Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly
Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly
Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile
Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser
Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu
Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110
Val Thr Val Ser Ser 115 99107PRTArtificial SequenceSynthetic
Construct 99Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp
Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys
Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Ala Gly His Thr Leu Pro Pro 85 90 95 Thr Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 100117PRTArtificial
SequenceSynthetic Construct 100Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met
Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg
Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75
80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95 Val Leu Ala Pro Arg Trp Tyr Phe Ser Ala Trp Gly Gln Gly
Thr Leu 100 105 110 Val Thr Val Ser Ser 115 101107PRTArtificial
SequenceSynthetic Construct 101Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr
Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
102117PRTArtificial SequenceSynthetic Construct 102Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys
Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg Trp Tyr Ala Ser
Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115
103107PRTArtificial SequenceSynthetic Construct 103Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg
Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35
40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly
His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 105 104117PRTArtificial SequenceSynthetic Construct
104Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser
Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp
Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg
Trp Ala Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val
Ser Ser 115 105107PRTArtificial SequenceSynthetic Construct 105Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20
25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
Gln Gly His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys 100 105 106117PRTArtificial SequenceSynthetic
Construct 106Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn
Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr
Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val
Leu Ala Pro Ala Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105
110 Val Thr Val Ser Ser 115 107107PRTArtificial SequenceSynthetic
Construct 107Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly
Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe
Ala Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro 85 90 95 Thr
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 108117PRTArtificial
SequenceSynthetic Construct 108Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met
Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg
Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75
80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95 Val Leu Ala Pro Arg Trp Tyr Phe Ala Val Trp Gly Gln Gly
Thr Leu 100 105 110 Val Thr Val Ser Ser 115 109107PRTArtificial
SequenceSynthetic Construct 109Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr
Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
110117PRTArtificial SequenceSynthetic Construct 110Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys
Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Pro Arg Ala Tyr Phe Ser
Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115
111107PRTArtificial SequenceSynthetic Construct 111Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg
Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35
40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly
His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 105 112117PRTArtificial SequenceSynthetic Construct
112Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser
Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr Ile Thr Arg Asp
Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Leu Ala Ala Arg
Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val
Ser Ser 115 113107PRTArtificial SequenceSynthetic Construct 113Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Gly His Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Val Glu Ile Lys 100 105 114117PRTArtificial SequenceSynthetic
Construct 114Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn
Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr
Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala
Leu Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105
110 Val Thr Val Ser Ser 115 115107PRTArtificial SequenceSynthetic
Construct 115Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly
Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe
Ala Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro 85 90 95 Thr
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 116117PRTArtificial
SequenceSynthetic Construct 116Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met
Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg
Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75
80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95 Val Ala Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly
Thr Leu 100 105 110 Val Thr Val Ser Ser 115 117107PRTArtificial
SequenceSynthetic Construct 117Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr
Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
118114PRTArtificial SequenceSynthetic Construct 118Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser119107PRTArtificial
SequenceSynthetic Construct 119Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
120114PRTArtificial SequenceSynthetic Construct 120Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser121107PRTArtificial
SequenceSynthetic Construct 121Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
122114PRTArtificial SequenceSynthetic Construct 122Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser123107PRTArtificial
SequenceSynthetic Construct 123Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
124114PRTArtificial SequenceSynthetic Construct 124Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp
Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser125107PRTArtificial
SequenceSynthetic Construct 125Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
126114PRTArtificial SequenceSynthetic Construct 126Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser127107PRTArtificial
SequenceSynthetic Construct 127Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
128114PRTArtificial SequenceSynthetic Construct 128Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser129107PRTArtificial
SequenceSynthetic Construct 129Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
130114PRTArtificial SequenceSynthetic Construct 130Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser131107PRTArtificial
SequenceSynthetic Construct 131Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Glu Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
132114PRTArtificial SequenceSynthetic Construct 132Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser133107PRTArtificial
SequenceSynthetic Construct 133Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Gln Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
134114PRTArtificial SequenceSynthetic Construct 134Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser135107PRTArtificial
SequenceSynthetic Construct 135Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Ala Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
136114PRTArtificial SequenceSynthetic Construct 136Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser137107PRTArtificial
SequenceSynthetic Construct 137Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Ala Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
138114PRTArtificial SequenceSynthetic Construct 138Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Arg Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser139107PRTArtificial
SequenceSynthetic Construct 139Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
140114PRTArtificial SequenceSynthetic Construct 140Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Arg Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser141107PRTArtificial
SequenceSynthetic Construct 141Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
142114PRTArtificial SequenceSynthetic Construct 142Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Arg Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser143107PRTArtificial
SequenceSynthetic Construct 143Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Phe Lys Leu Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
144114PRTArtificial SequenceSynthetic Construct 144Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60
Lys Gly Arg Val Thr Leu Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65
70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly Gln Gly Thr
Leu Val Thr Val 100 105 110 Ser Ser145107PRTArtificial
SequenceSynthetic Construct 145Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
146114PRTArtificial SequenceSynthetic Construct 146Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser147107PRTArtificial
SequenceSynthetic Construct 147Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Ala His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
148114PRTArtificial SequenceSynthetic Construct 148Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser149107PRTArtificial
SequenceSynthetic Construct 149Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val Ala Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
150114PRTArtificial SequenceSynthetic Construct 150Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser151107PRTArtificial
SequenceSynthetic Construct 151Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Ala Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
152114PRTArtificial SequenceSynthetic Construct 152Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser153107PRTArtificial
SequenceSynthetic Construct 153Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Ala Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
154114PRTArtificial SequenceSynthetic Construct 154Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser155107PRTArtificial
SequenceSynthetic Construct 155Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Ala Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
156114PRTArtificial SequenceSynthetic Construct 156Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser157107PRTArtificial
SequenceSynthetic Construct 157Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Ala Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
158114PRTArtificial SequenceSynthetic Construct 158Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser159107PRTArtificial
SequenceSynthetic Construct 159Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Ala
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
160114PRTArtificial SequenceSynthetic Construct 160Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser161107PRTArtificial
SequenceSynthetic Construct 161Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
162114PRTArtificial SequenceSynthetic Construct 162Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Ala Leu Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser163107PRTArtificial
SequenceSynthetic Construct 163Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
164114PRTArtificial SequenceSynthetic Construct 164Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser
Thr Ala Tyr65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Ala Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ser165107PRTArtificial
SequenceSynthetic Construct 165Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Tyr Gln
Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
166113PRTArtificial SequenceSynthetic Construct 166Glu Val Gln Leu
Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15 Thr Leu
Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asp Tyr 20 25 30
Gly Val Leu Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35
40 45 Gly Met Ile Trp Ser Gly Gly Thr Thr Asp Tyr Asn Ala Ala Phe
Ile 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln
Phe Ser Leu65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr Cys Val 85 90 95 Arg Glu Glu Met Asp Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser 100 105 110 Ser167107PRTArtificial
SequenceSynthetic Construct 167Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Ile Ser Asn Phe 20 25 30 Leu Asn Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr
Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Trp
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
168113PRTArtificial SequenceSynthetic Construct 168Glu Val Gln Leu
Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15 Thr Leu
Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asp Tyr 20 25 30
Gly Val Leu Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35
40 45 Gly Met Ile Trp Ser Gly Gly Thr Thr Asp Tyr Asn Ala Ala Phe
Ile 50 55 60 Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln
Val Ser Leu65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr Cys Val 85 90 95 Arg Glu Glu Met Asp Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser 100 105 110 Ser169107PRTArtificial
SequenceSynthetic Construct 169Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Ile Ser Asn Phe 20 25 30 Leu Asn Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr
Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Trp
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
170113PRTArtificial SequenceSynthetic Construct 170Glu Val Gln Leu
Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15 Thr Leu
Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asp Tyr 20 25 30
Gly Val Leu Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 35
40 45 Gly Met Ile Trp Ser Gly Gly Thr Thr Asp Tyr Asn Ala Ala Phe
Ile 50 55 60 Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln
Val Ser Leu65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr Cys Val 85 90 95 Arg Glu Glu Met Asp Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser 100 105 110 Ser171107PRTArtificial
SequenceSynthetic Construct 171Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Asp Ile Ser Asn Phe 20 25 30 Leu Asn Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr
Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Trp
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
1725PRTArtificial SequenceSynthetic Construct 172Xaa Xaa Tyr Met
Ser1 5 17317PRTArtificial SequenceSynthetic Construct 173Asp Met
Tyr Pro Asp Xaa Xaa Xaa Xaa Ser Tyr Asn Gln Lys Phe Arg1 5 10 15
Glu1748PRTArtificial SequenceSynthetic Construct 174Ala Pro Arg Trp
Xaa Xaa Xaa Xaa1 5 1759PRTArtificial SequenceSynthetic Construct
175Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr1 5 17617PRTArtificial
SequenceSynthetic Construct 176Val Ile Asn Pro Gly Ser Gly Asp Xaa
Tyr Tyr Ser Glu Lys Phe Lys1 5 10 15 Gly1777PRTArtificial
SequenceSynthetic Construct 177His Gly Thr Asn Leu Glu Xaa1 5
1789PRTArtificial SequenceSynthetic Construct 178Xaa Xaa Tyr Ala
Gln Phe Pro Tyr Xaa1 5 179107PRTArtificial SequenceSynthetic
Construct 179Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala
Ser Leu Gly1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln
Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp
Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Arg
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Lys
Asp Tyr Phe Leu Thr Ile Ser Asn Leu Glu Gln65 70 75 80 Glu Asp Val
Ala Ala Tyr Phe Cys Gln Gln Gly His Thr Leu Pro Pro 85 90 95 Thr
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 180117PRTArtificial
SequenceSynthetic Construct 180Glu Val Gln Leu Gln Gln Ser Gly Pro
Glu Leu Val Lys Pro Gly Ala1 5 10 15 Ser Val Lys Ile Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val
Lys Gln Ser His Gly Lys Thr Leu Glu Trp Ile 35 40 45 Gly Asp Met
Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg
Glu Lys Val Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr65 70 75
80 Met Glu Phe Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95 Val Leu Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Thr Gly
Thr Thr 100 105 110 Val Thr Val Ser Ser 115 181107PRTArtificial
SequenceSynthetic Construct 181Asp Ile Leu Met Thr Gln Ser Pro Ser
Ser Met Ser Val Ser Leu Gly1 5 10 15 Asp Thr Val Ser Ile Thr Cys
His Ala Ser Gln Asp Ile Ser Ser Tyr 20 25 30 Ile Val Trp Leu Gln
Gln Lys Pro Gly Lys Ser Phe Arg Gly Leu Ile 35 40 45 Tyr His Gly
Thr Asn Leu Glu Asp Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Ala Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser65 70 75
80 Glu Asp Phe Ala Asp Tyr Tyr Cys Val His Tyr Ala Gln Phe Pro Tyr
85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105
182114PRTArtificial SequenceSynthetic Construct 182Gln Val Gln Leu
Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30
Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45 Gly Val Ile Asn Pro Gly Ser Gly Asp Thr Tyr Tyr Ser Glu Lys
Phe 50 55 60 Lys Gly Lys Val Thr Leu Thr Ala Asp Lys Ser Ser Ser
Thr Ala Tyr65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser
Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asp Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser183451PRTArtificial
SequenceSynthetic Construct 183Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Thr Met Asn Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile
Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75
80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95 Ala Lys Asp Arg Tyr Ser Gln Val His Tyr Ala Leu Asp Tyr
Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp
Tyr Phe Pro Glu Pro Val Thr Val145 150 155 160 Ser Trp Asn Ser Gly
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200
205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
Leu Gly225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys
Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe
Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325
330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn
Asn Tyr Lys Thr Thr Pro Pro385 390 395 400 Val Leu Asp Ser Asp Gly
Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445
Pro Gly Lys 450 184219PRTArtificial SequenceSynthetic Construct
184Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Pro Val Thr Pro Gly1
5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His
Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Ala
Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg
Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly
Thr Asp Phe Thr Leu Lys Ile65 70 75 80 Ser Arg Val Glu Ala Glu Asp
Val Gly Val Tyr Tyr Cys Gln Gln Tyr 85 90 95 Tyr Asn His Pro Thr
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135
140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
Gln145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp
Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu
Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu
Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe
Asn Arg Gly Glu Cys 210 215 185219PRTArtificial SequenceSynthetic
Construct 185Asp Ile Gln Met Thr Gln Ser Pro Asp Ser Leu Pro Val
Thr Pro Gly1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln
Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr
Leu Gln Lys Ala Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu
Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly
Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65 70 75 80 Ser Arg Val
Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Tyr 85 90 95 Tyr
Asn His Pro Thr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn
Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val
Asp Asn Ala Leu Gln145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val
Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser
Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val
Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val
Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 186450PRTArtificial
SequenceSynthetic Construct 186Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val His Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala
Gly Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met His Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile
Gly Thr Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Met 50 55 60 Gly
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu65 70 75
80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95 Arg Tyr Asp Asn Val Met Gly Leu Tyr Trp Phe Asp Tyr Trp
Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr
Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr
Phe Pro Glu Pro Val Thr Val Ser145 150 155 160 Trp Asn Ser Gly Ala
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200
205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp
210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
Gly Gly225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val
Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn
Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325
330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn
Tyr Lys Thr Thr Pro Pro Val385 390 395 400 Leu Asp Ser Asp Gly Ser
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445
Gly Lys 450 187214PRTArtificial SequenceSynthetic Construct 187Glu
Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10
15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Glu Pro65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Arg Ser Asn Trp Pro Pro 85 90 95 Ala Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe
Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala
Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145
150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser
Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210
188118PRTArtificial SequenceSynthetic Construct 188Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30
Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35
40 45 Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Asp Tyr Ala Asp Ser
Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
Ser Leu Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ser Gly Trp Tyr Leu Phe
Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115
189107PRTArtificial SequenceSynthetic Construct 189Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg
Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35
40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr
Asn Ser Tyr Pro Pro 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 105 190124PRTArtificial SequenceSynthetic Construct
190Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1
5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp
Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Ala Lys Asp Gln Ser
Thr Ala Asp Tyr Tyr Phe Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly
Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 191106PRTArtificial
SequenceSynthetic Construct 191Glu Ile Val Val Thr Gln Ser Pro Ala
Thr Leu Ser Leu Ser Pro Gly1 5 10 15 Glu Arg Ala Thr Leu Ser Cys
Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala
Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65 70 75
80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr
85 90 95 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
192122PRTArtificial SequenceSynthetic Construct 192Gln Val Gln Leu
Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30
Ser Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Lys Trp Met 35
40 45 Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp
Phe 50 55 60 Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser
Thr Ala Tyr65 70 75 80 Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Pro Tyr Tyr Asp Tyr Val Ser
Tyr Tyr Ala Met Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 193107PRTArtificial SequenceSynthetic Construct
193Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr
Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Leu Tyr Thr Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe
Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr
Cys Gln Gln His Tyr Ser Thr Pro Arg 85 90 95 Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 194120PRTArtificial
SequenceSynthetic Construct 194Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala
Ala Ser Glu Tyr Glu Phe Pro Ser His 20 25 30 Asp Met Ser Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val 35 40 45 Ala Ala Ile
Asn Ser Asp Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Met 50 55 60 Glu
Arg Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65 70 75
80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95 Ala Arg His Tyr Asp Asp Tyr Tyr Ala Trp Phe Ala Tyr Trp
Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120
195111PRTArtificial SequenceSynthetic Construct 195Glu Ile Val Leu
Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15 Glu Arg
Ala Thr Leu Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 20 25 30
Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35
40 45 Arg Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro
Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Thr Ile Ser65 70 75 80 Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr
Cys Gln His Ser Arg 85 90 95 Glu Leu Pro Leu Thr Phe Gly Gly Gly
Thr Lys Val Glu Ile Lys 100 105 110 196469PRTArtificial
SequenceSynthetic Construct 196Met Tyr Leu Gly Leu Asn Tyr Val Phe
Ile Val Phe Leu Leu Asn Gly1 5 10 15 Val Gln Ser Glu Val Lys Leu
Glu Glu Ser Gly Gly Gly Leu Val Gln 20 25 30 Pro Gly Gly Ser Met
Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 35 40 45 Ser Asp Ala
Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu 50 55 60 Glu
Trp Val Ala Glu Ile Arg Ser Lys Ala Asn Asn His Ala Thr Tyr65 70 75
80 Tyr Ala Glu Ser Val Asn Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser
85 90 95 Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
Asp Thr 100 105 110 Gly Ile Tyr Tyr Cys Thr Trp Gly Glu Val Phe Tyr
Phe Asp Tyr Trp 115 120 125 Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
Ala Ser Thr Lys Gly Pro 130 135 140 Ser Val Phe Pro Leu Ala Pro Ser
Ser Lys Ser Thr Ser Gly Gly Thr145 150 155 160 Ala Ala Leu Gly Cys
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 165 170 175 Val Ser Trp
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 180 185 190 Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 195 200
205 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Thr Cys Asn Val
210 215 220 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
Pro Lys225 230 235 240 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
Pro Ala Pro Glu Leu 245 250 255 Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys Asp Thr 260 265 270 Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val Val Asp Val 275 280 285 Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 290 295 300 Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser305 310 315 320
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 325
330 335 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
Ala 340 345 350 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
Arg Glu Pro 355 360 365 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
Leu Thr Lys Asn Gln 370 375 380 Val Ser Leu Thr Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp Ile Ala385 390 395 400 Val Glu Trp Glu Ser Asn
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 405 410 415 Pro Pro Val Leu
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425 430 Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 435 440 445
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 450
455 460 Leu Ser Pro Gly Lys465 197233PRTArtificial
SequenceSynthetic Construct 197Met Arg Pro Ser Ile Gln Phe Leu Gly
Leu Leu Leu Phe Trp Leu His1 5 10 15 Gly Ala Gln Cys Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser 20 25 30 Ala Ser Leu Gly Gly
Lys Val Thr Ile Thr Cys Lys Ser Ser Gln Asp 35 40 45 Ile Asn Lys
Tyr Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro 50 55 60 Arg
Leu Leu Ile His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser65 70 75
80 Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser
85 90 95 Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln
Tyr Asp 100 105 110
Asn Leu Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr 115
120 125 Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
Leu 130 135 140 Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
Phe Tyr Pro145 150 155 160 Arg Glu Ala Lys Val Gln Trp Lys Val Asp
Asn Ala Leu Gln Ser Gly 165 170 175 Asn Ser Gln Glu Ser Val Thr Glu
Gln Asp Ser Lys Asp Ser Thr Tyr 180 185 190 Ser Leu Ser Ser Thr Leu
Thr Leu Ser Lys Ala Asp Tyr Glu Lys His 195 200 205 Lys Val Tyr Ala
Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val 210 215 220 Thr Lys
Ser Phe Asn Arg Gly Glu Cys225 230 198138PRTArtificial
SequenceSynthetic Construct 198Met Tyr Leu Gly Leu Asn Tyr Val Phe
Ile Val Phe Leu Leu Asn Gly1 5 10 15 Val Gln Ser Glu Val Lys Leu
Glu Glu Ser Gly Gly Gly Leu Val Gln 20 25 30 Pro Gly Gly Ser Met
Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 35 40 45 Ser Asp Ala
Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu 50 55 60 Glu
Trp Val Ala Glu Ile Arg Ser Lys Ala Asn Asn His Ala Thr Tyr65 70 75
80 Tyr Ala Glu Ser Val Asn Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser
85 90 95 Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
Asp Thr 100 105 110 Gly Ile Tyr Tyr Cys Thr Trp Gly Glu Val Phe Tyr
Phe Asp Tyr Trp 115 120 125 Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
130 135 199126PRTArtificial SequenceSynthetic Construct 199Met Arg
Pro Ser Ile Gln Phe Leu Gly Leu Leu Leu Phe Trp Leu His1 5 10 15
Gly Ala Gln Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser 20
25 30 Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Ser Ser Gln
Asp 35 40 45 Ile Asn Lys Tyr Ile Ala Trp Tyr Gln His Lys Pro Gly
Lys Gly Pro 50 55 60 Arg Leu Leu Ile His Tyr Thr Ser Thr Leu Gln
Pro Gly Ile Pro Ser65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Arg
Asp Tyr Ser Phe Ser Ile Ser 85 90 95 Asn Leu Glu Pro Glu Asp Ile
Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp 100 105 110 Asn Leu Leu Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125 200119PRTArtificial
SequenceSynthetic Construct 200Glu Val Gln Leu Gln Gln Ser Gly Pro
Glu Leu Val Lys Pro Gly Ala1 5 10 15 Ser Val Lys Met Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Val Met His Trp Val
Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Lys
Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr65 70 75
80 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95 Ala Asn Tyr Tyr Gly Ser Ser Leu Ser Met Asp Tyr Trp Gly
Gln Gly 100 105 110 Thr Ser Val Thr Val Ser Ser 115
201108PRTArtificial SequenceSynthetic Construct 201Asp Ile Gln Met
Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly1 5 10 15 Asp Arg
Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35
40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn
Leu Glu Gln65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly
Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu
Ile Lys Arg 100 105 202121PRTArtificial SequenceSynthetic Construct
202Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala1
5 10 15 Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Lys Asp
Tyr 20 25 30 Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu
Glu Trp Ile 35 40 45 Gly Gly Ile Tyr Pro Asn Asn Gly Gly Ser Thr
Tyr Asn Gln Asn Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp
Lys Ser Ser Ser Thr Ala Tyr65 70 75 80 Met Glu Phe Arg Ser Leu Thr
Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Met Gly Tyr
His Gly Pro His Leu Asp Phe Asp Val Trp Gly 100 105 110 Ala Gly Thr
Thr Val Thr Val Ser Pro 115 120 203108PRTArtificial
SequenceSynthetic Construct 203Asp Ile Val Met Thr Gln Ser His Lys
Phe Met Ser Thr Ser Leu Gly1 5 10 15 Asp Arg Val Ser Ile Thr Cys
Lys Ala Ser Gln Asp Val Gly Ala Ala 20 25 30 Val Ala Trp Tyr Gln
Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Trp Ala
Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Gly
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser65 70 75
80 Glu Asp Leu Thr Asp Tyr Phe Cys Gln Gln Tyr Ile Asn Tyr Pro Leu
85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105
204119PRTArtificial SequenceSynthetic Construct 204Gln Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30
Val Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 35
40 45 Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys
Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ser Asp Thr Ser Ala Ser
Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Tyr Tyr Gly Ser Ser Leu Ser
Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser
115 205108PRTArtificial SequenceSynthetic Construct 205Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp
Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25
30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe
Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val
Glu Ile Lys Arg 100 105 206108PRTArtificial SequenceSynthetic
Construct 206Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly
Lys Ala Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr
Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe
Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 100 105
207119PRTArtificial SequenceSynthetic Construct 207Gln Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30
Val Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile 35
40 45 Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys
Phe 50 55 60 Lys Gly Arg Ala Thr Ile Thr Ser Asp Thr Ser Ala Ser
Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Tyr Tyr Gly Ser Ser Leu Ser
Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser
115 208119PRTArtificial SequenceSynthetic Construct 208Gln Val Gln
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15 Ser
Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25
30 Val Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
35 40 45 Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu
Lys Phe 50 55 60 Lys Gly Arg Ala Thr Leu Thr Ser Asp Lys Ser Ala
Ser Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Tyr Tyr Gly Ser Ser Leu
Ser Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser
Ser 115 209121PRTArtificial SequenceSynthetic Construct 209Gln Val
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Lys Asp Tyr 20
25 30 Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
Met 35 40 45 Gly Gly Ile Tyr Pro Asn Asn Gly Gly Ser Thr Tyr Asn
Gln Asn Phe 50 55 60 Lys Asp Arg Val Thr Ile Thr Ala Asp Lys Ser
Thr Ser Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Met Gly Tyr His Gly
Pro His Leu Asp Phe Asp Val Trp Gly 100 105 110 Gln Gly Thr Thr Val
Thr Val Ser Ser 115 120 210108PRTArtificial SequenceSynthetic
Construct 210Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
Ser Val Gly1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln
Asp Val Gly Ala Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly
Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Trp Ala Ser Thr Arg His
Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe
Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Asn Tyr Pro Leu 85 90 95 Thr
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 100 105
211108PRTArtificial SequenceSynthetic Construct 211Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg
Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Ala Ala 20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35
40 45 Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Ser
Gly 50 55 60 Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr
Ile Asn Tyr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys Arg 100 105 212121PRTArtificial SequenceSynthetic Construct
212Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Lys Asp
Tyr 20 25 30 Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Gly Ile Tyr Pro Asn Asn Gly Gly Ser Thr
Tyr Asn Gln Asn Phe 50 55 60 Lys Asp Arg Val Thr Leu Thr Ala Asp
Lys Ser Thr Ser Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Met Gly Tyr
His Gly Pro His Leu Asp Phe Asp Val Trp Gly 100 105 110 Gln Gly Thr
Thr Val Thr Val Ser Ser 115 120 213121PRTArtificial
SequenceSynthetic Construct 213Gln Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ser1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Lys Asp Tyr 20 25 30 Thr Met His Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Gly Ile
Tyr Pro Asn Asn Gly Gly Ser Thr Tyr Asn Gln Asn Phe 50 55 60 Lys
Asp Arg Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr65 70 75
80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95 Ala Arg Met Gly Tyr His Gly Pro His Leu Asp Phe Asp Val
Trp Gly 100 105 110 Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
21425PRTArtificial SequenceSynthetic Construct 214Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu
Arg Leu Ser Cys Ala Ala Ser 20 25 21513PRTArtificial
SequenceSynthetic Construct 215Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val1 5 10 21630PRTArtificial SequenceSynthetic
Construct 216Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
Tyr Leu Gln1 5 10 15 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 20 25 30 21711PRTArtificial SequenceSynthetic Construct
217Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser1 5 10
21823PRTArtificial SequenceSynthetic Construct 218Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg
Val Thr Ile Thr Cys 20 21915PRTArtificial SequenceSynthetic
Construct 219Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
Ile Tyr1 5 10 15 22032PRTArtificial SequenceSynthetic Construct
220Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr1
5 10 15 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
Cys 20 25 30 22110PRTArtificial SequenceSynthetic Construct
221Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys1 5 10 22217PRTArtificial
SequenceSynthetic Construct 222Asp Met Tyr Pro Asp Ala Ala Ala Ala
Ser Tyr Asn Gln Lys Phe Arg1 5 10 15 Glu2238PRTArtificial
SequenceSynthetic Construct 223Ala Pro Arg Trp Ala Ala Ala Ala1 5
2249PRTArtificial SequenceSynthetic Construct 224Gln Ala Ala Ala
Ala Ala Ala Ala Thr1 5 225117PRTArtificial SequenceSynthetic
Construct 225Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn
Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr
Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val
Leu Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105
110 Val Thr Val Ser Ser 115 226117PRTArtificial SequenceSynthetic
Construct 226Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Asp Ser 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Met Tyr Pro Asp Asn
Gly Asp Ser Ser Tyr Asn Gln Lys Phe 50 55 60 Arg Glu Arg Val Thr
Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Leu Glu Leu
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val
Leu Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 100 105
110 Val Thr Val Ser Ser 115
* * * * *